Synthesis and conformational analysis of mitochondrial targeting peptides by Pitkeathly, Maureen C.
THE SYNTHESIS AND CONFORMATIONAL ANALYSIS OF 
MITOCHONDRIAL TARGETING PEPTIDES. 
Maureen C. Pitkeathly 
Doctor of Philosophy 
University of Edinburgh 
August 1991 
This thesis is submitted in part fulfilment of the 
requirements of the degree of Doctor of Philosophy in 
the University of Edinburgh.. Unless otherwise stated 
the work described is original and has not previously 
been submitted, in whole or in part, for any degree at 
this or any other university. 
University of Edinburgh 
August 1991 
Acknowledgements. 
I would like to thank Professor R. Ramage and Dr. 
R.L. Baxter for their advice, encouragement and 
guidance during the course of this work. I would also 
like to thank Dr. G. Reid for his help and advice in 
the microbiological work carried out. 
I wish to thank Mr. K. Shaw and Mr. B. Whigham for 
their technical assistance, and SERC for their 
provision of a grant. 
I would like to thank Drs. A. Hayman, A.S.J. Stewart 
and D.W. Thomas for helpful discussions and advice, and 
for proof reading this thesis. Finally I would like to 
thank my parents and my husband for their support 
throughout. 
To my parents. 
, t. r. r' 
The thesis discusses protein targeting within cells, 
and in particular targeting to the mitochondrion. The 
synthesis and conformational analysis by CD and NMR of 
a mitochondrial targeting presequence peptide,and a 
non-functional deletion peptide are described. The' 
intramitochondrial sorting of proteins is also 
discussed and investigated. 
Ch.. 1 reviews the currently available knowledge of 
the mechanisms and factors involved in protein targeting. 
Ch. 2 describes the synthesis and purification of the 
25 residue peptide corresponding to the mitochondrial 
targeting presequence of subunit IV of yeast cytochrome 
ox i dase 
Ch. 3 describes the conformational analysis by CD and 
NMF< studies of the synthetic peptide and discusses the 
structural information that can be drawn from the data. 
Both sets of data indicate that the peptide appears to 
adopt a partially helical structure. 
Ch. 4 describes the synthesis and purification of a 
23 residue peptide corresponding to a non—functional 
deletion mutation of the cytochrome oxidase subunit IV 
targeting peptide. The CD and NMR studies carried out 
on this peptide, the preliminary results of which 
indicate an absence of any regular structural motifs, 
are discussed. 
Ch. 5 reviews the current understanding of the, 
mechanisms of intramitochondrial sorting and their 
evolutionary relationship to protein secretion. 
E.Coli cells expressing cytochrome bz, with various 
portions of the presequence removed were subfractionated 
to determine whether any form of the presequence showed 
a strong tendency to target the protein to the cell 
membranes. Conclusive results were not obtained due to 
the formation of inclusion bodies within the cells. 
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ATP Adenosine triphosphate 
BCM Bacterial cytoplasmic membrane 
Boc tertButylo<ycarbonyl 
CD Circular dichroism 
COSY Correlated Spectroscopy 
DCM Dichioromethane 
DHFR Dihydrofolate reductase 
DIC Diisopropylcarbodiimjde 
DMAP N, N-Di methyl ami nopyri dine 
DMF N,N-Dimethyl4ormamide 
ER Endoplasmic reticulum 
ERM Endoplasmic reticular membrane 
FAEI Fast atom bombardment 
Fmoc Fluorenylmethoxycarbonyl 
SIP General 	insertion protein 
HOBT 1."-Hydroxy-1 ,2,3-ben±otriazole 
hplc High performance liquid 
chromatography 
Hrms High resolution mass spectrometry 
HSP Heat shock protein 
IM Inner membrane 
IMS Intermembrane space 
IF< Infra red spectroscopy 
MPP Mitochondrial 	processing peptidase 
nOe Nuclear Overhauser enhancement 
NOESY Nuclear Overhauser Enhancement 
Spectroscopy 
NTP Nucleoside triphosphate 
OCT Ornithine carbamyltransferase 
I 
-ii - 
OM 	 Outer membrane 
p15 
Forms of the cytochrome oxidase 
P33 	 subunit IV preseguence 
PEP Process enhancing peptidase 
Pmc 2,2,5,7, 8-Pentametyl chroman-6- 
sul phony 1 
PreCox IV Synthetic peptide corresponding to 
the Dresecluence of cytochrome oxidase 
subunit IV 
Pr- eCox 	IV11,12 Synthetic peptide corresponding to 
the A11,12 deletion of the 
presequence of cytochrome oxidase 
subunit 	IV 
SDS Sodium dodecylsuiphate 
SPPS Solid phase peptide synthesis 
SRF Signal 	recognition particle 
StBu tertButylthiol 
TFA Trifluoroacetic acid 
TFE 2,2,2-Trifluoroethanoi 
THF Tetrahydrofuran 
TOCSY Total Correlated spectroscopy 
uv Ultraviolet spectroscopy 
GLOSSARY 
Promoter 	A region of DNA to which RNA polymerase 
binds to initiate transcription 
Repressor 	A protein which binds to DNA in a manner 
that reduces the expression of a gene 
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Eukaryotic cells, in contrast to their prokaryotic 
counterparts, are subdivided into functionally distinct 
compartments or organelles (Figure 1.1), each of which 
is surrounded by one or more membranes. Each organelle 
contains a unique set of proteins which enable it to 
carry out specific functions within the cell, and 
therefore for the viability of the cell it is essential 
to have accurate and efficient delivery of proteins to 
organelles. 
The nucleus of the eukaryotic cell contains the main 
genome of the organism, encoding the majority of the 
proteins within the cell. Protein synthesis starts with 
the transcription of nuclear DNA into messenger RNA 
(mRNA) which, after splicing, is translated into 
protein by cytoplasmic ribosomes. Thus proteins are 
synthesised in the cytoplasm and are subsequently 
directed to their appropriate intracellular locations. 
After synthesis on cytoplasmic ribosomes, the paths 
- -followed-by different proteins diverge. Those proteins 
targeted-to the endoplasmi-c reticulum (ER), Golgi 
apparatus, 1 ysozome and outwi th the cell wall enter the 
secretory pathway, whereas those targeted to 
intracellular organdies such as the nucleus, 
mitochondrion, chloroplast or peroxisome are processed 
in a different manner. 
Proteins entering the secretory pathway are 
synthesised on cytoplasmic ribosomes bound to the 
surface of the ER membrane (ERM) and translocation 
occurs cotranslationally i.e. chain elongation and 
translocation across the membrane occur simultaneously. 
The proteins then proceed through the ER and the Golgi 
apparatus, often being covalent].y modified in the 
process. They are then stored in secretory vesicles 
FIgure  
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before being released to the cell exterior by 
exocytosis, either continuously - "constitutive 
secretion" or on stimulation by some extracellular 
signal - "regulated secretion". 
Transfer of proteins between two topographically 
equivalent organelles, as occurs in the secretory 
pathway, operates by vesicular transport. (A cargo of 
protein from the lumen of an organelle is captured by a 
vesicle budding off from the membrane of that organelle 
and is released into the lumen of the targeted 
organelle when the vesicle fuses with the membrane of 
that organelle. During such a process the proteins 
involved do not cross any membranes. 
The targeting of proteins from the cytoplasm to other 
organelles involves the protein crossing a membrane, 
and will be discussed in more detail later. 
Thus in eukaryotic cells there are a variety of 
different pathways for protein traffic (summarised in 
Figure 1.2). There must therefore be some sort of 
process by which proteins destined for the different 
organelles are specifically recognised and then 
accurately targeted to the correct destinations. 
Some insight into the mechanisms by which such 
processes might operate were gained when in 1972 it was 
discovered that the immunoglobulin light chain protein 
was synthesised as a precursor that was slightly larger 
than the secreted protein (1). 
Studies of this and other secretory proteins (2,3) 
indicated that the extra material contained within the 
precursor proteins consisted of a polypeptide extension 
to the N-terminal of the protein. 
It was surmised (1) that the extra material initially 
synthesised could contain information necessary for the 
targeting of the proteins into the secretory pathway 
and the term "signal peptide" was applied to the 
- 
precursor extensions. 
There has been considerable interest in these signal 
peptides since their discovery, and a considerable 
amount of knowledge has been gained into the processes 
by which they target parent proteins to their correct 
locations within cells. However there is still little 
evidence as to the actual mechanisms by which large, 
water soluble proteins are translocated across the 
hydrophobic environment of the phospholipid bilayer 
core. 
Signal peptides are necessary for the targeting of 
endoplasmic reticular, nuclear, per - oxisomal, 
mitochondrial and chioroplast proteins of eukaryotic 
cells, and are also required for the secretion of 
secretory proteins in prokaryotic organisms. In the 
latter case the signal sequences are required to direct 
secretory proteins to and across the bacterial 
cytoplasmic membrane (SCM). 
1.2 Targeting to the ER and SCM. 
Protein targeting to the ER and SCM have been the 
areas most studied, and the two processes have been 
found to be very similar. 
Detailed analysis of ER and bacterial signal 
sequences by von Heiine (4-6) and others (7-10) have 
revealed that although the signal sequences show very 
little primary sequence homology, they possess a number 
of putative structural characteristics shared to a 
greater or lesser extent by all signal sequences. 
These observations lead to the conclusion that the 
feature of signal sequences recognised by the import 
machinery may be structural rather than a specific 
sequence of amino acids. 
The analysis carried out (4-10) on large numbers of 
these signal sequences revealed them to vary in length 
-4- 
from 15 to 35 residues, and to be exclusively 
N-terminal, although not always proteolytically 
removable.. They consist of several distinct regions 
(Figure 1.3) although there are slight differences 
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Figure 1.3 
The charged N-terminal region of bacterial sequences 
is generally 2 to 10 residues in length, containing one 
or more lysine or arginine residues. The longer signal 
sequences tend to have longer charged regions. The 
N-terminal residue does not contribute to the charge in 
this region since it is generally N-formylated (10). 
However the charge at the N-terminal of eukaryotic 
signal sequences generally arises from the protonated 
N-terminal residue, which is not formylated in 
eukaryotic cells, although charged residues are 
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occasionally present in this region. Bacterial signal 
sequences generally have a net positive charge near the 
N-terminal of the signal sequence arising from side 
chain residues 
The second, core region of the signal sequence is 
essential in both pro- and eukaryote sequences. It 
consists of a stretch of at least nine hydrophobic 
residues, with a predicted strong tendency to form an 
-helix.  
A turn-inducing residue such as praline or glycine is 
generally located at the C-terminus of the core region, 
usually approximately six residues from the cleavage 
site. 
The final C-terminal region containing the signal 
peptidase cleavage site consists of -five to seven 
residues of higher polarity than those in the 
hydrophobic-region and small, apolar residues such as 
alanine or glycine are generally located in the 
positions 1 and 3 residues downstream of the cleavage 
site (4,11). 
In recent years much progress has been made in 
identifying the other components of the secretory or 
export mechanisms, the components of the export 
apparatus in higher eukaryotes having been most fully 
characterised. 
Protein synthesis has been found to occur co-
translational.ly on organised arrays of ribosomes, 
"polysomes", associated with the ER membrane (12,13). 
In consideration of the highly fluid nature of the ER 
membrane, such organisation suggests specific 
interactions between the ribosomes synthesising the 
proteins and a receptor embedded in the ER membrane. 
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In 1978 a cytoplasmic protein implicated in the 
export machinery was identified (14). This signal 
recognition particle (SRP) was found to bind to the 
nascent polypeptide chain (15-19) as it emerged from 
the ribosome,i.e when a chain of 70 to 80 residues 
had been synthesised (20). 
The SRP was shown to be a ribonucleoprotein, the 
54kDa component of which was observed to bind to the 
hydrophobic portion of the signal sequence (21,22), but 
only in the presence of ribosomes (23). 
All the evidence suggests that there exists only one 
SRP in a particular organism, and it follows therefore 
that it must recognise many different signal sequences. 
The SRP is essential for the targeting of most 
secreted, soluble lysozomal and integral membrane 
proteins, even though the latter contain non-cleavable 
signal sequences. 
Under some experimental conditions in vitro (24) 
binding of the SRP to the signal sequence has been 
shown to cause a pause in translation which is only 
resumed on the release of the SRP after interaction 
with the SRP docking-protein (SRP receptor) in the ER 
membrane (25-27). 
If this phenomenon does occur in vivo as has been 
postulated (28) , it would couple translation with 
translocation, ensuring the targeting of the protein to 
the correct membrane before the resumption of 
translation. Such a mechanism would also prevent the 
folding or more importantly the mis-folding of the 
protein before transiocation across the lipid bilayer. 
The SRP receptor is a heterodimeric complex the 
a-subunit of which consists of a 3OkDa integral 
membrane protein. The a-subunit is a peripheral 
membrane protein which can be anchored to the 
cytoplasmic face of the ER membrane through 
-7- 
interactions with the a-subunit (29-31). The -subunit 
has been shown by sequence analysis (29) to contain 
sequences similar to those in nucleic acid binding 
proteins, and may therefore bind-to the 7S RNA 
component of the SRP. The SRP receptor is much less 
abundant than ribosomes on the RERM, and is therefore 
not thought to be involved in subsequent stages in 
translocation. 	 - 
Cross-linking studies have identified two ER membrane 
proteins of 35kDa (20) and 45 kDa (32) as possible 
components of the import machinery. A 35kDa protein has 
been proposed to be a signal sequence receptor (SSR) 
(20). However at present little is known about these 
processes and there may be a series of interactions 
between the nascent chain and receptors occurring at 
the membrane surface or within the membrane. 
Posttranslational translocation of some secretory 
proteins does occur (33-36) , however such proteins tend 
to be small, generally less then 100 residues, and as 
such may not adopt a strong secondary structure.. It has 
therefore b een _postulated (37) that the cytosolic 
proteins found to be required for targeting may ensure 
that translocation-competent structures are adopted by 
the incoming proteins. 
A family of 70kDa Heat Shock Proteins (HSP70) has 
been found necessary for the posttranslational 
translocation of proteins (38). These proteins are 
produced in increased amounts at elevated temperatures, 
and are thought to bind to cytosolic proteins 
preventing denaturation by tighter folding.. Their 
transitory involvement in protein export may be as 
competence factors, maintaining the secretory proteins 
in import competent conformations. 
Wickner's "membrane trigger hypothesis" (39,40) 
proposed that signal peptides affected the folding 
(1) 64~~" 
SUflth8S1S begins on ribosomes. P 
zpossible(2) 
 
Interaction of the growing chain 
with SRI'and cUtOSOliC factors. 
 pause in translation. 
(3) interaction of the SRI' with the SRI' receptor 
(docking protein) Resumption of translation. 
-----:: 
(4) Interaction of the signal sequence 
with the SSR. 
TransloCatlOn of the protein, possibly 
via a proteiflaCeoUS pore. 
EjL4 
Targeting to the endoplasifliC reticulum. 
-8-- 
pattern of secretory proteins as they emerge from the 
ribosome, allowing them to adopt a translocation-
competent conformation, and, that the signal peptide 
itself contains the information required for targeting 
to the appropriate membrane. He has also proposed that 
signal peptides insert into the lipid bilayer and not 
into protein-lined water-filled channels. The energetic 
requirements for the translocation of proteins through 
the lipophilic environment of the lipid bi].ayer are, 
however, prohibitively high (41,42) ,and evidence has 
been advanced that protein translocation must occur 
through water-filled channels (43). The possibility 
that the signal peptides could form the pore has been 
discounted (42). 
One possibility is that the channel could be formed 
by lipids in a non-bi].ayer formation with their 
hydrophilic headgroups lining the channel. Another 
alternative is that the channel could be formed by a 
membrane protein. Although none of the putative 
"translocases" that should be involved in such a 
mechanism have been ietified, recent electro-
physiological experiments (44)..,indicate the existence 
of a protein-conducting channel in the endoplasmic 
reticulum. The results of the experiment appeared to 
indicate that the observed channel closed upon the 
dissociation of the ribosome from the membrane, 
suggesting that the ribosome may interact directly with 
one or more subunits of the proposed protein-conducting 
channel. The purification and reconstitution of the 
components of the import machinery so far discovered 
may allow the identification of the proposed channel 
protein. 
A summary of the targeting mechanism is shown in 
Figure 1.4. 
PROTEIN LOCATION FUNCTION / PROPOSED RULE. 
SecA cytoplasm 
- Role thought to be similar to that 
peripherally asociated of the eukarUotic SRP since the 
with membrane through protein shows affinity for SecS 
affinity for SecV/E and the signal peptide / mature 
protein as well as SecY/E. 
cytoplasm 
Thought to act as a chaperone 
SeCD for many cytoplasmic proteins. 
May prevent misfolding of. the 
protein and binding to non- 
productive sites. 
SecY/E membrane 
Essential for import. Possible roles 
as: 
Receptor for the signal sequence 
(c.f. 	oukarljotic SSR) 
- Pore / tunnel. 
Receptor for the SecA/export 
complex (c.f eukaryotic docking 
protein.) 
SecD/F Integral membrane 
May be involved in the later steps 
proteins. in translocation 
- possibly In the 
release of newly processed proteins. 
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1.3 Prokaryotic secretion. 
The steps involved in prokaryotic protein secretion 
are less well-dc-Fined than those in eukaryotic 
secretion, however, recent -findings have greatly 
increased our understanding of the components involved 
in the bacterial export pathway (45-48). 
Much of our current knowledge has derived from the 
genetic approach (45,46) which has implicated several 
gene products found to be important in protein export: 
SecA (priD), SecB, SecD, SecE (prlG), SecF and SecY 
(priA) and the two signal peptidases. 
An accumulation of biochemical evidence (49) has led 
to the identification of several other species, 
including soluble competence factor (50,51) and a 
protein, trigger factor (52-54), which forms a complex 
with the signal sequence of the E.Col.x. outer 
membrane protein (OMP A) maintaining the protein in an 
import competent -Form. 
The properties of the E.Co2i Sec gene products are 
summarised in Table 1.1. 
SecA is an essential player in protein export and is 
bound to the bacterial membrane by its affinities for 
SecY and SecE (55). SecB acts as a "chaperone", forming 
a complex with many, but not all, precursor proteins 
(56) which is thought to prevent mis-Folding of the 
precursor protein and binding to nonproductive sites 
(55). The SecB/precursor complex then binds to the 
membrane by interaction with SecA, which has been shown 
to have an affinity for SecEi and for the signal and 
mature domains of precursor proteins (57). Upon binding 
a precursor SecA becomes active as an ATPase, this 
activity being required for translocation (58). The 
function of SecA is thought to be similar to that of 
the SRP in eukaryotic secretion. 
SecY and SecE are integral membrane proteins (49,59, 
- 10 - 
45) interacting with each other within the membrane. 
Genetic evidence strongly suggests interactions between 
signal sequences and these proteins (60). 
SecD and SecF are integral cytoplasmic membrane 
proteins which may be involved in a late step in 
transi ocati on. 
The progress of the protein chain through the 
membrane (61) is driven by ATP hydrolysis (62) and the 
proton motive force (63). 
E.Coli proteins (Ffh and FtsY) and 4.5S RNA species 
(Ffs) have recently been identified that exhibit 
sequence similarities to subunits of mammalian signal 
recognition particle (SRP) (Ffh and Ffs) and docking 
protein (FtsY) (64-66). These similarities, although 
intriguing, do not in themselves constitute evidence 
for the involvement of these bacterial proteins in the 
prokaryotic export pathway, and there is currently no 
data supporting the role, of a bacterial SRP in protein 
export. In contrast, the available evidence clearly 
establishes that the known Sec proteins constitute the 
primary protein export pathway in E.Coli. 
Although the basic pathway for prokaryotic secretion 
is well established, there is still much to be learned 
about the exact roles of each component in the pathway. 
The mechanism by which ATP and the membrane potential 
drive translocation, is still not understood, likewise 
whether translocation occurs through the lipid phase or 
through a proteinaceous pore possibly involving SecY 
and/or SecE. 
1.4 Targeting to the nucleus. 
The nucleus of eukaryotic cells is surrounded by a 
double bilayer membrane which is contiguous with the ER 
membrane. The targeting of nuclear proteins is, 
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however, completely independent of the secretory 
pathway. 
Nuclear proteins are synthesised on cytoplasmically 
free ribosomes and are often stockpiled in the 
cytoplasm until import is induced by a hormonal or 
developmental stimulus (67). Free diffusion of proteins 
less than 9 or 10 nm in diameter occurs through nuclear 
pores (68,69) , although the rate of diffusion decreases 
rapidly with increasing protein size. 
There is strong evidence for the existence of nuclear 
targeting (karyophilic) signals, which can be 
N-terminal (MATx2; yeast) , central (glucocorticoid 
receptor; rat) or C-terminal (nucleoplasmin; frog 
oocytes) and are not proteolytically cleaved on entry 
into the nucleus. 
As was observed for signal sequences, there is little 
sequence homology between karyophilic sequences which 
appear to consist of short basic sequences rich in 
lysine and to a lesser extent arginine residues,and 
usually contain a turn-inducing residue such as praline 
or glycine. 
It is thought that nuclear targeted proteins may 
contain several karyophilic signals and that 
multivalent interactions between these signals and 
receptors may increase the efficiency of import (70, 
71). There is also strong evidence for the presence o-F 
nuclear retention signals within nuclear proteins 
(72-75). 
The outer and inner membranes of the nucleus are 
contiguous, and are perforated by nuclear pores that 
have been shown to play a key part in protein import 
(76,77). The pores have a well-defined structure with 
an internal diameter of 80 nm, and are not uniformly 
distributed, possibly being anchored in place. 
There is good evidence (76) that protein import 
- 12 - 
occurs through these pores, and it has been postulated 
that there may be a karyophilic signal receptor within 
the pore. The exact mechanism by which the pore 
operates is, however, unknown. 
ATP has also been shown to be necessary for protein 
import, but its role has not been thoroughly 
investigated. In addition it has not been determined 
whether cytoplasmic factors are required for nuclear 
protein import (78-80). 
1.5 Targeting to the peroxisome. 
Few peroxisomal proteins are synthesised as larger 
precursors, and in those cases where processing does 
occur it is not thought to be related to import. 
The few putative peroxisomal targeting sequences 
identified so far have been C-terminal with little 
sequence homology (80). Specific receptors on the 
peroxisomal surface are indicated (81) , but little is 
known about peroxisomal import. 
1.6 Targeting to mitochondria and chioroplasts. 
Mitochondria and chioroplasts are the energy-
converting organelles of cells, converting energy from 
oxidation reactions into more useful forms such as ATP. 
Mitochondria show many similarities to prokaryotic 
organisms, and chloroplasts carry out photosynthesis in 
much the same way as prokaryotic cyanobacteria. These 
and other observations have lead to speculation that 
such energy converting organelles derive from the 
capture of a prokaryotic organism by a primitive 
eukaryotic cell and the subsequent development of a 
symbiotic relationship between the two. lhe prokaryote 
provided the energy required by the cell, allowing the 
eukaryotic cell and the subsequent developement of a 
- 13 - 
symbiotic relationship between the two -3. The prokaryote 
provided the energy required by the cell, allowing the 
eukaryote to diversify, and in return the genes for the 
majority of the prokaryotic proteins were transferred 
to the nuclear genome. Mitochondria and chioroplasts, 
there-Fore, although they do contain their own genome, 
import more than 90% of their proteins from the 
cytosol. 
1.6.1 Targeting to mitochondria. 
Mitochondria consist of four major compartments,the 
outer membrane (OM) , the inner membrane(IM) , the 
intermembrane space (IMS) , and the matrix. 
The outer membrane contains large amounts of porin, a 
protein that -Forms aqueous channels through the lipid 
bilayer, and makes it permeable to proteins of up to 
lOkDa. The intermembrane space is chemically equivalent 
to the cytosol. The inner membrane is impermeable. 
Import into mitochondria is a complex process, since 
mechanisms must be present for the targeting of 
specific proteins to their correct locations within the 
organelle, and there have been many reviews on this 
subject (82-87). 
Generally an N-terminal presequence is responsible 
for targeting to the mitochondrial matrix, and a second 
targeting sequence similar to that of bacterial 
exported proteins is responsible for targeting to 
intramitochondrial locations other than the matrix. 
Outermembrane (OM) proteins contain non-cleavable 
sequences. The 70kDa OM protein contains additional 
information starting at residue 10 (88). This uncharged 
region is thought to function as a "stop-transfer" 
signal, since even a slight alteration of the region 
(deleting 2 residues) causes the protein to be imported 
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into the matrix.. 
Proteins destined for the intermembrane space 
generally contain two presequences. The first is a 
matrix-targeting type signal, and the second, an 
"intramitochondrial sorting signal", is very similar to 
bacterial secretory signals, containing a large 
hydrophobic segment. Such sorting signals will be 
discussed in more detail in chapter 5. 
Import into mitochondria is thought to occur 
posttranslationally, although there is some evidence 
(89) that cotranslational import could be occurring in 
vivo at contact sites between the outer and inner 
membrane (90-93). 
It has been observed that nucleoside triphosphates 
(NTP's) are required for the import of mitochondrial 
precursors, and cannot be replaced by their 
non-hydro].ysable analogues (33). It was shown by 
Pfanner and Neupert (34) that NTP's are required for 
several steps in mitochondrial import, but that the 
steps all appear to involve the the translocation of 
precursor domains from the cytosol onto and across the 
mitochondrial surface. It was suggested (37) that ATE 
dependent "unfoldases" which are known to he involved 
in biochemical reactions in which a relaxation of 
tertiary structure is involved, could perform an 
unfolding function in mitochondrial import.. 
Studies have shown that the precursor proteins exist 
in the cytosol as high molecular weight aggregates, 
possibly consisting of the nascent peptide chain and 
cytosolic competence-cofactors that stimulate the 
import of the proteins (94). 
As is the case for secretory proteins destined for 
the ER, the HSP70 family of cytosolic proteins has been 
shown to stimulate mitochondrial protein import in 
vitro (38,95). It is thought that they may bind to the 
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partially unfolded precursors in such a manner as to 
expose the presequence to the cytosol, and to maintain 
the precursors in an import competent unfolded 
structure. Release of the precursors from HSP70 
requires the hydrolysis of ATP and it is thought that 
this may be a reason for the demonstrated requirement 
of ATP outside the mitochondrion for import of 
precursors (96) 
The existence of proteinaceous receptors on the 
mitochondrial surface with which the presequences are 
thought to interact has been proposed following the 
observation (97) that mitochondria pretreated with a 
low concentration of protease are unable to import or 
bind certain mitochondrial precursors. Binding of 
precursors to the mitochondrial surface occur -s in the 
absence of a transmembrane potential (98) and is 
therefore independent of import. 
It is currently thought (87) that there are four 
different types of receptor interacting with different 
classes of mitochondrial proteins, three types 
interacting with specific proteins - porin, 
apocytochrome C and the inner membrane ATP/ADP carrier 
protein (AAC)- and a fourth interacting with all other 
proteins having presequences.. 
A 45 kDa protein of the outer membrane of yeast 
mitochondria has been identified as a possible 
component of the import machinery (99). Antibodies 
directed against this protein inhibited the level of 
import in mitochondria which had been pretreated with 
protease. 
Similar evidence (100) implicates two other outer 
membrane proteins one of 19kDa (MOM19) and one of 72k-Da 
(M0M72)\as candidates for targeting presequence 
receptors, each possibly recognising different subsets 
of mitochondrial proteins. It has also been shown (101) 
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that antibodies against a 30 kDa protein from mammalian 
mitochondria interact with the synthetic presequence of 
ornithine carbamyltransf erase (pOCT). 
Studies on the ATP/ADP carrier protein (87) indicate 
the presence of a second type of receptor in the outer 
membrane that is in a more protected environment than 
the surface receptors.. It is thought that this receptor 
may be common to all import pathways since competition 
occurs at this level in translocation, and it has been 
speculated that the receptor may mediate insertion of 
the presequences into the membrane, hence its name the 
"general insertion protein" (SIP). 
Transfer from the general insertion protein into the 
inner membrane requires an electrical potential across 
the inner membrane (negative inside). The precise role 
of this potential is not understood since the mechanism 
of protein translocation across the membrane is not 
known. Once the targeting sequence has crossed the 
membrane into the matrix, the remaining protein follows 
independent of the membrane potential (90,93,102). 
Once translocated into the matrix _the precursor -
proteins are processed by a chelator-sensiti.ve.. 
processing peptidase the mitochondrial processing 
peptidase (MFP) (103-105). MPP is a soluble matrix 
protein (57kDa in N.Crassa (104) and 52kDa in 
S.Cerev.isiae (105) requiring the divalent metal ions 
Mn 	or Zn. MF'P is almost inactive in the absence 
of a second processing component, process-enhancing 
protein (PEP) (104). The process enhancing peptidase 
stimulates the activity of MPP 50-fold. Possibly the 
two components act co-operatively recognising different 
structural elements specific of presequences. PEP is 
70% associated with the inner membrane and plays a role 
in the translocation process. An a-helical segment of 
PEP consisting of a 20 residue motif with a net 
(1) Free in cytoplasm. Interaction with cytosolic factors 
followed by presentation of the targeting peptide. 
	
(2) Interaction with targeting 	 tikA 	GIP 






(3) Unfolding of protein and interaction 
R 	 with the GIP.  
(4) Translocation of targeting peptide 
across membranes. (requires 
electrochemical gradient)-  R 
possible via a channel protein. 
/GIP 
(5) Complete tran3location and R 	
proteol yti cal removal of the targeting 
signal. i7 
Figure 1.5 
Targeting to mitochondria. 
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negative charge may play some role in releasing the 
positively charged presequence from a translocation 
component..The process is summarised in Figure 1.5. 
1.6.2 Targeting to chioroplasts. 
Import into chioroplasts is thought to operate in a 
manner similar to mitochondrial import. A statistical 
analysis of chioroplast "transit peptides" has shown 
them to be N-terminal with little or no primary 
sequence homology (106) , and it can only be assumed 
that specific conserved structural features in the 
transit peptides are recognised by the import 
machinery. 
The nature and composition of the translocation 
system is not as thoroughly understood as in the 
mitochondrial case, nevertheless various proteins have 
been implicated as components of the import machinery. 
The inhibition of protein import by the 
pretreatment of chioroplasts with protease (107) 
suggests that receptor proteins on the surface of 
chloroplasts must exist. Several chloroplast proteins 
have been implicated (108-110), however at present the 
nature and composition of the translocation system is 
not known. 
The only energy source found to be required for 
import is ATP (111,112). Unlike mitochondrial import, 
an electrochemical gradient across the membrane is not 
required. 
Intraorganelle sorting is a more complex process than 
for mitochondria due to the more complex nature of the 
chioroplast, however it would appear that sorting 
signals exist (113-115), the thylakoid-transfer domains 
of transit peptides strongly resembling bacterial and 
eukaryotic signal sequences (116). 
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1.6.3 Characteristics of mitochondrial targeting 
pr es e9ences. 
tlaccecchini et al.. (41) has observed that 
mitochondrial proteins are smaller than their in 
vitro synthesised precursors, and sequence analysis of 
mature and precursor proteins (117) has resulted in the 
identification of mitochondrial presequences. 
Mitochondrial targeting sequences are N-terminal 
presequences of up to 70 residues, which are 
proteolytically cleaved in one or two steps inside the 
mitochondrion. Recombinant DNA techniques have shown 
that they generally contain sufficient information to 
target any attached protein to the mitochondrion (97, 
118) 
The largest class of mitochondrial proteins are those 
contained in the mitochondrial matrix, and matrix 
targeting sequences have been widely studied. 
Von Heijne (119) analysed 23 mitochondrial 
presequences and reported that they showed no primary 
sequence homology, and were very different in character 
from ER and bacterial signal sequences, containing no 
extended hydrophobic regions. 
Comparison of a large number (119) of such sequences 
has shown that they all contain the following elements 
of primary structure 
High basicity, containing a large number of 
arginine and/or lysine residues spaced out 
throughout the presequence. 
No acidic residues. 
A large number of hydroxylated residues. 
The analysis carried out by von Heijne (119) indicated 
that most matrix-targeting presequences are capable of 
adopting amphiphilic cx-helical structures in which the 
positive charges all line up along one edge of the 
helix. If the presequence of yeast cytochrome oxidase 
+ 
Met 	+ 
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The projection of the PreCox IV (1-18) sequence on an 
"a-helical wheel". (Roise et al, 1986) 
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subunit IV is plotted on a "helical wheel" (Figure 1.6), 
the resultant view down the helical axis shows a clear 
segregation of positive charges from hydrophobic 
residues. 
Amphiphilical peptides are known to possess 
surfactant properties and presequence peptides would 
there-fore be expected to have a strong affinity for the 
surface of negatively charged phospholipids. 
Studies carried out by Raise (120) on a synthetic 
peptide corresponding to the presequence of cytochrome 
oxidase subunit IV (henceforth referred to as PreCox 
IV) indicated that the peptide inserted spontaneously 
into phospholipid monolayers and disrupted phospholipid 
bilayers at micromolar concentrations. Similar results 
were reported for the presequence of rat ornithine 
carbamyltransferase (121,122) 
Analysis of synthetic PreCox IV by circular dichroism 
indicated that in aqueous environments the peptide 
adopts a largely random structure, but in the presence 
of detergent micelles a structural change occurs and 
the peptide appears to adopt a helical structure 
(120). 
Artificially constructed presequences consisting o-F 
only leucine, serine and arginine which can in theory 
adopt a-helical structures have been found to be able 
to target proteins into the mitochondrial matrix 
(123,124) and the synthetic peptides were found to 
insert into phospholipid monolayers and to disrupt 
phospholipid bi].ayers with efficiencies similar to the 
wild type. Circular dichroism measurements of the 
peptides in the presence of detergents indicate that 
one of the peptides appeared to be largely ac-helical 
but a second peptide appeared to be almost exclusively 
-sheet. It was concluded (124) that the main 
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Figure 1.7 
The helical hairpin model for the insertion of ER signal sequences 
into membranes. (a) Association of the positively charged N-terminus 
with the lipid headgroups. (b) Insertion of the signal peptide into the 
membrane in a 13-sheet like conformation. (c) The hydrophobic core 
region of the signal sequence undergoes a conformational change to a 
a helix, in the process forming a channel through which the translocation 
of the protein can occur. 
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amphiphilicity rather than specifically amphiphilic 
-hel icity. 
Various mechanisms for the interactions of the 
different types of targeting sequences with membranes 
have been formulated. Briggs and Gierasch (7) proposed 
that bacterial signal sequences could interact with the 
lipids in the membrane of the ER in such a manner as to 
lower the energy barriers for protein translocation. 
They propose that the N-terminal charged residues 
interact with the phospholipid headgroups forming a 
0-sheet-like conformation which then inserts into the 
lipid bilayer, forming an -helix in the process.The 
remainder of the protein is then transported through 
the resultant channel (Figure 1.7). 
It has been suggested that mitochondrial targeting 
sequences would also be able to cause local defects in 
lipid bilayers allowing the translocation of 
mitochondrial proteins. The mechanism suggested for 
such a process involves the formation of amphiphilic 
-helices in lipid environments which would be able to 
insert into the membrane bilayer in such a manner that 
the positively charged residues on one edge of the 
helix could interact with the phospholipid headgroups 
and the hydrophobic residues inserted into the membrane 
(Figure 1.8). It has been suggested that the 
electrochemical potential required for import could 
then drive the presequence through the membrane by an 
electrophoretic effect, resulting in the rearrangement 
of the lipid molecules and the formation of a channel 
through which the remainder of the protein is 
transl ocated. 
Although there is-evidence (43) that protein import 
may occur via water-lined channels and that protein-
conducting channels may exist in the endoplasmic 
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Figure 1.8 
A model proposed for the insertion of mitochondrial targeting peptides 
into membranes. (a) Association of the positive charges with the lipid 
headgroups. (b) Insertion of the presequence into the lipid bilayer in the 
form of an amphipathic helix. (c) Electrophoretic migration of the presequence 
through the membrane, forming a channel through which the protein is then 
translocated. 
- 21 - 
demonstrated to exist for mitochondrial membranes, and 
the alternative mechanism via channels formed by 
lipids in non-bilayer conformations cannot therefore be 
ruled out since the rearrangement of the lipid bilayers 
could be accompanied by the formation of a water-lined 
channel. In addition, despite the discovery of various 
outer membrane proteins involved in the translocation 
processes, no channel forming proteins have been 
identified. 
Thus although various proteins have been indicated as 
components of the mitochondrial import machinery, the 
precise mechanisms by which they operate have not been 
identified, and the role of the presequence in a lipid 
channel forming mechanism cannot be ruled out. 
Clarification of the mechanism of import could be 
achieved if some method of determining the structure of 
the presequence during the import process could be 
found. Demonstrating such a proposition is, however, 
beyond the realms of possibility using techniques 
currently available. An approach which is 
experimentally feasible using current techniques is the 
determination of the structure of presequences in the 
environment encountered during import i.e.. a lipid 
bilayer.. The presence or absence of defined secondary 
structural features of the targeting elements in such 
environments would lend credence to the truth of the 
various mechanisms proposed. 
Circular dichroism has been a widely used technique 
in the field of protein structure determination, and 
the use of detergent micelles allows a simulation of a 
lipid bilayer type environment. The insights into 
structure gained from such a technique are, however, 
limited to generalisations. The helicity obtained from 
circular dichroism spectra being a time average of all 
conformations of the peptide. 
- 
technique which is capable of determining the 
precise conformation of a peptide in a fluid 
environment, assuming that it adopts defined 
conformations is proton Magnetic Resonance ('H- NMR). 
Unlike CD, NMR does not give a general idea of the 
structural elements present, but gives information on 
the precise geometry of the peptide conformation. 
Unfortunately, due to the coincidence of chemical 
shift values, such an analysis would be impossible on a 
system containing a large protein and phospholipid 
vesicles Nevertheless, analogous conditions could be 
simulated using structure-inducing solvents or 
deuterated phospholipids, and since the presequence has 
been shown to contain all the information necessary for 
the targeting of proteins, a short segment of the 
N-terminal region of the protein could be studied. 
Thus the main aim of the work carried out was to make 
a synthetic peptide corresponding to the preseqLtence to 
yeast cytochrome oxidase subunit IV (PreCox IV) and to 
determine whether the peptide adopts defined structure 
in a lipid-like environment. 
rLJD 
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THE SYNTHESIS AND PURIFICATION OF THE COX IV PREPEPTIDE 
2.1 Introduction. 
The twenty five residue presequence of cytochrome 
oxidase subunit IV (Figure 2.1) (henceforth referred to 
as PreCox IV) was synthesised by solid phase peptide 
synthesis (SPPS). 
H Met Leu Ser I_eu Arg Gin Ser lie Arg Phe Phe Lys Pro 
Ala Thr Arg Thr Leu Cys Ser Ser Arg Tyr Leu Leu OH 
Figure 2.1 
Solid phase synthesis was introduced by Merrifield in 
1962 (125,126) and involves the covalent attachment of 
the C terminal amino acid in a sequence to an insoluble 
resin support. Chain elongation is then carried out 
using procedures similar to those developed for 
solution phase peptide synthesis. The major advantage 
of this approach is that the separation of the reagents 
from the resin-bound growing peptide chain can be 
easily achieved by filtration and the resin-bound 
peptide can be thoroughly washed after each step to 
ensure the complete removal of soluble contaminants.. 
The chemistry originally used by Merrifield for SPPS 
involved the attachment of the peptide to the resin 
through a linker which was cleaved by hydrogen 
fluoride.. The temporary protection of the x-amino 
function of the amino acids was achieved using the TEA 
labile tert.- butyloxycarbonyl (Boc) group. The side 
chain functionalities therefore had to be protected by 
groups stable to TEA cleavage conditions e . g. bezyl. 
Recent methodology has involved the protection of the 
cx-amino function with a base-labile protecting group 
which has allowed the utilisation of side chain 
protecting groups and a resin linker that can be 









cleaved under milder acidic conditions than those used 
for Boc chemistry. 
2.2 Protecting group strateciy_for PreCox IV. 
The base-labile protecting group of our choice was 
the 9—f luorenylmethoxycarbonyl (Fmoc) group developed 
by Carpino and Han (127) which protects the a-amino 
function as a urethane (1). A number of bases react 
with the Fmoc group via a -elimination reaction 
(Figure 2.2) to release dibenzo-fulvene (2) which then 
usually reacts further with the base to form an adduct 
(3). Fiperidine was found to be a suitable reagent 
for this purpose. 
The resin used was the p-alkoxybenzylalcohol resin 
(Figure 2.3) developed by Wang (128) from which the 
peptide is cleaved by 95% aqueous trifluoroacetic acid 
(TFA). 
HOCH2 -(I)---- OCH2 	Polystyrene 
Figure 2.3 
The Wang resin 
The use of the Fmoc protecting group strategy (129) 
allowed the protection of the hydroxyl functions of 
serine, threonine and tyrosine as tert.-butyl ethers, 
cleavable under the same conditions as the resin 
linker. The CI-amino group of lysine was protected by 
the Boc group (4) and the arginine guanidino function 
was protected with the 2,2,5,7,8-pentamethyl--6-
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Protecting groups used. 
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Ramage et al (1:30,131) (Figure 2.4). 
In view of the resistance of the carboxamide nitrogen 
of glutamine to acylation or alkylation, it was not 
necessary to protect this side chain function during 
synthesis. 
Due to the presence of one cysteine residue in FreCox 
IV it was possible that the peptide might dimerise, 
forming disulphide bridges and lead to problems in the 
purification of the peptide. Since the formation of 
mixed dimers between the desired peptide and truncated 
peptides might impede purification we elected to 
protect the cysteine using a group that was stable to 
both acidic and basic conditions. The cysteine could 
therefore remain protected during the initial stages of 
purification and be independently deprotected during 
the final stages of purification when the possibilty of 
the formation of mixed dimers would be lower. 
Two possible protecting groups were considered as 
suitable. The acetamidomethyl (Acm) group (6) is 
commonly used for the protection of the thiol function 
(Figure 2.4) and can be cleaved by mercuric salts (132, 
133) or by iodine (134). The S-t-butylsulptenyl 
(SBu) protecting group (7) offers an alternative 
strategy since it also is resistant to acid- and 
base-induced cleavage and can be removed reductively by 
mild reagents such as thiols (135-137) or phosphines 
(138). However its use has not been as widely reported 
in the literature. 
The Fmoc protected amino acids were all commercially 
available except for FmocArg(Pmc)OH and 
FmocCys(StBu)OH. The former was prepared by 
modifications to the synthetic scheme developed in this 
laboratory (Scheme 1 Figure 2.5) (130) and the latter 
was prepared from the commercially available 


































(CH2)3 	 -. 
NH 	Me 	Me 
HN 	NH-S02 
ii> Me 
Me 	 Me 
Scheme 1 continued. 
Reagents used: (i) TFMSA/CHC1 3 (ii) C1S03H (iii) Benzyl chloroformate/ 
NaOH / NáHCO3 (iv) (a) 3.2 M NaOH/acetone (b) saturated citric acid 
(c) cyclohexylamine. (v) (a) Saturated citric acid (b) Hydrogenation in MeOH 
over 10% palladium on charcoal (vi) N-(9-fluorenylmethoxycarbonyloxy)-
succinimide. 
FmocNHC}IRCOOH + >—N =C=N 
(8) 
>—NH —C =N 
"C —CHRNHFm0c 
0 	(9) 
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2.3 Activation of amino acids. 
The formation of a peptide bond requires that the 
carboxy component of the incoming amino acid is 
activated in some manner. The standard reagents for -
this purpose are the symmetrical anhydride or an active 
ester of the amino acid. 
We used a procedure involving both of these reagents 
in tandem. The "double couple" cycle used consisted of 
an initial coupling with the symmetrical anhydride of 
the amino acid, followed by a coupling with the 
1-hydroxybenzotriazoie (HOBT) active ester of the 
amino acid with an intermediate washing step. This 
cycle was carried out for all amino acids except 
arginine and qiutamine, for which a double couple cycle 
involving two portions of the HOE4T active ester was 
used. 
The symmetrical anhydrides of the amino acids were 
generated in situ by the reaction of the amino acid 
with diisopropylcarbodiimide (DIC) (Figure 2.6). This 
is a modification of the method first introduced by 
Sheehan and Hess (140) which-used-.,- 
dicyciohexyicarbodiimide. 	 .• . 	 -. 
The amino acid reacts with the DIC (8) to form the 
0-acylisourea (9) which then further reacts with the 
carboxy component of an unreacted amino acid component 
to produce the anhydride (10). 
Although the symmmetrical anhydride is formed rapidly 
and is very reactive, there are several side reactions 
associated with the carbodiimide activation of Asn, Gin 
(141) and Arg (142). These problems can, however, be 
circumvented (143,144) by the activation of these amino 
acids as active esters. In addition, the symmetrical 
anhydride procedure does not make efficient use of 
sometimes costly protected amino acids since two 












FmocNHCHRCO —N' N 
(12) 
Figure 2.7 
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one equivalent of the activating agent.. 
The second activation method used was first 
introduced to peptide chemistry as a solution to side 
reactions experienced in carbodiimide activation. Konig 
and Geiger (145) proposed that the addition of 
1-hydroxybenzotriazole as an auxiliary nucleophile to 
the symmetrical anhydride reaction mixtures would 
suppress the formation of N-acyl-isoureas and hence 
suppress racemisation. The HOBT active ester (12) 
formed by the reaction of 1-hydroxybenzotria:ole (11) 
(HOBT) with the 0-acyl-isourea (9) generated from the 
reaction of the amino acid with DIC is itself a 
powerful acylating reagent and has subsequently been 
incorporated into SPPS as an activating agent (Figure 
2.7). This method of activation requires only one 
equivalent of the amino acid to generate one equivalent 
of acylating agent and is therefore more cost-effective 
than the symmetrical anhydride activating procedure. 
FmocNHCHRCOOH 




FmocNHCHR(OCH2 —_fj_OCH2 __/)__ Polystyrene 
Figure 28 
The loading of the C-terminal amino acid onto the 
Wang resin requires the formation of an ester rather 







FmocNHCHRCOCH2__r-0CH 2 -f--- Polystyrene 
11 
Figure 2.9 
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catalysed by the addition of p-dimethylaminopyridine 
(DMAF) to a reaction mixture containing the symmetrical 
anhydride of the amino acid and the Wang resin (Figure 
2.8).. An alternative method used was the conversion of 
the amino acid to its acid chloride which was 
subsequently coupled to the resin (Figure 2.9). 
The progress of both coupling reactions could be 
followed by the appearance of an ester peak in the 
infra red spectrum of the resin. 
The amount of amino acid covalently bound to the 
resin was then determined, to enable the amount of 
resin required for the synthesis to be calculated. This 
was initially determined from the nitrogen content of 
the resin as obtained from elemental analysis of the 
loaded resin. The nitrogen content for 100% loading of 
a resin of functionality 1 mmol g 1 with FmocLeuOH 
would be 0.9% and, since the error in the measurement 
of nitrogen content is +1- 0.3"/., the values obtained by 
this method were not very reliable. 
Resin loadings were subsequently evaluated using the 
spectroscopic method described below. Capping of the 
unreacted sites on the resin was then achieved by 
esterification of the free hydroxyl groups with benoyl 
chloride.. This was carried out to prevent them from 
acting as potential growth points for truncated 
peptides.. 
Experience has shown (146) that the synthesis of long 
peptides is better achieved if larger amounts of resins 
with a lower functionality of amino acid on the resin 
are used. Although the initial syntheses were carried 
out on resins with functionalities of about 0.8 mmol 
g 1 , later syntheses were carried out on resins with 
functionalities of about 0.4 mmol g_i 
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2.4 Monitoring the progress of peptide synthesis. 
The 'final purity of a synthetic peptide depends upon 
the efficiency with which each residue is incorporated 
into the growing peptide chain. The likel hood of 
obtaining a high yield of the peptide can only be 
determined if some form of continual monitoring has 
been carried out. This is not easily achieved in a 
system in which the usual analytical and spectroscopic 
techniques are of limited value. 
Amino acid analysis can give important information 
regarding the composition of the resin-bound peptide, 
but is not rapidly available and is therefore of 
limited value in the monitoring of automated syntheses. 
The ninhydrin or Kaiser test, carried out under the 
conditions suggested by Kaiser and Colescott (147), was 
used to follow the progress of one of the syntheses 
necessary in the course of this work. The test was 
carried out on small resin samples removed after each 
coupling cycle and detected the presence of free amine 
groups on the resin. One disadvantage of this method is 
that it requires the abstraction of resin samples with 
a consequent loss of material. 
The use of the Fmoc protecting group allows the 
direct spectrometric monitoring of SPS since the U.V. 
spectra of the dibenzofulvene and dibenzofulvene-
piperidine adduct generated upon deprotection of the 
Fmoc group (Figure 2.2) are characteristic of 
conjugated aromatic systems, absorption occurring at 
300 nm, thus differentiating the soluble product of the 
deprotection reaction from the non-aromatic reagents 
used (piperidine and DMF) which do not absorb at this 
wavelength. Each deprotection mixture was therefore 
pumped through a u.v. detector, and the absorbance 
recorded on a chart recorder. Comparison of the areas 
of the peaks recorded for each residue allows an 
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evaluation of the progress of synthesis to be made 
The above procedure does not allow for corrective 
action to be taken if a severe failure in coupling is 
observed, but can be modified to allow specific 
couplings to be monitored. This can be achieved by the 
removal of a resin sample which, after thorough drying, 
can be deprotected in a specific volume of reagents and 
the absorbance of the resultant solution can recorded 
and compared with standardised values to allow 
quantification of the functionality of the Fmoc present 
on the resin. 
Comparison of the experimental value with the 
theoretical value for that stage of the synthesis, or 
with the value obtained after the coupling of the 
previous residue can then be used to determine the 
efficiency of the coupling. If this is not satisfactory 
further couplings can be carried out. 
This modified procedure was also used to calculate 
the loading of the first amino acid in a sequence onto 
the resin. 
2.5 Automa ted solid phase synthesis. 
The synthesis of peptides was carried out on the 
Applied Biosystems 430A automatic peptide synthesiser 
using resins preloaded with the C-terminal amino acid 
in the sequence as described previously. The overall 
cycle for each residue consisted of an N-terminal 
deprotection sequence, followed by the coupling cycle 
which was then followed by a capping cycle in which any 
unreacted amino termini were covalently blocked. 
Deprotection of the a-amino function of the residues 
was achieved in four stages. The resin-bound peptide 
was treated with a portion of piperidine in DMF for 5 
mm. and then washed. The u.v. absorbance of the 
Loading of first amino acid onto the resin 
0.5 mmol scale synthesis. 
1 
Removal of N protecting group (Fmoc) 
20% piperidine in DMF 
1X5min.,2X3min., iXimin. 
/ 
Cap unreacted amino groups. 
Ac20 / pyridine / DMF 6 mm. 
Monitor eluent by u.v. at 313 nm 
to determine coupling efficiency. 
/ 
Couple next amino acid 
Fmoc-AA-OH (2 mmol) + DIC (1 mmol) 45 mm. 
Fmoc-AA-OH (1 mmol) + DIC (1 mmol) + HOBT 
(1 mmol) 45 mm. 
Sample resin to check coupling 
efficiency. 
Last amino acid 
Base cleavage of Fmoc group. - 
Cleavage of the peptide from the resin, and 
side chain deprotection. 
Purification. 
Figure 2.10 
Peptide synthesis on the ABI 430 A. 
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combined -Filtrates at 314 nm was then recorded as 
described previously. Three more short deprotections 
were then carried out in the same manner. Most of the 
protection was generally removed in the first reaction. 
The resin was then thoroughly washed before the double 
couple cycle of the next residue was carried out. 
Permanent blocking of any unreacted amine groups was 
achieved by acetylation with acetic anhydride 
("capping"). Theoretically the final peptides obtained 
should not therefore contain deletion peptides, only 
truncated peptide sequences. 
The overall synthetic strategy used is outlined in 
Figure 2.10. 
2. 6 Determination of the problem areas in the synthesis 
of PreCoxIV. 
An initial synthesis of the peptide was carried out 
in order to determine which couplings within the 
sequence were liable to problems. 
The synthesis was monitored continuously by the 
spectroscopi c.method. previously described, although no 
manual monitoring was carried out. The efficiency of 
couplings was determined by comparison of the areas 
under the deprotection peaks for each of the residues. 
The system indicated that the amount of peptide on 
the resin had decreased after the the coupling of Leu 
24 to Leu 25. This was found to be a common occurrence 
for the first coupling in a sequence, and may arise 
from incomplete solvation of the resin. 
Small decreases in the amount of growing peptide 
chain present on the resin were observed after cycles 
6, 13 and 17 (Table 2.1). These were minor, however, 
compared to the drop of 25% observed after the coupling 
of Thr 15. 
Cycle number Residue 
Apparent drop in functionality 
of the peptide on the resin. 
1 Leu24 30% 
6 Leu 18 <5% 
11 Thrl5 25% 
13 Pro 13 8% 
17 11e8 <5% 
Table 2.1 
Analysis of the data indicated that an unusual 
phenomenon was observed for cycles 11 to 13. The amount 
of the fulvene released by the first deprotection 
reaction of the residues in question was significantly 
lower than for previous residues, and the amount 
released by the later deprotections was correspondingly 
larger. It is possible that the effect arose from 
steric hindrance which prevented the close association 
of the deprotection reagent with the peptide chain. If 
this was the case he same effect would be expected with 
the subsequent incoming activated amino 
acid, in which case the efficiency of the next c:ouoling 
would be lowered. Indeed the coupling of Pro 13 was 
accompanied by a slight decrease in the apparent 
functionality of the growing peptide chain on the 
resin. The observed effect decreased after the Pro 
cycle, however. 
The less efficient coupling of Ile B to Al-a 9 can 
probably be attributed to the fact that both residues 
are bulky and a degree of steri c hindrance could 
therefore be expected. However, the -fact that no 
decrease in efficiency was observed for Couplings 
between certain other pairs of bulky residues would 
appear to indicate that difficulties may arise from 
particular sequences of several amino acids rather than 
simply the coupling of specific pairs. 
2.7_ The. synthesis and purification of PreCoxlvusinq 
the Acm protection for the thiol_function of cysteine. 
The synthesis of the peptide was carried out on 0.5 
mmol scale and the efficiencies of the couplings with 
which problems were, on the basis of earlier data, to 
be expected were monitored manually. 
Although the coupling of Thr 15 to Arg 16 was found 
Remove N-terminal Fmoc protecting group. 
Cleave from the resin, and remove all but Acm protecting groups. * 
Gel filtration of the crude peptide. * 
Preparative HPLC to obtain a pure peptide. * 
- 	 Removal of Acm group. 




to have been quantitative, problems were encountered in 
the coupling of lie B to Arg 9. Spectroscopic analysis 
o-f the deprotection solution from a resin sample 
indicated that the functionality of the desired peptide 
on the resin was only 67% of the theoretical value 
expected at that stage, a drop 0-F 30% compared to the 
value obtained after the previous cycle. The residue 
was recoupled twice, but no increase in the overall 
efficiency o-f the coupling was observed and the 
synthesis was continued. No further major coupling 
reaction failures were observed. The overall 
deprotection and purification strategy used is 
illustrated in Figure 2.11. 
The N-terminal Fmoc group was removed by treatment of 
the resin-bound peptide with 20% piperidine in DMF and 
the peptide was subsequently cleaved from the resin by 
treatment with a solution a-f 95/. aqueous TFA containing 
anisole and ethylmethylsulphide as scavengers. 
The resultant lipophilic material was dissolved in a 
mixture of ammonium hydroxide and urea and applied to a 
G25 gel filtration column which was eluted with the 
aforementioned buffer. The peptide fraction obtained 
was dialysed several times against ammonium acetate 
solution and was subsequently lyophilised. However the 
total amount of peptidic material recovered from the 
column was only 16% of the total material applied. It 
was conjectured that the low recovery of material from 
the column was due to the poor solubility of the 
peptide in aqueous buffers, and that purification might 
be better achieved in a system in which the peptide 
could be dissolved in organic solvents. 
The peptide was there-Fore dissolved in a mixture of 
acetonitrile and water, and purified by preparative 
HFLC. Recovery of peptidic material from the HPLC 
columns was found to be higher (62% on each run) than 
Figure 2.12 
An analytical HPLC trace showing a coinjection of the two major 
components of the Acm peptide. 
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from gel -filtration columns. The peptide mixture was 
observed to contain two major components which were 
both isolated in the purification process (Figure 
2.12). Material A was observed by mass spectroscopy to 
possess a molecular ion at the expected value of 3060. 
Material B, however, exhibited a molecular ion at 3049, 
11 units less than the expected value. The material did 
not therefore consist of partially deprotected FreCox 
IV, although it was possible that the material was a 
partially protected truncated peptide. Amino acid 
analysis of the two peptides however indicated that the 
ratios of the N--terminal methionine to the other 
residues obtained for the two samples were similar. 
The amino acid analysis also indicated that material 
B appeared to contain one fewer serine residue than 
expected. However, the amino acid analysis of all 
PreCox IV samples was consistently low in serine, 
possibly dt..te to the fact that one of the serine 
residues is adjacent to the cysteine in the sequence, 
and there is evidence in the literature (148) that in 
such cases cyclisation of the two residues can occur 
during the hydrolysis required for amino acid analysis. 
N-Terminal sequencing was carried out on both 
materials. The sequences obtained for both components 
matched the correct sequence, the only differences 
occurring in the cycle corresponding to the cysteine 
residue. Cysteine residues are usually derivatised 
before sequencing, however this was not carried in this 
case since the cysteine was protected by an Acm group. 
The phenylthiohydantoin derivatives isolated in the 
cysteine cycles of the Edman degradation of the two 
peptides, when analysed by HPLC, eluted from the column 
at different solvent compositions (Figure 2.13), 
indicating that they were not identical. Thus it would 
appear that some form of modification had occurred at 
AMINO tlCITJ : r 
ftita data 
 




HPLC traces from the cysteine cycles of the Edman degradation of 
The Acm peptide with a molecular ion of 3060. 
The Acm peptide with a molecular ion of 3049. 
The shaded peaks are species with retention times not corresponding 
to any of the standard amino acids. 
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the cysteine residue of material B. 
In an attempt to isolate more of the correct material 
it was decided to use thioanisole as a scavenger since 
this is reported to prevent oxidation of methionine 
residues (149) and to accelerate the deprotection of 
the F'mc group from arginine (15O) Analysis of the 
crude product obtained from the reaction indicated that 
the major product from the reaction was material B The 
reaction was repeated several times under identical 
conditions and the composition of the product was found 
to vary, although the major product was invariably 
material B 
Experience of other workers (135-137) has shown that 
modification of Acm and StB u protected cysteine can 
occur in the presence of 57. thioanisole. However, on 
repetition of the anisole scavenged TFA cleavage of the 
peptide, the same inconsistencies in the product 
composition were observed, and the major component of 
cleavage remained the incorrect peptide (material B). 
It was therefore decided to abandon the purification of 
the Acm peptide and to repeat the synthesis of the 
peptide using the alternative S -- Bu protecting group 
for cysteine. 
2.8Synthesis and purification of the Pr eCox IVpeptide 
usin the SBuprotectjg grop for cystei ne. 
The synthesis of this peptide was carried out using 
the synthetic cycles previously described, initially on 
a 0.5 mmol scale which was monitored spectroscopically. 
A subsequent synthesis on a 0.25 mmol scale, monitored 
by the qualitative ninhydrin test, was later required. 
Both syntheses appeared to proceed satisfactorily. 
Initially it was decided to purifiy the peptide with 
its x-amino function protected, allowing easy detection 
of the peptide due to the chromophoric properties of 
Remove N-terminal protecting group. 




HPLC or FPLC purification. 
Removal of StBu  protecting group. 
Removal of StBu  protecting group. 
if 
Gel filtration. 
HPLC or FPLC purification. 




Overall deprotection and purification plan. 
the Fmoc group. Cleavage from the resin and the 
deprotection of the side chain groups was therefore 
carried out. As a result of the problems encountered 
when using thioanisole as a scavenger for the 
deprotection of the Acm protected peptide, it was 
decided that anisole be used as a scavenger, 
supplemented with ethylmethylsuiphide to prevent the 
oxidation and alkylation of methionine. 
The partially protected peptide obtained was very 
lipophilic, and could only be dissolved in glacial 
acetic acid. The material was subsequently diluted to 
30% acetic acid in water and purified by gel 
filtration, however only 36% of the material was 
recovered from the gel column. 
Analysis of the resultant material indicated the 
presence of two major components. Isolation of the two 
components was attempted by preparative HPI.C, but pure 
samples were not obtained, and recovery of material 
from the HF'LC columns was very low. This appeared to be 
due to the lipophilicity of the peptide with both 
protecting groups intact and it was decided that 
removal of the Fmoc group would probably improve the 
solubility of the peptide and aid purification. A new 
purification strategy was therefore implemented (Scheme 
A, Figure 2.14). 
A sample of the resin-bound peptide was treated with 
piperidine in DMF to remove the Emoc group and 
subsequent TFA treatment of the resin-bound product 
afforded the crude peptide with only the cysteine 
protecting group intact. Gel filtration of the material 
produced two fractions, the first to elute from the 
column (material C) later being shown by HPLC analysis 
to contain the larger amount of the major peptidic 
component of the peptide mixture. The second fraction 
(material D) contained very little of this material, 
Deprotection of N-termnal Fmoc group. 
TFA cleavage and side chain deprotection. 
Gel filtration of crude peptide. 




containing two major peptide components. 
Anion-exchange 
I FPLC. 	 \ Cation exchange 
FPLC. 
Separation not achieved. 
Figure 2.15 
The HPLC analysis of material C indicated that the 
material consisted of two major components and many 
minor ones. Preparative HPLC was carried out 
on the material in an attempt to isolate the two major 
components for characterisation. However, the two 
compounds eluted from the column in eluents that 
differed in acetonitrile concentration by only 27., and 
the two fractions isolated both contained the two 
components. The fractions were therefore combined 
(material E) and attempts were made to achieve the 
separation of the two compounds by ion exchange 
chromatography using the method of Fast Protein Liquid 
Chromatography (FPLC) on anion or cation exchange 
columns. 
A portion of the sample was dissolved with difficulty 
in triethanolamine buffer and an ion exchange gradient 
was run on an anion exchange column (Mono 0), The 
eluent from the column was monitored at 214 nm, but no 
peptidic material was observed elute from the column, 
suggesting that the peptidic material had precipitated 
out either on the ion exchange column or in one of the 
filters in the FPLC system. A similar attempt to purify 
a portion of material E by cation exchange 
chromatography in malonic acid buffer failed for the 
same reason. (A summary of the purification steps is 
shown in Figure 2.15). 
Since the difficulties encountered in the 
purification of the peptide appeared to be due to the 
lipophilicity and resultant low solubility of the 
peptides in aqueous buffers, an alternative approach in 
which all the protecting groups were removed prior to 
chromatography was evaluated. It was hoped that the 
removal of the lipophilic SBu group could decrease 
the lipophilicity of the peptide, rendering it more 
soluble in solvents suitable for chromatography. 
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Having decided to remove the cysteine protecting group 
it was necessary to determine the optimal experimental 
conditions to achieve this. Protection of the thiol 
function of cysteine with the tert.— butyithiol group 
has not been employed extensively in peptide synthesis, 
although deprotection of the group was reportedly 
possible using a variety of reagents. Wuensch et al 
(151) reported the synthesis of somatostatin using the 
S-Bu group for the protection of cysteine. The 
conditions used by these workers for the removal of the 
cysteine protecting group involved stirring the peptide 
with tri-n-butylphosphine in 80% acetic acid for a 
period of six days. While no modification or 
racemisation of the product was reported, these 
conditions are relatively harsh and it should be noted 
that the peptide synthesised did not contain a 
methionine residue. In addition, S-alkylthio 
derivatives of N-acyl or N-urethane protected amino 
acids are known to undergo disulphide exchange in 
acidic conditions, although this has been shown to 
occur to only a limited extent for the tert.butyl 
derivatives (152). 
The above conditions also correspond to the Mukaiyama 
conditions for the formation of a peptide bond (153) 
and thus the presence of amino functions could lead to 
the formation of acetylated peptides. Although the 
above workers took measures to eliminate such side 
reactions occurring, carrying out the reaction in the 
presence of an excess of ammonium acetate, and indeed 
the formation of acetylated products was not reported, 
we decided to investigate alternative milder cleavage 
conditions which presented a lower risk of side 
reactions. 
We there-fore decided to determine suitable solvent 
systems for the deprotection of the sulphydryl 
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protecting group using tri-n-butylphosphine as the 
reducing agent. A sample of HCys(StBu)OH was stirred 
with a 10-fold excess of tri-n-butylphosphine in the 
solvent systems and the progress of the reactions was 
monitored by tic. 
Ruegg and Rudinger (154) reported the reductive 
cleavage of disulphides by tributyiphosphine in a 11 
mixture of 0.511 sodium bicarbonate and n-propanol, and 
this solvent system was evaluated for the deprotection 
of the SBu group. The other solvents systems 
investigated were so% acetic acid, and a 11 mixture of 
dioxan and water. 
The sole product formed from the reaction in 50 
acetic acid was the dimer, cystine, and the reaction 
was slow, being only 50% complete within 90 minutes and 
still incomplete within four hours as estimated from 
tic. 
The reaction in both the other solvent systems was 
fast, being complete in both cases within 30 mm. The 
product formed was monomeric cystei ne, confirmed by the 
R.F values and the -fact that development of the tic's 
with sodium nitroprusside spray indicated that the 
compound contained a free thiol group. 
The presence of small amounts of an additional 
product with a low R.c was observed. Comparison of R-f 
values indicated that the byproduct was not cystine or 
cysteic acid. The compound gave a positive reaction 
with sodium nitroprusside spray, but a negative 
reaction with Mary's reagent (4,4'-bis-dimethylamino-
benhydrol) used to detect carboxylic acids. It is 
possible that the byproduct is therefore some form of 
complex between the free amino acid and 
tributylphosphine. However since the impurity was 
present in only very small amounts the dioxan / water 
mixture was chosen as suitable solvent system. 
Deprotect in n-Bu 3P / dioxan 
4 
Dialyse into 6 M urea 
4 
Dialyse successively out of urea into urea-free buffer 
$1 
Concentrate solution * 
Purify by ion-exchange chromatography 
Dialyse into ammonium acetate 
Lyophilise 
Figure 2.16 
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A portion of material E (Figure 2.15) was therefore 
treated to the protocol shown in Figure 2.1.. The 
peptide was stirred with the phosphine/dioxan/water 
mixture until a clear solution was obtained. It was not 
possible to monitor the progress of the reaction 
directly using Ellman's test, since the phosphine 
present in the reaction mixture also reduced the 
reagent involved. An attempt was made to extract the 
phosphine from a portion of the reaction mixture by 
extraction into ethylacetate, but the peptide also 
showed a tendancy to partition into the organic layer.  
Dialysis into a concentrated solution of urea with 
subsequent dialysis into succesively lower 
concentrations of urea is a common method used for 
denaturing and then refolding proteins (155) , and we 
decided to follow this approach since this would 
potentially offer the advantage of removing the 
phosphine and dioxan from the sample at the same time. 
After dialysis into a urea-free buffer was achieved the 
sample was concentrated, and dialysed into a buffer -
suitable for ion exchange chromatography. The sample 
was purified on the FPLC system and the fractions 
obtained were dialysed into ammonium acetate and 
lyophilised. 
However, the amount of material obtained from the 
lyophilisation of the fractions (770 mg) far exceeded 
the amount expected from the reaction (10 mg) and 
analysis of the fractions by HF'LC indicated that none 
of the desired peptide was present. Since the 
deprotection of the peptide could not be achieved using 
the dioxan/water mixture and an alternative method was 
sought. 
Wuensch et al (15) published the synthesis of a 
fragment of human IgGI using the SE:u protecting  
group for cysteine. Cleavage of the cysteine protecting 
(a) 	 (b) 
Figure 2.17 
Analytical HPLC traces showing the PreCox IV peptide 
95% pure containing a small amount of the dimer 
and 
Purified for NMR. 
- 42 - 
group was achieved using tri-n-butylphosphine in a 
solution of 957. trifluoroethanol (TFE) in 3 h The 
reaction mixture was concentrated in i.'acuo and the 
peptide precipitated by the addition of ethyl acetate 
This method was applied to a sample of PreCox IV. The 
crude peptide was soluble in the solution, and a 
deprotection study indicated that the protecting group 
was completely removed within 1 hAnalysis of the free 
thiol content of the product (material F) by Ellman's 
test (157), using the 2,2'-dithiopyridine reagent (158) 
confirmed that the deprotection had been successful. 
Material F was not very soluble in water, but was 
soluble in mixtures of acetonitrile and water, and 
could be furthur purified by preparative HFLC. 
The optimum gradient for the HPL..0 purification was 
determined and several succesive preparative HPLC 
operations had to be carried out before a high degree 
of purity was obtained. A sample of the peptide that 
appeared on the basis of HPLC analysis to be 
approximately 95% pure was obtained (material 6, Figure 
2.17). The sample was characterised by amino acid 
analysis, N-terminal sequencing, E.l lman 's test and mass 
spectrometry and the data obtained was consistant with 
that of the desired monomeric peptide. 
Further experiments indicated that gel chromatography 
of the product obtained from the SEcu deprotection 
resulted in the separation of short truncated peptides 
and scavengers from the larger peptides, rendering the 
larger peptides more water soluble and making 
purification by HPLC easier. The optimised procedure 
for the purification of PreCox IV is shown in Figure 
2.18. The minor impurity observed in material S was 
later shown to be the dimer and this could be reduced 
by treatment of the solution with p-mercaptoethanol 
prior to HFLC. 
Deprotect Fmoc group. 
20% piperidine in DMF, 15 mm. 
TFA cleavage 
95% TFA, anisole, ethylmethylsuiphide, 4 h. 
it 
StBu  cleavage 
95% TFE, n-Bu phosphine, 1 h. 
Gel filtration. 
30% acetic acid, Sephadex G25 
Preparative HPLC 
20 to 40% acetonitrile in water (0.1 % TFA) over 20 mm. 
Several operations necessary. 
Figure 2.18 
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Having obtained satisfactory protocols for the 
synthesis, deprotection and purification of the title 
peptide, it was now possible to undertake with 
confidence a further synthesis of the peptide necessary 
to produce larger amounts. 
A second synthesis of the peptide was carried out as 
described above and the optimised purification strategy 
was followed. After cleavage, deprotect:Lon and five 
series of preparative HPLC runs, a pure sample of the 
peptide (132 mg) was obtained from 810 mg of the resin 
bound peptide, representing a yield of 28% based on 
the theoretical substitution of the resin after the 
final coupling This sample proved sufficient to carry 
out the necessary structural work 









MLSLRQSIRFFKPATRTLCSSRYLL wild type 
MQSIRFFKPATRTLCSSRYLL -L 2-5 
MPATRTLCSSRYLL -L 2-12 
MSSRYLL -L 2-19 
MTSMLSLRQSIRFFKPATRTLCSSRYLL +A 3 
MLSLRQSIRFPATRTLCSSRYLL 	-L 11,12 
Figure 3.1 
Mutant Cox IV prepeptides. 
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OONFORMATIONL_N(LYSIS OF TARGETING PEPTIDES.. 
3.1 Introduction. 
The decision to synthesise chemically the targeting 
presequence of subunit IV of the yeast mitochondrial 
protein cytochrome oxidase for furthur structural 
analysis, was based on the known targeting and physical 
properties of the protein. 
Techniques of molecular biology have enabled analysis 
of the "minimal regions of the above presequence 
those that are essential for targeting, to be 
determined by allowing the construction of modified 
forms of the presequence attached to the N-terminus of 
a protein that is not normally imported into the 
mitochondrion. Thus Hurt and Schatz (159) have shown 
that the twelve N-terminal residues of the presequence 
are sufficient to direct attached dihydrofolate 
reductase (DHFF<) into the mitochondrion, and that 
deletions in the C--terminal region abolish proteolytic: 
processing to the mature form but leave the matrix-
targeting function of the presequence intact. 
series of modified forms of the precursor protein 
were prepared (10) in _which various segments of the 
presequence had been deleted (Figure 3.1). The results 
indicated that deletion of as few as four residues from 
the N-terminal portion of the presequence abolished its 
matrix-tarqeting function. 
Incubation of the deletion peptides with an extract 
from the mitochondrial matrix containing the soluble 
processing-peptidase indicated that the 2-5 deletion 
significantly inhibited the processing of the protein 
to its mature form. Thus it would appear that the 
initial targeting properties of the presequence are 
conferred by its N-terminal portion, but that the 
processing of the protein to its mature form requires 
information from both the C- and N-terminal portions of 
MLSLRQSIRFFKPAT 
	 p15 
MLSLRQSIRFFKPATRTLCSSRYLL 	 p25 
MLSLRQSIRFFKPATRThCSSRYLLQQKPVVKTA 	p33 
Figure 3.2 
Forms of the Cox IV wild type presequence. 
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the presequence. 
As has been described earlier (Chapter 1, Section 
1.6.3) the targeting function of presequences has been 
proposed to arise from their ability to form 
amphiphilic x-helices. As a consequence such peptides 
would be expected to be surface seeking. 
Roise et a! (120) analysed three chemically 
synthesised forms of the PreCox IV peptide, p15, p25 
and p33 (Figure 3.2) for surface activity. When 
injected into a clean air-water interface of constant 
area, all three peptides shoved relatively high surface 
pressures indicating that the peptide accumulated at 
the water-air interface resulting in an increase in the 
surface tension of the solution. In the presence of a 
monolayer of mitochondrial phospholipids this effect 
as more pronounced, with even higher surface pressures 
being observed, suggesting that the peptides were not 
merely surface seeking, but involved in direct 
interactions with the lipids. These workers also 
demonstrated that the Cox IV prepeptides were able to 
disrupt unilamellar phosphlipid vesicles resulting in 
the release of trapped dye from the vesicles. 
A more detailed study by Tamm (161) concluded that 
the p25 peptide showed relatively high surface seeking 
tendencies compared to some cardiotoxins, and that 
incorporation of p25 into phospholipid monolayers was 
significant and was enhanced in the presence of 
negatively charged phospholipids in which mitochondrial 
phospholipids are enriched. 
Roise et a! (120) also showed that the presequence 
peptides were able to disrupt unilamellar phospholipid 
vesicles and that disruption was most rapid for 
vesicles containing a diffusion potential similar to 
that of mitochondria i.e. negative inside. 
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Circular dichroism (CD) measures the optical activity 
of asymmetric molecules in solution, making use of the 
unequal absorption of left- and right-handed circularly 
polarised light. The technique can be used to obtain 
structural information about peptides and proteins due 
to the fact that certain structural elements show 
strong characteristic spectra The far-uv (amide) 
region of the CD spectrum 	170-250 nm) is dominated 
by contributions from the peptide bonds in the protein, 
whereas the near-uv region of the spectrum contains 
contributions from the aromatic residues and disulphide 
bridges Structural information gained from CD spectra 
is therefore obtained from the amide region of the 
spectrum. 
The element of structure that shows the strongest CD 
spectrum is the a-helix Such spectra are highly 
characteristic, showing a double minimum with the 
minima at >. 20x)-206 and x 222 nm, 
The CD spectrum of a fl-sheet is relatively weak 
being dependant on the length and spatial arrangement 
of the strands, and characteristically shows a single 
minimum. Estimates of n-sheet content of proteins from 
CD spectra are considerably less reliable than those 
for x-helices. 
Conformational analysis by CD of the 25 residue 
chemically synthesised Cox IV prepeptide by Raise (120) 
indicated that although the peptide showed little 
secondary structure in aqueous solvents a 
conformational change in the peptide occurred in the 
presence of detergent micelles, characterised by marked 
-helicity.  
A study (162) using various different types of 
phospholipids indicated that the peptide might adopt 
different structures in different types of membrane 
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environments.. While the -halicity observed in the 
presence of natively charged phospholipids was 
confirmed, in this study the peptide appeared to adopt 
an aperiodic, unidentified structure in the presence of 
bilayers of the zwitterionic lipid phosphatidylc:ho].ine, 
and partially helical structures were observed in the 
presence of bilayers of cardiolipin, mitochondrial 
lipid extracts and mixtures of synthetic 
phosphatidylcholina and phosphatidylglycero]... 
A subsequent study by Roise et a.! (163) 
investigated the relationship between the observed 
elements of secondary structure of artificial synthetic: 
peptides consisting of only three types of amino acid 
specifically designed on the basis of helical plots to 
have varying tendencies to adopt arnphipi 1 ic -helices, 
and the ability of these sequences to target fused 
proteins into the mitochondrion Analysis of synthetic 
presequance peptides by CD indicated  that. active 
artificial sequences showed pronounced secondary 
structure in the presence of detergent micelles, 
whereas the artificial sequences unable to target fused 
proteins to the mitochondrion showed little or no 
Secondary structure under identical conditions. 
A form of the PreCox IV preseouence in which the Phe 
and Lys residues at positions It and :12 were deleted 
(163) showed a significant decrease in targeting 
efficiency compared to the wild typed The CD spectrum 
of the corresponding synthetic peptide (163) indicated 
little secondary structure in the presence of detergent 
micelles.  
As CD was the only method to have been extensively 
used previously in the con-formational analysis of 
targeting peptides it was decided to repeat the CD 
studies on the purified PreCox IV peptide.. 









.130.0 	210.0 	230.0. 	2E0.0 
LJ2c'elength (nm) 
ID 	: pre Cox IV 10mM Na Hepes, 150mM NaCI 
o 	: pre Cox IV 10mM Na Hepes, 150mM NaCl, 20mM sos 
Figure 3.3 
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presence and absence of sodium dodecylsuiphate (SDS) 
micelles were measured The results (Figures 3.3 and 
34) show that in aqueous solution the peptide adopts a 
largely  random coil structure, whereas the presence of 
detergent micelles appears to induce pronounced 
secondary structure. 
Buffer Contin Chen 
helix 	 13-sheet helix 
0.15 M NaCI 8.5% 38.5% - 
0.15 M NaCl 
30°! 96.9% 20.8% 2OmMSDS 
0.3 M NaCl - 53.5% - 
0.3 M NaCl 1.3% 69.6% 19.4% 
10 	m SDS 
Figure 3.4 
Estimates of helix content of PreCox IV in buffers at a 
concentration of 0.04 mg/ ml. 
Various methods for the estimation of helix or sheet 
content of proteins from CD data have been devised 
The method currently most extensively used is that of 
Chen (164) , in which the molar ellipticity of the- 
protein at > 222 nm is used to calculate percentage 
helicity. In addition to estimating helix content by 
the method of Chen, we used the Coritir, programm, 
which is based on the method developed by Provencher 
and Glockner (165) , and uses a linear combination of CD 
spectra of reference compounds with k:non secondary 
structure for the direct analysis of the CD spectrum of 
a protein by curve fitting. 
nalysis of the spectra of the PreCox IV peptide by 
200.0. 220.0 	240.0 	250.0 
Wavelength (nm)\ 
pre Cox IV 20mM Na phosphate 0% TFE 
pre Cox IV 20mM Na phosphate 25%TFE 
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the Coritir, curve fitting program indicated an o-helix 
content of 37 and a n-sheet content of 97% in the 
presence of SDS micelles. Evaluation of the helix 
content by the method of Chen indicated an a-helix 
content of 21% as compared with the 40-50% quoted by 
Roise et al. (120). Repeating the experiment under 
conditions identical to those used by Raise, indicated 
that the cx-helix content was still only around 20% as 
calculated by the Chen method (Figure 3.4). 
The results obtained do indicate that the peptide 
undergoes a structural change in the presence of the 
surface-modelling micelles, however the high a-helix 
content obtained by previous workers was not observed. 
Since NMR analysis of the peptide structure in the 
presence of SDS micelles or phosphol ipi d vesicles is 
not practicable using 1 H NMR, CD experiments were 
therefore carried out in aqueous mixtures of the 
structure-inducing solvent 2,2,2--trifluoroethanoi (TFE) 
to ascertain that the conformational changes observed 
in SDS micelles could he mimicked. 
The CD spectra of the peptide in solvents containing 
increasing proportions of TFE were measured,, and the 
results (Figure 3.5) show a pronounced change in the 
spectra upon the addition of TFE to the solvent. The 
spectrum of the peptide in aqueous buffers is typical 
of a random coil conformation whereas in 30% TFE a 
spectrum characterisitic of an -helix is observed. The 
amount of x-helix present was observed to reach a 
maximum for solutions containing about 50% TFE, 
solutions containing higher proportions of TFE showed 
no significant increase in helix content. 
The CD spectra of the peptide in TFE using a variety 
of buffers at different pH values were recorded (Figure 
3.6) and the results indicated that helix content was 
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Figure 3.7• 
The superimposition of the CD traces of PreCox IV in 50% TFE/F120 
at 0.04, 0.134, 0.23, 0.345 and 0.575 mg m11. 
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contents were observed as the ionic strength of the 
buffer was increased, 
Buffer % TEE CONTIN CHEN 
helix  
citrate 0 3.3 PH 3.9 - 
30 4.6 11.1 
50 - 11.7 
70 7.2 17.3 
phosphate CO 2.8 4.8 
PEI 7.0 
25 3.3 12.6 
50 25.2 23.7 
Tris 0 4.4 1.8 
PEE 25 8.9 10.6 
40 107 17.8 
50 14.0 17.8 
60 20.6 21.4 
Fiure 3.6 
Estimates of helix content of PreCox IV in different buffers 
at a concentration of 0.04 mgI ml. 
Experiments were also carried out to determine 
whether the helix content was dependent upon the 
concentration of the peptide. Although the Cotir, 
estimates of helix content vary, the values obtained by 
the Chen method are consistent, and when the spectra 
obtained for the different concentrations were 
superimposed on each other (Figure 37) it was apparent 
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that the helix content remained constant over a ten 
fold concentration range.. 
The absence of concentration dependence of the CD 
spectrum indicates that the peptide does not aggregate 
at the concentration range used For the CD analysis. On 
the basis of these results, NMR analysis was carried 
out in 50% doTFE/H:O at pH 3.9. 
3.3 Conformational analysis bv Nuclear a-j.a~~ 
Resonance.. 
Two-dimensional (2D) NMR has become a very useful 
tool in the determination of the secondary structure of 
peptides and proteins in sol uti on. 2D-correl ated 
spectroscopy (COSY) (166, 167) allows the detection of 
through-bond (scalar) connecti vi ties, which allow 
assignment of the resonances in the 'H spectrum, and 
2D-nuclear Overhauser effect spectroscopy (NOESY) (168, 
169) detects pairs of protons that are spatially close 
together. Data obtained from NOESY spectra can 
therefore be used in conjunction with other data such 
as proton exchange rates and coupling constants, to 
gain an insight into the secondary structure of 
peptides and proteins. 
The first step in the conformational analysis of a 
peptide by 'H NMR is the complete assignment of the 
resonances in the spectrum. In the case of FreCox IV 
this was achieved by a combination of total correlation 
spectroscopy (TOCSY) (170, 171) and NOESY 
connectivities as outlined by LAJuthr:ich (172).. 
While, on the basis of the CD experiments , it seemed 
unlikely that any aggregation of the peptide occurred 
in concentrations up to 0.6 mg m1' 	M , it was 
prudent to determine whether aggregation occurred under 
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Figure 3.8 
The 1D- 1H Nmr spectrum of PreCox IV in 50% d2-TFEIH20 at 
(a) 20, (b) 30 and (c) 40°C. 
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achieved by a comparison of the 1D 1 H spectra 
obtained on solutions of the peptide at varying 
concentrations (5 mM and 2.5 mM) and temperatures (293 
to 313 K). Very few resonances were observed to change 
chemical shift values under the different conditions 
(Figure 3.8) and the linewidths at the higher 
temperatures did not appear to be significantly 
narrower. It was therefore concluded that aggregation 
does not occur. 
3.3.1 Analysis of spin systems. 
The PreCox IV peptide contains five residues with 
unique spin systems, four residues with the AMX spin 
systems, and two pairs of residues with identical spin 







systems. A3B3MPTX Leu-2,4,18,24,25 
A3MPT(B3)X Ile-8 
A2(F2T2)MPX Lys-12 




AM(PT)X spin Met-1 
systems: Gln-6 
A2(T2)MPX spin Arg-5,9,16,22 
systems: Pro 13 
Table 3.1 
Spin systems in the PreCox IV peptide. 
- 
The use of TOCSY spectroscopy aids the assignment of 
proton resonances to residue types, since it correlates 
a proton to all the other protons within the same spin 
system, and each spin system has a particular pattern 
of correlations. Its use can also be helpful in the 
assignment of multiple copies of amino acids, since 
chemical shift dispersion of aCH resonances usually 
occurs even if side chain resonances are degenerate. 
Although the PreCox IV peptide contains multiple 
copies of Arg, Ser, Phe and Thr, the assignment of its 
'H-NMR spectrum was simplified by the presence of 
many unique residues. Assignment of the correlated sets 
of resonances to residue types was made on the basis of 
spin system type, aided in appropriate cases by the 
comparison of chemical shifts with random coil chemical 
shift data (172). 
Identification of the 1 H resonances of the Pro-13 
residue was the point from which our assignment was 
started. The spin system (A(T&MPX) was clearly 
defined in the TOCSY spectrum and could be 
distinguished from the identical Arg spin systems by 
the fact that the 6 protons of the Pro residue 
resonated at higher frequency than the 6 protons of the 
Arg residues. 
The Ile-8 residue resonances were distinguished from 
those of the Leu residues by its spin system. Although 
correlations from side chain to side chain protons were 
obscured by degeneracy, correlations from the CH to 
all side chain protons were readily identified in the 
TOCSY spectra. Correlations from the p and 6 protons 
of the side chain to the amide NH were observed and 
thus all the protons in the spin system could be 
assigned. 
The methyl resonance of Ala-14 was initially 
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at 1.37 ppm. The aCH and NH resonances were then 
identified by connectivities observed in the TOCSY 
spectrum. 
The Lys-12 residue was identified from its unique 
spin system (Figure 3.9). Connectivities between the 
protons in the spin system were well defined, 
correlations being observed from the cxCH and the NH to 
all the side chain protons. 
The identical spin systems of Gln-6 and Met-1 were 
assigned by comparison of the chemical shifts observed 
with random coil data. The random coil V protons of Met 
occur at lower field than those of Gin and the 
assignment of the resonances was made on this basis. 
The assignments were later confirmed by sequential 
analysis from the NOESY spectrum. 
Correlations from the Met aCH to p and V protons were 
observed and the E methyl group was identified from the 
1D spectrum. No correlations were observed from the 
side chain protons to any peak in the NH region. 
Full correlations were observed between the NH, xCH 
and p protons of the Gin residue. 
.-The ' methyl groups of the two Thr residues (15 and 
17) appeared degenerate as did the a protons of the two 
residues. However, two amide protons correlated to the 
degenerate cxCH and methyl resonances and the two Thr 
residues could therefore be fully assigned. 
Assignments for the resonances of the four Arg 
residues was possible due to the chemical shift 
dispersion of their a and 6 protons (Figure 3.9), since 
the chemical shifts of the p and ' protons of the four 
residues appeared degenerate. Complete assignment of 
the four residues (A-D) was possible since correlations 
between their amide resonances and a and side chain 
protons were observed. The four residues appeared to be 
















The fingerprint region of the TOCSY spectrum of PreCox P/ 
in 50% d2-TFE / H.,O, showing iniraresidue aCH-NH correlations. 
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residues of each type having very similar chemical 
shift values. Thus the four residues were distinguished 
but not sequentially assigned. 
Although the side chain protons of the Leu residues 
were obscured by degeneracy, chemical shift dispersion 
was observed for both aCH and NH protons which allowed 
the complete assignment of the-resonances for the 
protons in the five residues (A-E). Correlations 
between three NH resonances and resonances at chemical 
shift values characterstic of the side chain protons of 
the leucine spin system were observed (Figure 3.10). 
8.4 	 8.2 	 8.8 	 7.3 	 7.6 	 7.4 
F (pp. 
Figure 3.10 
Showing the chemical shift dispersion of the amide protons 
of the leucine residues. 
Analysis of the fingerprint region of the TOCSY 
spectrum (Figure 3.11), in which correlations between 
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Regions of the NOESY spectrum of 
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same residues. 
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cxCH and amide protons are observed, indicated the 
presence of four cross peaks corresponding to Leu 
residues. It was concluded that two of the Leu residues 
possessed degenerate aCH and NH resonances, and as one 
of the peaks appeared more intense than the others, it 
was tentatively assigned as the peak corresponding to 
two residues.. This assignment was later confirmed by 
sequential analysis.. 
Separation of the four AMX type spin systems did not 
prove straightforward. The four Ser residues were 
identified by the higher frequency positions of their 
proton resonances. However the residual water peak 
obscured the aCH resonances of two of the residues and 
the chemical shifts of the p protons of one residue 
could not be determined. Analysis of the NOESY spectrum 
of the peptide did, however, allow the assignment of 
these resonances (see section 3.3.2). 
The p protons of the other AMX spin systems were 
easily located in the spectrum, occurring at lower 
frequency than the serine p protons but at higher 
frequency than the protons in aliphatic side chains 
(Figure 3.12). The aromatic resonances of the Tyr 
residue were readily identified as doublets and the 
aromatic resonances of the two Phe residues appeared 
degenerate. 
Complete assignment of the aromatic residues was 
possible due to nOe's observed between their p protons 
and protons in the aromatic rings (Figure 3.12) 
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3.3.2 Sequential Assignment of PreCox IV. 
The intraresidue nOe correlations most commonly 
observed and used for sequencing are those between the 
or p protons of a residue and the amide of the next 
residue in the sequence Ed.(i,i+1) and d D (i,i+1)3, 
or between the amide protons of consecutive residues 
(dN,(i ,i+1) 
Correlations corresponding to d.r.'s are observed in 
the fingerprint region of the two dimensional spectra. 
The number of cross peaks observed in the TOCSY 
spectrum of the PreCox IV peptide was significantly 
lower than the number observed in the NOESY spectrum of 
the same sample, indicating that a large number of 
interresidue correlations were observed. 
The sequential analysis was started from the residue 
assigned as Gln-6 (Figure 3.13), the first unique 
residue in the sequence. In addition to the d.(i,i) 
correlation, an additional cross peak was observed 
between the resonances of the aCH of the Gin residue 
and an amide proton at 8.08 ppm, corresponding to the 
resonance of the amide proton of one of the serine 
residues (Ser-B) Thus the observation of the 
d(i,i+1) connectivity between Gln-6 and Ser-B 
confirmed any ambiguity in the assignment of the Gln 
and Met residues, since Met-1 is followed in the 
peptide sequence by a Leu residue, and enabled Ser-B to 
be assigned as Ser-7. 
The assignment of Ser-B was confirmed by the 
observation of a d.r(j,j+1) connectivity between Ser-
B and lie-S which is another unique residue in the 
sequence. 
The aCH of Ile-8 correlated to a resonance at 7..62 
ppm. Two residues possessed an NH resonance at this 
frequency, Leu-C and Arg-B. The residue adjacent to the 
only lie residue in the peptide sequence is Arg, and 
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thus Arg-B was identified as Arg-9. This was again 
confirmed by the presence of a d(i,i+1) connectivity 
between Arg-B and Phe-B, which was therefore assigned 
as Phe-10 and as a result Phe-A had to be Phe-11. 
A correlation between the aCH of Phe-10 and the NH of 
Phe-11 was tentatively assigned, but no correlations 
from Phe-11 to Lys-12 were observed. Due to the absence 
of an aNH in the Pro residue the sequential assignment 
terminated at this stage. 
Working backwards in the sequence from the unique Gln 
allowed the sequencing of the extreme N-terminal. A 
connectivity was observed between the aCH of Arg-
A and the NH of Gln-6 allowing the assignment of Arg-A 
as Arg-5. 
Similar sequential correlations also allowed the 
assignment of Leu-E as Leu-4, Ser-A as Ser-3 and Leu-D 
as Leu-2. A correlation between the NH of Leu-2 and the 
CH of Met was tentatively assigned. Thus we had been 
able to follow the sequence through from Met-1 to Phe-
10 (11). 
A d 	was observed between the xCH of Arg-C and the 
NH of Thr-B and between the NH of Arg-C and the xCH of 
Thr-A. Since the peptide sequence containing the two 
Thr residues is Thr Arg Thr, Thr-A was assigned as Thr-
15, Arg-C as Arg-16 and Thr-B as Thr-17. 
By elimination, the one remaining unassigned Arg 
residue had to be Arg-22. 
There remained the two unassigned Ser residues which 
occur at positions 20 and 21 in the sequence. The 
uCH/NH intraresidue correlation of both residues were 
observed in the spectrum and an additional correlation 
between the aCH of Ser-D and the NH of Ser-C was 
observed thus allowing Ser D to be assigned as Ser-20 
and Ser-C as Ser-21. 
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Figure 3.14 
The NH-NH region of the NOESY (200ms) spectrum of PreCox IV 
in 50% d2-TFEIH20 at 300  C, showing the correlations observed between 
the amide protons of adjacent residues. 
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connectivity was observed between the aCH of Leu-C and 
the NH of Leu A/B. The sequence LeuLeu occurs only once 
in the peptide thus resulting in the assignment of Leu-
C as Leu-24. The two degenerate Leu residues (A and B) 
were therefore Leu-18 and Leu-25. A d.N connectivity 
was also observed between Tyr-23 and Leu-C, confirming 
its assignment as Leu-24. 
Having completed the sequential assignment of the 
peptide on the basis of aN (i,i+1) correlations, the 
NOESY data was then searched for d,ir..i(i,j+1) and 
d(i ,i+l) correlations to confirm the sequential 
assignment. 
The NH-NH region of the NOESY spectrum was examined 
for correlations between the backbone amide protons of 
sequential residues in the peptide (Figure 3.14). The 
sequential assignment of the fifteen cross peaks 
observed was consistent with the sequential assignment 
previously obtained, the correlations being almost 
complete for the N-terminal portion of the peptide. 
The NOESY spectrum was also examined for correlations 
between the p protons of a residue and the amide proton 
of the next residue in the sequence. The detection of 
ten such correlations confirmed the sequential 	- 
assignment made, although again these correlations were 
prevalent for the N-terminal portion of the peptide. 
The unambiguous sequential assignment of the peptide 
was therefore achieved using a combination of NOESY 
correlations between a, p and backbone amide 
resonances. 
3.3.3 Conformational analysis of the PreCox IV peptide. 
Due to the nature of the NMR experiment, most NMR 
parameters observed are averages rather than a super-
imposition of all values, and careful analysis of all 
data must be carried out before drawing conclusions 
RESIDUE NH aCH OTHERS 	CHIRAL B's? 
Met 1 - -0.465 
Leu 2 -0.06 -0.02 x 
Ser 3 -0.09 -0.07 
Leu 4 -0.06 -0.21 x 
Arg 5 -0.215 -0.38 B's -0.15, -0.17 
y's -0.16 
Gin 6 * -0.59 -0.32 x 
Ser 7 -0.29 -0.22 
Ile 8 -0.36 -0.32 x 
Arg 9 * -0.64 -0.33 B's -0.26, -0.16 
y's -0.32 
Phe 10 -0.50 -0.24 B's -0.25, -0.20 
aromatics -0.22, 
-0.29 
Phe 11 -0.39 -0.19 B's -0.03, -0.20 
aromatics -0.22, -0.29 
Lys 12 -0.41 0 D's -0.27 
Pro 13 - -0.22 BCH -0.21 
Z) CH -0.23 
Ala 14 -0.32 -0.18 - 
Thr 15 -0.34 -0.22 B -0.21, - 
Arg 16 -0.245 -0.26 a -0.32 
Thr 17 -0.44 -0.21 B -0.31 - 
Leu 18 -1.03 -0.20 - 
Cysl9 0 - BCH-0.18  
Ser 20 -0.53 -0.25 
Ser2l -0.40 -0.15 
Arg 22 -0.30 -0.23 x 
Tyr 23 -0.48 -0.16 
Leu 24 -0.78 -0.11 x 
Leu 25 -1.03 -0.20 '1 
Table 3.2 
Showing the deviations of the PreCox IV peptide from random coil values. 
Residues with an asterix represent those for which significantly low 
temperatures were observed. 
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about specific elements of secondary structure present. 
Short acyclic peptides are likely to be flexible in 
solution, any elements of secondary structure present 
being in fast exchange with random coil conformations, 
and the detection of multiple conformations is not easy 
due to the averaging of NMR parameters. A close 
examination of all NMR data is therefore necessary to 
determine whether it is consistent with a single 
peptide conformation before conclusions about secondary 
structure can be made. 
Chemical shift can give an indication of the presence 
of secondary structure, since in an unstructured 
peptide, proton chemical shifts depend only on amino 
acid type and large deviations from these "random coil" 
values indicate some form of preffered structure. The 
chemical shifts observed for the PreCox IV peptide were 
compared to the random coil data (172). The results, 
shown in Table 3.2, indicate that the chemical shifts 
of a large proportion of the amide and -CH protons of 
the peptide deviate from the random coil values by 
significant amounts ( > 0.4 ppm for NH and >0.2 ppm for 
other protons), and give a preliminary indication that 
the peptide does indeed adopt a preferred structure. 
A measure of the strength of amide hydrogen bonding 
can be determined from the temperature coefficients of 
the amide residues. These values were determined for 
the PreCox IV peptide from the data recorded at 30 and 
40C. Most of the values fell into the range of 10 x 
10 	ppm / C, although two amide resonances showed 
values outside this range : Gln-6, 5 x 10 	and Arg-9, 
2 x 10. indicating that the amide protons of these 
residues are involved in well-formed hydrogen bonds. 
In addition to sequential assignment information, the 
observation of nOs's between NH, uCH and pCH protons 
can also provide information as to stable elements of 
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secondary structure adopted by the peptide. The nOes 
observed for a regular cx-helix are different from those 
observed for a p-sheet structure since the 
characteristic distances between sets of protons are 
different for the two structures.. Due to the extended 
nature of a p-sheet structure, only the a proton of a 
residue and the amide proton of the subsequent residue 
are in close enough proximity for a nOe to be observed, 
whereas the more compact nature of the helix ensures 
that its range of characteristic correlations is larger 
and the observation of certain types of correlation can 
even be used to distinguish between the different types 
of helix. 
The observation of correlations between the amide 
protons of sequential residues is highly characteristic 
of helices and many such correlations were observed in 
the NOESY spectrum of PreCox IV (Figure 3.14). 
In particular, the N-terminal portion of the peptide 
between residues 4 and 12 was characterised by eight 
consequetive d m" correlations. On this basis the 
N-terminal portion of the peptide appears to be 
helical. The NOESY spectrum was examined for d.. 
(i,i+3) and (i, i+4) correlations to confirm the 
assignment. However most of these such correlations 
were either not observed or could not be assigned 
unambiguously due to degeneracy with other resonances. 
Correlation was observed however between the a proton 
of Gln-6 and the p protons of Arg-9 (Figure 3.15), 
i.e. a d.... r (i ,i+3) correlation characteristic of an 
a-helical structure. d(i ,i+3) correlations were 
also observed between the amide protons of Ser-3 and 
Arg-5 and side chain protons of Gln-6 and Ile-8 
respectively (Figure 3.15). 
As was noted earlier, the NOESY correlations observed 
for the C-terminal portion of the peptide were not as 
_..I 
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Figure 3.16 
A summary of the NOESY correlations observed for the PreCox IV 
peptide. 
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numerous as for the N-terminal portion. Although five 
NH-NH correlations were observed within the final seven 
residues, they did not occur consequetively and helical 
structure cannot be advanced for this region with any 
degree of certainty. No d...,(i,i+2, i+3 and i+4) 
correlations were observed, although a d,, 
correlation was observed between Thr-17 and Cys-19 
(Figure 3.1) suggesting that these protons are close 
in space at least part of the time within the time 
scale of the experiment. This observation would 
indicate that this region may adopt a spacial 
relationship approximating to 3io helical geometry. 
Several interresidue correlations were also observed 
for the sequence of amino acids preceeding the second 
proposed helical region of the peptide. Correlations 
between the Pro 13 6 protons and the Lys 12 backbone 
amide proton and one of the Lys 12 p protons were 
observed, as were correlations between the p and ' 
protons of the Pro residue with the amide of Ala 14. 
Until modelling studies have been carried out it cannot 
be determined whether these correlations are indicative 
of a particular element of secondary structure. -. 
A summary of all interresidue correlations observed 
is shown in Figure 3.16.. 
The correlations observed from our NN1R experiments 
carried out in the presence of TEE corroborate the 
experimental evidence recently obtained by Roise and 
Endo (172) 9 who reported weak inter residue nOc's 
possibly arising from line broadening effects due to 
the presence of the dodecyiphosphocholine (DPC) 
micelles in which the NMR spectrum of the peptide was 
recorded. 
These workers suggest that the N-terminal portion of 
the peptide adopts a helical conformation whereas the 
C-terminal portion of the peptide shows no inter 
111114111 	II Iq I I I III4 lIllilIji £ 11 1 1111 1 141 u1 	lhhlhluhlhllhhhJim. 	 II 	I 	111(11 	ll 	111111111! I 	uhf I 	LI I 	fill I 	III 
	
8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 	ppm 
Figure 3.17 
The 1D- 1H Nmr spectrum of PreCox IV in 
50% d2-TFE I HO 
50% d2- TFE / D20 after 5 mins. 
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residue nOes indicative of regular secondary 
structure. In addition they reported that whilst 
residues in the N-terminal portion of the peptide 
experienced significant chemical shift changes upon 
change from aqueous solvent to DPC micelles, those in 
the C-terminal portion of the peptide did not, leading 
them to propose that the N-terminal half of the peptide 
is directly involved in binding and experiences a 
conformational change on doing so whereas the 
C-terminal portion of the peptide may not.. 
In an attempt to corroborate the evidence from nOe 
data, a proton exchange experiment was carried out on 
the PreCox IV peptide. Backbone amide protons involved 
in stable helical structures are protected against 
exchange with solvent protons due to the additional 
energy required to break H-bonds within the structure. 
However, all the backbone amide protons underwent 
exchange with the deuterated solvent within five 
minutes.. This is consistent for the most part with the 
amide temperature coefficients observed, although a 
slow exchange rate might have been expected for 
residues 6 and 9 for which low coefficients were 
observed, and suggests that the N-terminal region of 
the peptide does not adopt a rigidly helical structure, 
but a population of structures in which a-helical 
geometry can be assumed by localised regions, such that 
the structure oscillates between distorted or partially 
unravelled helices and the regular helical structure. 
The adoption of such a mobile structure would also 
explain some of the spectral anomalies. The line widths 
of the resonances in the H-NMR spectra were broader 
than expected for a peptide of this size and could be 
explained by the fact that the spectrum recorded for a 
dynamic structure would be a population weighted 
average spectrum.. In addition the lack of corroborating 
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medium and long range nOe correlations in the spectrum 
for the proposed helical regions of the peptide could 
be attributed to the fact that such correlations would 
be more affected by dynamics within the structure than 
the shorter range NOE correlations. 
In an attempt to force the peptide into a more stable 
structure the peptide was dissolved in a 907. volume TFE 
solution and its 1 H-spectra recorded. However the 
number of nOes observed did not increase noticably, 
and it can be concluded that the mobile helical 
structure is not stablilised to any great extent by the 
increase in the amount of TEE present. 
The results obtained from the NMR analysis of the 
peptide are in agreement with those obtained from the 
CD studies, in that both methods indicate the presence 
of a helical elements of structure. Moreover the NMR 
studies were able to pinpoint the more stable elements 
of helical structure to a particular region of the 
peptide, residues 3-11, with the possibility that a 
second, less extended, region of helical structure was 
present at the C-terminus of the peptide.. The NMR data 
is consistent with a dynamic situation with the peptide 
oscillating between different conformations, a 
situation that cannot easily be defined by NMR, 
although a more complete picture of the possible 
conformations adopted by peptide could be built up by 
modelling studies based on the'H- 1 H distances 
obtained from the through space NOESY correlations.. The 
quantification of the intensities of the NOESY cross 
peaks observed and their conversion into proton-proton 
distances would be the next step in the conformational 
analysis of the PreCox IV peptide. 
It might also perhaps be worthwhile to attempt to 
lock the peptide into a single conformation by lowering 
the temperature of the solution. 
r E= FR FD1J FR 
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THE SYNTHESIS, PURIFICATION AND CONFORMATIONAL 
ANALYSIS OF A MUTANT MITOCHONDRIAL TARGETING PEPTIDE.. 
4.1 Introduction. 
The decision to synthesise a mutant mitochondrial 
targeting peptide arose from the results obtained on 
the conformational analysis of the PreCox IV peptide, 
which showed that the peptide could adopt some stable 
secondary structure. The question then arises whether 
non-active mutant signals fail to target mitochondrial 
proteins through a failure to adopt a stable structure, 
or whether this is a result of the formation of 
alternative stable structures adopting conformations 
unable to interact with the mitochondrial import 
machinery. To explore these possibilities we decided to 
synthesise one of these mutant peptides, and analyse 
its solution structure by CD and NMR. 
H Met Leu Ser Leu Arg Gin Ser lie Arg Phe Pro Ala 
Thr Arg Thr Leu Cys Ser Ser Arg Tyr Leu Leu OH 
Figure 4.1 
One mutant was of particular interest (Figure 4.1), 
since it had been designed specifically, and prepared 
by site directed mutagenesis, to create maximum 
disruption of the amphiphilic helix of PreCox IV. As a 
result of the deletion of two residues of the PreCox IV 
sequence (Phe 11 and Lys 12) the targeting efficiency 
of the mutant presequence has been found to be 
considerably decreased. CD analysis of the synthetic 
presequence of this this mutant (PreCox IV 11,12) had 
shown (163) that the peptide adopted very little 
secondary structure in the presence of SDS micelles but 
no solution phase NMR analysis had been carried out on 














190.0 	210.0 	230.0 	250.0 
Wavelength (nm) 
pre Cox IV (A11,12), 0.3M NaCI 
: pre Cox IV (M1,12), 0.3M NaCI, 10mM SIDS 
Figure 4.2 
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for furthur analysis.. 
4.2 Synthesis of PreCox IV a11,12. 
The synthesis of this peptide was carried out using 
the cycles described for the synthesis of the PreCox IV 
peptide in chapter 2.. Since the peptide differed from 
the PreCox 1V peptide by only two residues, the areas 
in the synthesis with which problems could be expected 
were already fairly well characterised. Several 
couplings were monitored manually, although problems 
were encountered for only two of these, the coupling of 
Thr 15 to Leu 16 for which three aditional couplings 
were required for satisfactory efficiency, and the 
coupling of the final Met residue which was recoupled 
once. 
4.3 Cleavage and purification of PreCox IV 11,12. 
The TEA cleavage of the peptide from the resin and 
removal of the acid labile side chains was carried out 
using a reaction mixture containing anisole and 
ethylmethylsuiphide as scavengers, and the optimal 
cleavage time was found to be 2.5 h. The crude peptide 
was found to be sparingly soluble in aqueous buffers, 
and the cysteine protecting group was removed prior to 
purification using a slight excess of tri-n-butyl-
phosphine in aqueous TFE. 
An impurity which was not separated by preparative 
HPLC, despite appearing as a distinct peak during the 
preparative runs was later shown to be the dimer of the 
free peptide. Separation of the dimer from the monomer 
by HPLC was followed by immediate redimerisation 
under the HPLC conditions, even when HPLC fractions 
were collected in ice-cooled containers under hexane. 
Sequencing of the pure peptide obtained indicated the 
presence of a small amount of the truncated peptide 
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with the N-terminal Met residue absent. Amino acid 
analysis of the peptide confirmed it to be low in 
methionine, however the peptide also appeared to be low 
in cysteine and both these amino acids are degraded 
slightly under the amino acid hydrolysis conditions, 
thus making it difficult to detect the presence of 
truncated peptide by amino acid analysis. Mass 
spectrometry of the peptide showed a molecula- ion at 
the expected value, the elemental composition of which 
was confirmed by high resolution mass spectrometry. 
The data was consistent with the desired peptide 
containing a small amount of the Met-truncated peptide 
and a proportion of the dimer of the desired peptide. 
We decided that, since the missing residue is not in an 
important conformational area of the peptide, the small 
proportion of the truncated peptide present would 
probably not affect the CD analysis to too great an 
extent and we proceeded to use the peptide at this 
level of purification for conformational analysis 
experiments. 
4.4 CD analysis of the PreCox IV ,1112 peptide. 
The first experiment carried out was to repeat the 
study carried out by Raise et a! (163) in which the 
peptide conformation in the presence and absence of SDS 
micelles. The results (Figure 4.2) show that the 
spectra of the peptide in the presence and absence of 
SDS micelles are almost identical, in agreement with 
the results obtained by Raise. 
The spectra of the peptide in solutions containing 
increasing proportions of TFE were measured, and as can 
be seen from the results (Figure 4.3) the proportion of 
TFE in the solution is around 707 before any 
significant change in the spectra is observed. 
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+ : 70%TFE 
Figure 4.3 
The helical content of the peptide at 707. TFE was 
calculated by the Contin program to be 37.. 
(a) 	 (b) 
Figure 4.4 
Analytical HPLC of the NMR sample (a) before and (b) after the 
addition of a small amount of 3mercaptoethano1. 
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4.5 NMR analysis of PreCox IV 11.,12. 
A preliminary 1-D spectrum of the PreCox IX 11,12 
peptide indicated that two distinct species were 
present in the mixture, the second species being 
present in a significant amount. Analytical HPLC showed 
that a significant amount of the dimeric peptide was 
present. Treatment of the sample with 10% p-mercapto-
ethanol resulted in a significant decrease in the 
amount of dimer present (Figure 4.4). 
We therefore decided that for NMR analysis of the 
peptide to be viable, the presence of a reducing agent 
to minimise dimerisation would be required. The direct 
addition of p-mercaptoethanol to the NMR tube was not 
the solution to the problem, however, since at the 
concentrations required to be effective, the resonances 
arising from the -mercaptoethanol obscured important 
resonances of the peptide 
The next step in the NMR analysis of the deletion 
peptide is therefore the addition of an NMR invisible 
reducing agent, such as deuterated -mercaptoethanol, 
to the NMR sample in the hope that it will prevent the 
formation of the dimer and thus reduce the peptide to a 
single species on which NMF< analysis can be carried 
out. 
Q F-I 	 F= I '/ 
C__ N 
I 	 .'rrs- 	pre-ct b2 
C 
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IMs/Y \ ___ 
(2) 
Figure 5.1 
The "stop transfer" theory for intramitochondrial sorting. 
The targeting signal targets the protein to the surface of the 
mitochondrion, and initiates translocation across the membranes. 
The second signal sequence then acts as a "stop transfer" sequence, 
preventing the complete translocation of the protein. The first signal 
sequence is proteolytically removed in the matrix. 
The "stop transfer" sequence is then cleaved at some later stage, 
releasing the protein into the intermembrane space. 
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INTRAMITOCHONDRIAL SORTING.. 
The targeting of proteins destined for the inter-
membrane space of mitochondria is a more complex 
process than that for proteins destined for the 
mitochondrial matrix and requires steps additional to 
those common to both pathways. 
Experiments carried out in yeast on the mitochondrial 
intermembrane space protein cytochrome bm indicated 
that the protein was processed to its mature form via 
an intermediate molecular weight species (174). The 
intermediate species was shown upon subcellular 
fractionation to be associated with the mitochondrial 
inner membrane. 
Based on these observations a model was proposed by 
Daum et a1. (175) for the import of cytochrome b 
and cytochrome c1 (Figure 5.1). It proposed that the 
precursor protein is only partially translocated across 
both mitochondrial membranes, the N-terminal 
presequence being removed as it enters the matrix. The 
intermediate form then would remain anchored in the 
membrane until cleaved by an uncharacterised protease, 
thus releasing the mature cytochrome b into the 
intermembrane space. 
The sequencing of the gene encoding the cytochrome 
b m precursor (176) allowed a comparison to be 
made of the predicted N-termic%l presequence 
with those of other intermembrane space proteins.. 
The presequences of cytochrome b, cytochrome c 
and cytochrome c peroxidase (CCP) were all found to be 
unusually long, 80 residues for cytochrome b, 61 
(177) and 70 residues (178) for yeast and Neurospora 
cytochrome c1 respectively and 68 residues for CCP 
(179). Analysis of the sequences showed that there was 
no primary sequence homology between the presequences, 
although the sequences all appeared to possess similar 
C 	N 
	












Intramitochondrial sorting of the Rieske Fe/S protein. 
(1) The matrix targeting signal targets the protein to and (2) 
into the mitochondrial matrix, where it is proteolytically 
removed. (3) The sorting signal then targets the protein to 
and across the inner membrane and is then proteolytically 
removed. 
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structural features.. 
The extreme N-termini of the precursors were all 
rich in basic and hydroxylated amino acids in common 
with matrix targeting sequences. However they all 
contained an additional long stretch of uncharged amino 
acids. This region has been proposed by Daum et al. 
(175) to act as a "stop transfer" sequence preventing 
complete translocation of the protein. 
The intermediate form of cytochrome bm was found to 
be localised in the inner membrane and enzyme assays 
indicated that the intermediate form displays 
cytochrome b activity only slightly lower than that 
of the mature protein, indicating that it had already 
acquired its heme and flavin prosthetic groups.. 
Studies of the import and assembly of the Rieske Fe/S 
protein of the ubiquinol : cytochrome c reductase 
complex of the mitochondrial inner membrane (180) have, 
however, suggested an alternative pathway for targeting 
to the intermembrane space. This protein is located on 
the outer face of the inner membrane and is synthesised 
as a precursor with a 32 residue N-terminal 
presequence. Experimental evidence has indicated that 
the protein is completely translocated into the 
mitochondrial matrix whereupon a 24 residue segment of 
the presequence is proteolytically removed and the 
intermediate sized protein is then retranslocated 
across the inner membrane (Figure 5.2). Once 
translocated across the membrane the final 8 residues 
of the presequence are removed by an uncharacterised 
protease. Thus the second signal sequence consisting of 
a non-polar region would appear to be operating as an 
export signal rather than a "stop-transfer" sequence. 
In the light of the endosymbiotic theory for the 
evolution of mitochondria, and the fact that the 
non-polar signal sequences of these proteins closely 
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resemble bacterial signal sequences, the authors 
proposed that protein is targeted to the matrix by a 
"matrix targeting" signal sequence. Once located in the 
matrix the protein follows its ancestral pathway, and 
is targeted to the inner membrane by a signal sequence 
very similar to bacterial export signals. 
Harti et al. (180) have reexamined the import of 
the native precursors of cytochrome b and cytochrome 
c, and found that upon inhibition of the matrix 
protease, the precursor and to a lesser extent the 
intermediate form can be detected in a soluble form 
inside the mitochondrial matrix. Thus it is possible to 
show that cytochrome bm and the Rieske Fe/S protein 
share a similar mechanism of import. 
However van Loon and Schatz (181) have observed that 
a protein consisting of the presequence of cytochrome 
c1 fused to the N-terminus of the mature portion of 
subunit IV of cytochrome oxidase is only found inside 
the mitochondrial matrix if the uncharged region of the 
presequence is deleted. Even upon careful kinetic 
analysis none of the protein containing the entire 
presequence was observed in the matrix. 
Evidence obtained by Pfanner et al. (182) indicates 
that intermediate cytochrome b2 can be extracted from 
mitochondria using 0.1 M sodium carbonate, suggesting 
that it is likely to exist in a hydrophilic 	- 
environment, possibly a proteinaceous channel. This 
evidence further contradicts the theory that a stop 
transfer sequence anchors the protein in the inner 
membrane during the initial translocation step. 
Although studies on the precursor protein have 
allowed the observation of several important factors 
relating to targeting, a general overview of the 
physical properties required for targeting has not been 
gained due to the unavailability of alternative 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Met Leu Lys Tyr Lys Pro Leu Leu Lys lie Zer Lys Mn Cys G1u 
16 1718 19 20 21 22 23 24 25 26 27 28 29 30 
Ala Ala Ile Leu Arg Ma Ser Lys Thr Arg Leu Mn Thr lie Arg 
1st cleavage site. 
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 
Vol Pro Lvs SerLSer Phe Gin Gin As 
A101 
Intermediate cytochrome b 2 
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 
Ser Arg Lys Arg Thr In Ser Tip Th Ala Leu Arg Vol Gly Ala 
..
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 
His Mn 
A103 
2nd cleavage site. 
76 77 78 79 80 81 82 
Gly Gin Ile Asp Mn Glu Pm- mature protein 
Intermediate cytochrome b2, Met Gly Ser Thr 
swomm MOl form of cytochrome b2, residues 15 to 55 deleted. 
A103 form of cytochrome b 2, residues 58 to 72 deleted. 
Figure 5.3 
Forms of the 80 residue presequence to cytochrome b2. 
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precursor proteins.. 
Work carried out in the laboratory of Reid (184) 
identified the first cleavage site in the cytochrome 
b= sequence (Figure: 5.3) and allowed the construction 
of modified forms of the cytochrome bm gene in which 
the first targeting sequence had been deleted, leaving 
a gene encoding the intermediate form of cytochrome 
b 
In order to investigate further the relationship 
between bacterial export and mitochondrial targeting, 
it was decided to express the precursor, intermediate 
and mature forms of cytochrome b in bacteria and to 
determine, if possible, whether the different forms of 
the presequence possessed different targeting 
properties. It would be of particular interest to 
determine whether the intermediate form of the protein 
showed a strong tendancy to associate itself with 
membranes, which could indicate that the sorting 
domains of mitochondrial proteins could indeed have 
evolved from bacterial export signals. 
The precursor, intermediate and mature forms of 
cytochrome b= were cloned (184) into a vector (pRC23). 
containing the temperature sensitive ),c1857 gene which 
allows accumulation of gene products in E.Coli in a 
relatively short time after the induction of gene 
expression by the elevation of growth temperature from 
30 to 42C. 
Subfractionation of the cells into inclusion, body, 
membrane and cytoplasmic fractions indicated that all 
forms of the protein were found predominantly as 
insoluble aggregates (inclusion bodies) within the 
cell, with preliminary evidence for the targeting of 
the intermediate form, but neither mature or precursor 
form, to the E.coli membrane. This was probably due 
to the use of a high copy number vector with resultant 






Precursor cytochrome b2 - plasmid pTZ401. 
Intermediate cytochrome b 2 - plasmid pRC4O4. 
Mature cytochrome b 2 - plasmid pGR403. 
Cytochrome b2 with A101 deletion - plasmid pGR401& 101. 
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overexpression of the protein.. 
Expression of the intermediate form of cytochrome 
b in the bacterium resulted in the inhibition of 
cell growth, possibly indicating that association of 
the intermediate cytochrome b with the cytoplasmic 
membrane with a resultant interference in the normal 
protein export of the cells.. 
The main aim of this work was therefore to analyse 
the targeting of various forms of cytochrome b in 
E.coli under conditions where the formation of 
inclusion bodies would not interfere with 
interpretation. The approach was to clone the genes for 
various forms of the precursor into an expression 
vector in which the degree of expression could be 
controlled to allow lower levels of expression than 
previously obtained.. 
The genes encoding the precursor, intermediate and 
mature forms of cytochrome bm had previously been 
cloned into the pTZ vector as had two additional 
mutated forms of the protein, the first with residues 
15 to 55 deleted (the &101 form of the protein) , and 
the second with residues 58 to 72 deleted (the &103 
form of the protein). These plasmids (Figure 5.4) were 
to be used to obtain the genes encoding the various 
forms of cytochrome bm required for the experiments. 
It was decided to use for these experiments the 
pKK223-3 expression vector (Figure 5.5) containing the 
strong tac promotor which is regulated in the 
appropriate host by the lac repressor. Gene 
expression can be induced by the addition of 
isopropyl--thiogalactoside (IFTG) to the medium, 
induction in a lacIQ strain being dependent on the 















EcoRl / Hindlil digest. 
EcoRl / Hindi I digest. Purify smell fragment. 
Purify large fragment. 
"I. 
Ligate fragments. 
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The pKK223-3 vector contains the pUC8 Multiple 
Cloning Site (Figure 5.6) allowing the insertion of 
Ec,RI / Hir,dIII fragments, and an ampicillin 
resistance gene, which enables the selection of cells 
carrying the plasmid. 
GAATTCCCGGGGATCC3TCGACCTGCAGCCAAGCTT 
I 	PL~y 	I 	I 	II 	I EcoRl 	BamHl 	Sell 	 Pstl 	 Hindlil 
Sinai 	 McI 
Hincil 
Figure 5.6 
The pUC8 multiple cloning site. 
The gene fragments for the precursor, intermediate, 
mature, &101 and &103 forms of cytochrome b= were 
obtained from the plasmids mentioned above by a double 
digest using EcoRI and HiridIII restriction enzymes.. 
The small fragment, containing the cytochrome b 
encoding sequence, obtained from each digest was 
isolated using agarose gel electrophoresis. 
The vector was prepared by an EcoRI/Hir,dIII 
digest of pKK223-3. Initial experiments indicated that 
only partial digestion of the p].asmid was occurring. 
The pKK223-3 plasmid was therefore purified by a phenol 
/chloroform wash with a subsequent ethanol 
precipitation, and the restriction enzyme digests were 
repeated.. The large fragment obtained from the digest 
was purified. 
The purified vector was then ligated with each of the 
small fragments encoding the different cytochrome b 
sequences (Figure 5.7) and an aliquot of each of the 
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ligation mixtures was used to transform the E.coli 
strain TG1. 
The transformed cells were subsequently grown up on 
LB plates containing the antibiotic ampicillin. Since 
the vector contained an ampicillin resistance gene any 
colonies growing on the plate should contain either the 
desired construct or the intact pKK223-3 vector which 
can be easily distinguished by isolating DNA obtained 
from the colonies, carrying out restriction enzyme 
digests (EcoRI/HiridIII) and screening the digest 
mixtures for multiple bands by agarose electrophoresis. 
Recombinant plasmids could be detected by the presence 
of two bands of DNA, one of about 1.6 kb corresponding 
to the cytochrome b fragment and one of 4.6 kb 
corresponding to the vector fragment. DNA samples 
containing only one band of DNA represented cases where 
digestion of the vector had been incomplete and 
religation had occurred. 
Controls on each set of ligations were carried out in 
which a portion of cells were left untransformed and 
grown up to detect any contamination of the cells,and 
portions of the cells were also transformed with 
samples containing only the vector, and a mixture 
containing the vector and the ligase. 
The colonies obtained for each of the ligations were 
screened by isolating DNA from each (quick plasmid 
preparations) and observing the linearized DNA obtained 
from restriction enzyme digests of the DNA. In all 
cases no recombinant vectors were observed, only the 
pKK223-3 vector. The control experiments indicated that 
this was probably due to the fact that the EcoRI / 
HiridIII digest on the vector had been incomplete. 
The fragment that should be extruded from the 
pKK223-3 vector upon EcoRI/Hiridlll digest contains 






Linearized DNA 	+ 
b2 
Figure 5.8 
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ligate the fragments and carry out a PstI digest on 
the ligation mixtures before transforming the cells 
with the resultant mixture. Thus any vector fragments 
which had been incompletely digested and had simply 
recombined would be cleaved and would no longer confer 
ampicillin resistance on transformed cells, whereas 
recombinant plasmids consisting of the vector and a 
cytochrome b fragment combined would be unaffected 
and should still confer ampicillin resistance on cells 
transformed with the plasmid (Figure 5.8). 
Aliquots of the ligation mixture were incubated with 
PtI for 2 h. and overnight, and a portion was used 
to transform competent 161 cells. The vector/ligase 
control still contained many colonies for the aliquots 
that had only been incubated for 2 h., and digests on 
the DNA obtained from the colonies that no recombinants 
had been formed. The aliquots that had been incubated 
overnight with the PstI produced clean control 
plates, and reduced numbers of colonies on the ligation 
mixture plates. Restriction enzyme digests on the DNA 
isolated from the colonies indicated that recombinant 
vectors had been produced for the precursor, mature 
101 and &103 constructions. 
The recombinant plasmid for the &101 protein was 
prepared on a large scale and an aliquot was subjected 
to an EcoRI/Hir,dIII digest. The large fragment 
produced was isolated by preparative agarose 
electrophoresis and purified. Ligations carried out 
using the vector isolated in this manner produced 
recombinants for the intermediate and mature forms of 
the protein. 
Having obtained recombinant plasmids, the next stage 
was to confirm that they could indeed express the 
desired protein. To this purpose, whole cell extracts 
from cells harbouring each of the recombinant plasmids 
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were obtained. The proteins were then separated by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to a nylon membrane. The Western blots were 
then probed by antiserum directed against mature 
cytochrome b and visualised using horse radish 
peroxidase (HRP)-conjugated IgG. 
The results indicated that the cells trans-formed with 
the recombinants for the intermediate, mature and AIOI 
-forms of cytochrome b= did indeed express the protein 
but those harbouring the recombinants -for the precursor 
and &103 forms did not. 
A fresh sample of the vector fragment was obtained 
from an EcoRI/Hir,dIII digest o-f the recombinant 
101 vector, and was ligated with freshly prepared 
portions of the fragments containing the required forms 
of the cytochrome b= gene. Recombinants for the 
precursor form were obtained, but on agarose gels the 
vector fragment appeared to be smaller than it should 
have been and Western blots indicated that cells 
transformed with the plasmid did not express cytochrome 
b ~ . 
A new strategy was adopted in which the preparation 
of the fragents for ligation was achieved by an ECORI 
/Kpril digest of the recombinant pKK223-3/101 plasmid 
to produce the vector fragment, and the pTZ401 plasmid 
to produce the precursor cytochrome b gene (Figure 
5.9). Ligation of the large -fragment from the -former 
with the small -fragment from the latter resulted in the 
production of recombinant constructs for the precursor 
form of the protein. 
An EcRI/HindIII digest was carried out on the 
DNA isolated from these constructs and aliquots of the 
digest mixture, when run on an agarose gel, showed 
three bands of DNA. The largest -fragment corresponded 
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cytochrome bm fragment. The third band was an 
intermediate size. Western blots of the transformed 
cells, however, indicated that cytochrome b= was 
being expressed. 
Samples of cells transformed with the four 
	
recombinant plasmids were grown to 	 of 0.3.. 
whereupon protein synthesis was induced in half of each 
sample by the addition of IPTG, and the samples were 
subsequently incubated for a -furthur 90 mm. Western 
blots of the cell lysates (Figure 5.10) indicated that 
expression of cytochrome b was occurring even 
without induction. 
-a .. 





Western blots of the whole cell lysates of E.Coli harbouring plasmids 
encoding for the wild type (WT), intermediate (I), mature (M) and t 101 
forms of cytochrome b2 and a standard sample of cytochrome b 2 (S). 
.-. 
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This was probably due to the fact that the strain of 
Eco1i used did not overexpress the lac repressor, 
and repression of gene expression was therefore 
incomplete. 
E.coli expressing the precursor, intermediate, 
mature and &101 forms of cytochrome b were grown 
without induction and were subfractionated as described 
in the experimental methods section. 
Equal amounts of the fractions obtained were 
electrophoresed on a 10% polyacrylamide gel and western 
blots performed. The results, shown in Figure 5.11, 
indicate that all forms of cytochrome b= accumulate 
as inclusion bodies in the cells. 
The &101 form of cytochrome b was, however 
observed to be present in the membrane fraction 
although none of the other froms were, contradicting 
the results obtained by Taylor (184) in which the 
intermediate form of cytochrome b m was observed to be 
present in the membrane fraction in proportionally 
larger amounts than the other forms. 
The &101 form of cytochrome b = also appeared as two 
bands, one the size of the mature form of cytochrome 
b m and one slightly larger. The other forms appear 
only as one band, the size of the mature form of 
cytochrome b. Thus it is possible that the 
genes encoding the precursor and intermediate forms of 
the protein could have mutated, resulting in the 
expression of mature instead of (modified) precursor 
protein. 
Before conclusions may be drawn from the results 
obtained, analysis of the DNA encoding the precursor, 
intermediate and mature forms of cytochrome bm must 
be carried out to ensure that the entire gene of each 
form of the protein is present in an unmutated form. 
I X 
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EXPERIMENTAL 
é,..1 Notes. 
All amino acids used for solid phase synthesis were 
purchased from Novabiochem and were used as supplied. 
Melting points were recorded on a Buchi MP1O melting 
point apparatus (NUB the arginine compounds 
synthesised were generally amorphous and difficult to 
dry completely and melting points were therefore not 
well defined).  
Thin layer chromotography was carried out on plastic 
sheets precoated with silica gel 60SF (Merck 5735) in 
the following systems: A CHCl-MeOH (9:1), B 
CHCl-MeOH-AcOH (9:1:0.5), C n-BuOH-AcOH-HO 
(3-1:1), D Petrol (b.p.. 40-60C)-EtOAc (4:1). 
Visualisation was carried out by a suitable combination 
of the following: iodine-vapour, uv.. absorption at 
254 nm, ninhydrin for free amino groups, Sakaguchi 
reagent for arginine with free side chains and sodium 
nitroprusside for the detection of free thiols.. 
Amino acid analysis was carried out on an LKB 4150 
alpha amino analyser following sealed tube hydrolysis 
in constant boiling hydrochloric acid at 110C. 
Infra red spectra were run on a Perkin Elmer 781 
spectrophotometer. Ultraviolet spectra were run on a 
Pye-Unicam SPS-400 spectrophotometer in the solvents 
indicated 
Mass spectrometry was carried out on a Kratos MS50TC 
machine and NMR spectra of amino acid derivatives were 
recorded on Brucker WP200 or WH360 spectrometers as 
indicated in the given solvents, using 
tetramethylsilane as the externel standard.. 
Peptides were sequenced on an Applied Biosystems 477A 
Protein Sequencer.. 
All solvents were distilled before use and the 
following were dried over the reagents given in 
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parentheses when required: chloroform (phosphorous 
pentoxide) , dichioromethane (calcium hydride) , diethyl 
ether (sodium wire) , N,N-dimethylformamide (calcium 
hydride or 4A molecular sieves). 
6.2 The synthesis of protected amino acids. 
N()-Ben:yloxycarbonyl-L-inine. EZ.ArgOH] 1) 
The compound was made by the method of Zervas (185). 
M.p. 162-164C (lit.(184) 175C), t.l.c.-C F 
0.7, [Found: C, 53.5; H, 6.7; N, 17.9. Caic. for 
0.5 H=O 	C, 53.0; H, 6.7; N, 
17.77.3,H (d-DMSO, 200MHz) 9.42 (1H, br, NH), 7.75 
(4H, br, guanidine NH's) , 7.35 (SH, m, Z-aromatics), 
6.65 (1H, d (37.3H) ,urethane NH) , 4.98 (2H, s, Z-
CH), 3.70 (1H, m, 	-CH), 3.03 (2H, br, CH), 
1.75-1.30 (4H, m, pCH= and '&CH:,) . 
This compound was prepared using a slightly modified 
version of the literature method (186). 
2,3,5-Trimethylphenol (734 mmol, 100.0 g) was stirred 
with dry chloroform (300 ml) and isoprene (734 mmol, 74 
ml) and cooled to -15C. Trifluoromethanesuiphonic 
acid (TFMS) (0.1 ml) was added and the reaction 
mixture was then allowed to return to room temperature. 
The mixture was then heated gently under reflux for lh. 
and subsequently stirred overnight at room temperature. 
Following dilution of the reaction mixture with water 
(100 ml) the product was extracted into petrol (b.p. 
40-60-C). The aqueous layer was then washed with 
petrol (X2). The combined extracts were then washed 
with Claisen's Pdkali42 X 500 ml), water (2 X 500 ml), 
and brine (1 X 500 ml) and were then dried (CaCl), 
filtered and evaporated. The crude product was purified 
LcLc5a1, A,1t1.) ,qiq, 4.Ii Qb. 
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by distillation under reduced pressure to produce the 
required compound as a yellowy-white low-melting 
solid (63.31 g, 42%), b.p. 84102cC at 0.8 mbar, m.p. 
32-38C (lit. (185) 40-41-C), t.l.c.-D R 0.65, 
Wound 	C, 82.2; H, 10.0. Calc.for Ci.H : O: C, 
82.3; H,9.9X3 6H (CDCl3, 200 MHz) 6.54 (1H, s, 
aromatic protons), 2.59 (2H, t (3=6.8Hz), CH), 2.19, 
2.15, 2.06 (3H each, 3 X s, 3 X aromatic CH's), 1.78 




Pmc (2) (254 mmol, 51.9 g) was dissolved in dry 
chloroform (500 ml) and cooled to -10C with 
stirring. A solution of chlorosulphonic acid (1.05 mol, 
70 ml, freshly distilled) was added at such a rate that 
the temperature of the reaction mixture remained below 
-10CC. 
The solution was stirred at the same temperature for 
15 mm. and was then poured onto a mixture of ice (500 
ml) and brine (250 ml). The organic layer was then 
separated, washed with sodium carbonate solution (57.; 
1500 ml), saturated sodium bicarbonate solution (1500 
ml), water (1500 ml) and brine (1500 ml) and then dried 
over MgSO.. The extract was stirred with activated 
charcoal to decolourise it and was then filtered and 
the solvent removed in vacuo. Trituration of the 
resultant thick oil with petrol (b.p. 40-60C) gave 
the required compound as white crystals (24.01 g, 
317.) after standing at 3C for several days. Further 
crops of the crystals could be obtained by evaporation 
of the mother liquor and repetition of the trituration 
process. The product was unstable and was used 
immediately in the next reaction. Analytical data 
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obtained was consistent with the literature (130). 
NW-Benz yloxycarbonyl -N-(2.2,5,7,8-pentamethyl-
chroman-6-sulphonyl)-L-arginineyclohexylamine salt 
C Z. ArQ (P mc) OH CHA J (4) 
ZArgOH (1) (35.6 mmol, 10.97 g) was dissolved in 
sodium hydroxide solution (44 ml) and acetone (130 ml) 
and cooled to 0C. A solution of Fmc-C1 (3) (85.9 
mmol, 17.55 g) in acetone (80 ml) was added and the 
reaction mixture was stirred at 0C for 2h. and then 
room temperature for 2h. After acidification to pH6.5 
(saturated citric acid solution) , the acetone was 
removed under reduced pressure, and the remaining 
solution was acidified to pH3 (saturated citric acid 
solution). The solution was then diluted with water 
(167 ml) and the product was extracted into ethyl 
acetate. The extract was washed with water (2 X 300 ml) 
and brine (2 X 300 ml) and dried (MgSO1). After 
filtration the extract was concentrated in vacuo to a 
total volume of ca 250 ml, cooled to 0'C, and 
cyclohexylamine (4.1 ml, 35.9 mmol) was added. The 
product was then precipitated by the addition of 
anhydrous ether. The crude product was purified by 
recrystallisation from methanol /diethyl ether to give 
the required compound as a white crystalline solid 
(18.5 g , 777.), m.p 	154-155C(1it. (130, 131) 
156C.), tl.c-D R 0.39, CFound 	C, 60.3; H, 80; 
N, 10.5. Calc. for C: H, 1 NO-7S : C, 60.6; H, 
7.6; N, 10.47.3, gH (d-DMSO, 200MHz) 7.75, 6.9 (3H, 
br, guanidino NH's), 7.33 (5H, s, Z-aromatics), 6.59 
(1H, d (J=6.SHz), -CH), 4.98 (2H, s, Z-CH), 3.62 
(1H, m, CH), 2.99 (3H, m, gCH Y and cyclohexylamine 
CH), 2.55 (2H, t, CH), 2.48 (6H, 5, 2 X CHn ortho 
to SO.2 ), 2.03 (3H, s, CH meta to SO.2), 2.0-1.1 
(20H, m, pCH.2, '&CH:2, 5 X CHA CH.2's and 2XPmc 
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CH-.'s) - 
N's- (22 5 78-Fntametflyj chroman-6--sul phonyl ) -L-
arginineCH..Arg(Pmc)OH] (5) 
ZArg(pmc)OH.CHA (4) (18 mmol, 12.13 g) was stirred 
with ethyl acetate (100 ml) and saturated citric acid 
solution (100 ml) for 1 h. The organic phase was then 
washed with saturated citric acid solution (2 X 100 
ml), water (2 X 100 ml) and brine (100 ml) and the 
washings were re-extracted with ethyl acetate. The 
combined extracts were dried (NaSO.) and the 
solvent was removed in i'acuo to produce ZArg(pmc)OH 
as a white foam. The foam was then taken up in methanol 
(150 ml), and 5% palladium on charcoal (1.11 g) was 
added with cooling, under nitrogen. The solution was 
stirred under hydrogen for two days. The catalyst was 
then removed by filtration through Kieselguhr, and the 
solvent was removed in vacuo. Addition of diethyl 
ether to a concentrated methanol i c solution of the 
resultant foam gave the required compound as a white 
crystalline solid. (7.78 g, 98%), m.p. 140"C. 
(lit. (10, 131) 145'C.), t.l.c-B R & 048, GH 
(d,-DMSO, 200MHz) 7.4-6.55 (3H, br, guanidino NH's), 
3.43 (1H, m, CH), 3.06 (2H, m, SCHzO, 2.62 (2H, t, 
Pmc-CH), 2.48 (6H, 5, 2 X aromatic CH's ortho to 
S0), 2.03 (aromatic CHw meta to SOP ), 1.80-1.30 
(6H, m, Pmc-CH, DCH y & ?CH), 1.26 (6H, s, 2 X 
Pmc-CH's). 
N W-Fl uor el methoxycarbonylNG (22,58-
ptamet hyl chroman-6-sulphonyl)-L-ari n i ne. 
Hrg(Pmc)OH (5) (7.78 g, 17.65 mrnol) was stirred 
with sodium carbonate solution (67.; 65 ml) and cooled 
to 0C. A solution of 9-fluorenylmethylsuccinimidyl 
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carbonate (6.02 g, 17.83 mmol) in DMF (0 ml) was added 
dropwise and the reaction was left to stir with the ice 
bath removed for 3h. before being diluted with water 
(300 ml). 
The diluted solution was washed with ethyl acetate 
and subsequently acidified to pH3 by the addition of 
saturated citric acid solution. The product was then 
extracted into ethyl acetate and the separated organic 
layer was washed with water (X2) and brine and dried 
(MgSO.). The dried extract was then concentrated in 
vacuo to c.a. 100 ml and the product was precipitated 
by the addition of petrol (b.p. 40-60w'). The product 
was purified by recrystallisation from chloroform / 
n-hexane (10.3 g, 88%) , m.p. 98-100'C (lit. (130, 131) 
80-93C), t.l.c.-B Rw 0.48, [Found: C, 63.0; H, 
7.1; N, 7.9. Calc. for CH NO.S: C, 63.4; H, 
6.4; N, 8.45%3, SH (CDCl:, 360MHz) 7.68-7.17 (8H, m, 
Fmoc aromatics), 6.8-6.3 (3H, br, guanidino NH's), 6.25 
(1H, d (3= Hz) , urethane NH) , 4.38-4,28 (3H, m, Fmoc CH 
< CH), 4.11 (1H, t Q= Hz), CH), 3.22 (2H, br, 
CH), 2.52, 2.49 (SH, 2 X s, Pmc-CH. & 2 X ortho 
aromatic CHs), 2.05 (3H, s, meta CH), 1.79 (2H, 
t (3= Hz) , Pmc-CH.) , 2.0- 1.5 (6H, m, Pmc-CH, 
3CH, 'CH:), 1.25 (6H, s, Pmc- CH's). 
N)-Fluorenymethoxyarbonyl--S--(t ert.butylthio)-L-
çyteineCFm 	 H](7) 
S-tertButylthio-L-cysteine (0.51 g, 2.44 mmol) was 
stirred with sodium carbonate solution (6%; 10 ml) and 
cooled to 0C. A solution of 9--f luorenylmethyl-
succinimidyl carbonate (0.91 g, 2.69 mmol) in DMF (5 
ml) was added dropwise over a period of ten minutes, 
and the solution was then stirred at room temperature 
for 2 h. After dilution with water (100 ml) the 
solution was washed with diethyl ether (2 X 25 ml) and 
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acidified to pH3 (saturated citric acid solution). The 
product was then extracted into diethyl ether and the 
extracts were washed with water (2 X 100 ml) and brine 
(50 ml) and dried (MgSO.), filtered and evaporated. 
The resultant white foam was recrystallized from 
dichioromethane I n-hexane to give the required 
compound as a white crystalline solid (0.89 g, 85Y.). 
m. p. 73-74C. (lit. (187) 74_76vC.), t.l. c. - R 
0.4, EFound : C, 60.7; H, 6.0; N, 3.2. Caic. for 
CHNO.S C, 61.2; H, 5.8; N, 34251.1, gH 
(CDCl, 200MHz) 7.8-7.2 (BH, in. Fmoc aromatics), 6.7 
(1H, d, urethane NH), 4.7 (1H, m, Fmoc CH), 4.4 (2H, m, 
Fmoc CH:;.'), 4.22 (1H, m, 	CH), 3.22 (2H, m, 
1.05 (9H, s,'Bu). 
6.3 	 pha 
6.3.1 Resin load.LELq.,_ 
Method 1 - via the acid chloride. 
N()-Fluorenylmethoxycarbonylleucine (0.71 g, 2 mmol) 
was heated under reflux with Dclvi (20 m1) and thionyl 
chloride (1.53 ml, 20 mmol) for 1. h. The solvent was 
then removed in vacuo and the resulting oil was 
washed with DCM which was then removed in vacuo. This 
process was repeated a furthur two times to ensure the 
complete removal of all thionyl chloride. 
The p-alkoxybenzylalcohol resin (1.08 mmol g 1 ; 1.5 
g, 1.52 mmol) was treated with enough DCM to give a dry 
swollen resin (approx. 3 ml) and pyridine was then 
added to give a thick slurry (approx. 7 ml). The acid 
chloride was then dissolved in the minimum amount of 
dry DCM and added to the resin slurry. 
After sonication for 3 h. the resin was filtered off 
and washed thoroughly with DCM and the extent of 
C. 
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coupling of the amino acid to the resin was determined 
(see below). 
The coupling reaction was monitored by the appearance 
in the I. R. spectrum of an ester peak at 1730 cm -1 . 
The infra-red spectra were obtained by the KBr disc 
method 
Method 2-via  the symmetrical anhr i d e 
N()-Fluorenylmethoxycarbonylleucine (1.4:3 g, 4.055 
mmol) was dissolved in the minimum amount of dry DMF, 
and diisopropylcarbodiimide (0.32 ml, 255 mg, 2.025 
mmol) was added. The mixture was stirred or sonicated 
for 15 mine 
Meanwhile the resin (1.05 mmol g' 1 ; 1.5 g, 1.58 
mmol) was swollen in the minimum amount of dry DMF a 
catalytic amount of DMAP was added and the mixture was 
sonica€ed for 5 mm. 
The FmocLeuOH/DIC solution was then added to the 
resin and the mixture was sonicated for 3 h. After 
which the resin was filtered off, washed thoroughly 
with dry DMF then DCM and dried in a desiccator 
overnight. The reaction could be monitored as described 
above. The extent of coupling of the amino acid was 
then determined (see below). 
6.3..2 Evaluation of resin1oad . g_ffc lency 
Method I  ........  via .....elemental ...na1sis. 
A small sample of the loaded resin was thoroughly 
dried under vacuum and was submitted for elemental 
analysis. The value obtained for the nitrogen content 
was then used to calculate the percentage loading of 
the resin. 
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Method2 -Spectrometric. 
A sample of the resin (2.8 mg) was sonicated with a 
solution of piperidine (207. (v/v) in DMF in a 10 ml 
volumetric flask for 15 mm. The flask was then filled 
to the mark with the piperidine solution, mixed and 
allowed to settle. A U.V. spectrum of the solution was 
then run against a blank of the piperidine solution. 
The absorbance of the solution at 300 nm was 
measured. Comparison of this value with standard values 
obtained from protected amino acids allowed the 
evaluation of the resin substitution. 
6.3.3 Ca-ppLD_q­__qf _. the loaded resin.- 
The coupled resin obtained from either Method 1 or 
Method 2 (1.5 g; functionality 0.43 mrnoi g) was 
stirred with dry DCM (30 ml) and cooled to 0C in an 
ice/salt bath. Pyridine (0.5 ml) and benzoyl chloride 
(0.5 ml) were added and the mixture was stirred at the 
same temperature for 20 min 
The resin was then filtered off and washed thoroughly 
with DCM (resin functionality now 0.423 mmol g). 
Continuous monit 
synthesis. 
The combined reaction mixture and washings from each 
of the Fmoc deprotections was pumped through a u.v. 
detector (LK8 Uvicord) operating at 314 nm by an HPLC 
pump and the output of the detector was recorded on a 
standard chart recorder. The area recorded under each 
deprotection peak was then calculated and used to 
evaluate the efficiency of each coupling reaction. 
As1111110  
A small sample (2-3 mg) of the resin bound peptide 
was removed from the reaction vessel, washed and dried 
thoroughly, and analysed either spectrometrically 
(Method 1) or by the Kaiser test (Method 2). If the 
coupling had been satisfactory the synthesis was 
restarted, if not an additional DIC/HOBt coupling was 
carried out and the resin bound peptide rechecked if 
desi red 
Analysis by this method was carried out exactly as 
for the evaluation of the coupling efficiency of the 
first amino acid to the resin (Section 	Method 
2) The substitution obtained could be compared either 
to the theoretical substitution calculated for that 
stage of the synthesis or to the substitution obtained 
from a sample removed prior to the coupling in 
question.  
Method 2 - the ninhydrin  (Kaiser) colour test 
The resin sample obtained was washed down the sides 
of the test tube with a DOM / methanol solution (3:2). 
The tubes were then vortexed and any resin adhering to 
the sides of the tubes was washed down with a furthur 
portion of the DCM/methanol solution. 
Most of the liquid was removed with a pasteur pipette 
and the resin sample was rewashed with furthur portions 
of DCII/rnethanol. The resin samples were then dried 
overnight under vacuum, and the weight of the resin was 
recorded. 
The following reagents were then added to each of the 
test tubes and the tubes were subsequently incubated at 
100r'C for 7 mm. 
Solution 1: phenol (Bt) g) in ethanol (60 ml), 4 drops 
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Solution 2: KCN in pyridine (20 liFi), 8 drops 
solution 3: Ninhydrin (1 g) in ethanol (10 ml), 
4 drops 
The tubes were then removed and aqueous ethanol (607., 
4.8 ml) was immediately added, after which the tubes 
were vortexed and the resin allowed to settle. 
The absorbánce of each solution (referenced to a 
blank of 60% aq. ethanol) was measured at 570 nm. Care 
was taken to ensure that no resin was transferred to 
the cuvette. The quantity of free amine present was 
calculated as follows: 
Q 	= 	(Abs (sample)-Abs(blank] X dilution 
(mol/pg) 	 . X weight sample (mg) X 10 
Dilution = S ml 
extinction coefficient = 15000Mcm' 
6.3.6 Automated 	 es. 
Automated solid phase peptide synthesis was carried 
out on the Applied Biosystems 430A or 431 peptide 
synthesisers. Synthesis on the 430A was carried out on 
a 0.5 mmol scale, whereas synthesis on the 431 was 
carried out on a 0.25 mmol scale. Appropriate amounts 
of pre-loaded resins for which the loading of the 
C-terminal amino acid had been evaluated were used. 
The overall cycle for each residue consisted of 
several steps, an initial capping step involving the 
blocking of unreacted free amine groups being followed 
by a step in which the N-terminal protecting Fmoc group 
was removed. The final step in' each cycle was the 
coupling of the resin bound peptide with the activated 
form of the next amino acid in the sequence. 
The capping step was eliminated in the first cycle of 
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the sequence, since capping of the loaded resin had 
been accomplished manually. 
The initial synthesis was carried out using DMA as 
the solvent Subsequent syntheses were carried out 
using identical cycles, but with DMF as the solvent. 
Thj_cjRR i 	_yc . 
Acetic anhydride (1 ml; 0.5 M in DMA), pyridine (imi; 
0.5 M in DMA) and DMA (8 ml) were transferred to the 
reaction vessel and vortexed with the resin for 2.5 
mm. The resin was then incubated with a second portion 
of the above mixture for a furthur 3.5 mm. The resin 
was then washed with DMA (6 X 10 ml) 
The Fmoc deprotection cycle .,_ 
Four deprotections were carried out with interleaved 
washes. 
The resin was vortexed with a solution of piperidine 
in DMA (20% (v/v); it) ml) for 5 mm. The deprotection 
solution was then collected and the resin was washed 
with DNA (3 X 10 m1). The combined washings were then 
pumped through the Uvi cord, as were all subsequent 
deprotection solutions and washings. The resin was then 
vortexed with a second portion of piperidine in DMA 
(207. (v/v); 10 ml) for 3 mm. and subsequently washed 
with DMA (3 X 10 ml). The third deorotection was 
carried out exactly as for the second. Finally, the 
resin was vortexed with a solution of piperidine in DMA 
(207. (v/v); 10 ml) for 1 mm. and then washed with DMA 
(8 X 10 ml). 
activationThe 	 ......  cy 
The activation cycle consisted of a double—couple 
cycle involving either a D(C and an HOBT coupling 
(DIC/HOBT double—couple cycle), or two HOBT couplings 
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(the HOET double-couple cycle) 
The amino acid (2 mmol) was dissolved in 
DMA (6 ml) and transferred to the activation vessel 
where activation of the amino acid was achieved by the 
addition of a solution of DIC in DMA (05 Fi 2 mmol, 4 
ml) and mixing. The activated amino acid was then 
transferred to the reaction vessel and was vortexed 
with the resin for 1 	h. 
Meanwhile the active ester of the amino acid was 
generated by dissolving a second portion of the amino 
acid (1 mmol) in DNA (4 ml) and adding a solution of 
HOET in DMA (0...5 M 1 mmol; 1 ml) and a solution of DIC 
in DMA (05 M 1 mmo].; 2 ml) The first coupling reagent 
was then drained from the reaction vessel and the resin 
was washed (. X 10 ml) before the HOET-activated amino 
acid was transferred to the reaction vessel and 
vortexed for 1 h The coupling reagent was then removed 
and the resin was washed (3 X 10 ml). 
This coupling procedure was used for all amino acids 
except g:Lutamine and arginine, when the HOST 
double-couple cycle was used, The HOET double-couple 
coupling cycles were carried out in the manner 
described for the HOBT portion of the DIC/HOET 
double-couple cycle. 
....purification of peot ides. 
ho.  
Sephadex 625 or 650 columns (30 cm X 0.9 cm diameter) 
were used and unless otherwise stated the eluent was 
30% aqueous acetic acid which was degassed prior to 
use. Columns were run under gravity and were monitored 
by u.v. at 254 nm and in certain cases by continuous 
ooticai rotation measurement. Fractions were collected 
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by a fraction collector, with a collection time per 
fraction of 20 mind 
Soluble compounds were dissolved in the minimum 
amount of aqueous acetic acids Insoluble compounds were 
sonicated with a small amount of glacial acetic acid 
and were then diluted.  
HFLC of peptides was carried out on the dual pump 
instruments from the following manufacturers: 
Waters: Model 60(:)0 liquid delivery system, Model 680 
Gradient controller, Model 441 Absorbance detector. 
Applied Biosystems: 151 Separation system. 
The columns used for HPL..0 were all reverse phase 
silica columns the following being most commonly used: 
NLYTICL COLUMNS: 
Column 1: Partisil 5 pm ODS--3-(L5, 	250 X 3.5 mm 
Column 2: Fartisi:L 5 pm oDs-FL.5-393 	250 X 3.5 mm 
Column 3: Far- tisil 5 pm ODS-FL5-385 	250 X 3.5 mm 
Column 4: Aquapore RF300 100 X 4.6 mm CS 
Column 5: Aquapore RP300 220 X 4.6 mm CS 
Column 6: Apuapore RP300 100 X 4.6 mm CIS 
Column 7: (quapore RP300 220 X 4.6 mm C18 
PREPARATIVE COLUMNS: 
Column 8: 	F'ar-tisi i OOS:3-FL10-250 1 	 250 x ic: mm 
Column 9: Aquapore RP300 100mmprep CS 	250 X 10 mm 
Column 10: Aquapore RP300 100 mm prep CIS 250 X 10 mm 
Column 11: Aquapore RP300 220 mm prep CS 	250 X 10 mm 
The solvents used for HPLC were acetonitrile and 
water. HFLC Grade acetonitrile was filtered through a 
Millipore By 0.45 pm membrane before use and was 
degassed if not used immediately after filtering. The 
water used was double distilled which was then filtered 
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through a Millipore Norganic cartridge and a Millipore 
GV 0.45 pm membrane, and degassed before use. Both 
solvents were made up to 0.1% TFA with HFLC grade 
tr- ifluoroacetic acid before use,, 
Analytical HPLC was carried out on peptides dissolved 
in an appropriate solvent, usually a combination of 
acetonitrile (0.17. TF) and water (0.17. TFA), to a 
concentration of approximately 2 mg mi. Samples 
were dissolved with the aid of sonication if necessary 
and were subsequently filtered either through a cotton 
wool filter or a FP-450 (::).45 pm (FP Vericel) membrane. 
20-25 p1 portions of the sample were injected on each 
run. Runs were monitored by U.V. at either 214 or 229 
nm, 
Gradients were run between the two solvents, with 
initially a low proportion of organic solvent, 
increasing to a high proportion of organic solvent at 
the end of a run. Gradients were optimised for 
individual peptides at each stage of their 
purification. The following linear Qrdients were most 
commonly used: 
Gradient 1: 10 to 507. MeCN in HO over 5 mm. 
	
50 to 80'. 	11 	 11 	 11 over 20 min. 
807. 	it 	 It over 5 	mm. 
Gradient 2: 10 to 407. 	It " 	over 5 mm. 
40 to 807. 	It ' 	 U over 30 mm.. 
807. 	is U 	over s mm. 
Gradient  10 to 907. 
90%  
Gradient  20 to 707. 
Gradient  10 to 307. 
30 to 507. 
Gradient  10 to 307. 
30 to 507. 
MeGN in H.O over 30 mm. 
U 	 It 	over S mm. 
It 	 It over 25 min. 
IS 	 over S min. 
It 	 It 	 it 	 over 20 mm. 
II 	 u 	over 5 mm. 
U 	 U 	over 10 mm. 
- 96 - 
Preparative HPLC was carried out on peptides 
dissolved in a mixture of acetonitrile and water. The 
amount of organic solvent used for dissolving the 
peptides was kept to an absolute minimum to prevent 
large amounts of the peptide emerging from the column 
with the solvent peak 
Samples were made up to a concentration of approx. 10 
mg m1 1 , filtered through a cotton wool plug and 
volumes of 0.5-1 ml were injected. Optimisation of 
purification was achieved by varying the volume of 
sample injected, the gradient used and the flow rate of 
solvent used (generally 4 ml min). Runs were 
monitored by u.v. generally at 229 nm, although 
relatively pure compounds were monitored at 235 nm. 
Certain peptides were sensitive to oxidation by air 
and were therefore collected in ice-cooled containers 
under a layer of petrol (b.p. 40-60'C). 
6.4.3 Fast Protein Liouid Purification. (FPLC) 
FF1_C was carried out on a Pharmacia instrument. 
Gradients were run on ion exchange columns, either 
anion exchange (Mono Gi) or cation exchange (Mono S). 
The buffers used were triethanolamine (pH 7.7; 20 
mM), malonic acid (pH 2.5; 20 mM) and piperazine (pH 
5.9 20 mM) and gradients were run between a solution 
of buffer containing no salt (Solvent ) and a solution 
of buffer solvent containing 1 N sodium chloride 
(Solvent B). 
Gradients were run from 07. B in A to 367. B in A over 
20 mm. The column was then flushed with 1007. B. 
The peptides were dissolved in the buffer to a 
concentration of 3-5 mg ml, filtered through a 
cotton wool plug and injected onto the column (200 pi). 
The runs were monitored by u.v. at 214 nm. 
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6.4.4 Dialysis. 
Dialysis was carried out using Spectra For 6 lOCx) 
molecular weight cut-off dialysis tubing in the buffer 
solutions indicated.. 
6.5 Cleavage technicues. 
6.5.1 Fmocdeprot.ection. 
The resin-bound peptide (200 mg) was sonicated with 
5-10 ml of a solution of 20% (v/v) piperidine in DMF. 
After 15 mm. the resin was filtered off, washed 
thoroughly (firstly with D!IF and subsequently with 
DCM) , ano dried in a desiccator.. 
6.5.2 Resin cleavaae and side chain deorotection 
The cleavage of the peptide from the resin and 
removal of acid labile side chain protecting groups was 
carried out using the following procedure and either 
cleavage mixture A or B. The reaction volume was scaled 
up or down as required. 
Cleavaoe mixture A. 
TFA 	(95% aq. 25 ml) 
iniso:Le (1,25 m1 
Ethyl methyl si.ti phi de 
(1,25 ml). 
Cleavaae mixture E. 
"I"F 	(957. aq. 	25 ml) 
Thioanisole (1.25 ml) 
Ethyl methyl sul phi de 
(1.25 ml) 
The resin-bound oeptide (150-200 mg) was sonicated 
under nitrogen with the scavengers for 15 mm.. The TF\ 
was then added and the mixture was sonicated under 
nitrogen for 2 hours or for the time determined for 
optimum cleavage. 
The resin was then filtered off and washed with a 
portion of 957. aq. TFA. The filtrate and washings were 
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then concentrated in vacuo and the peptide was 
precipitated by the addition of diethyl ether. The 
peptide was left standing at 4C overnight before 
being filtered, washed with ether and dried in a 
desiccator. 
6..5.3 Time delDrotection studies. 
A 10 ma sample of the resin-bound peptide was treated 
with 10 ml of either cleavage mixture A or B as 
described in section .5.2. Portions of the reaction 
mixture (1 ml) were removed by pipette after 30 mm., 1 
h, 2 h, etc and treated as follows. The sample was 
filtered through cotton wool to remove any resin 
present and the filtrate was concentrated in i.'acuo. 
The peptide was then precipitated by the addition of 
diethyl ether was collected by filtration. A portion of 
the precipitate was dissolved in a suitable solvent to 
a concentration of 2 mg ml 	and analysed by HF'LC 
The HPLC traces recorded for each sample were then 
compared to determine the oDtimum cleavage time. 
6-6 Initial synthesis ofPreCox IV 
An initial synthesis was carried out using the cycles 
described in section 6.3.6. The synthesis was monitored 
by the spectroscopic method described in section 6.3.5, 
and the data recorded was used to evaluate the areas of 
the synthesis in which problems could be expected. The 






Height of deprotection peaks 
1st 	 2nd 	 3rd 
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Ser2l 133 5.5 3 3 145 
5cr 20 146 A. 2 2 154 
Cys 19 154 5 2 2 153 
Leu 18 13::; 5 5 5 148 
Thr 17 131 7 6 5 149 
Arg 16 133 7 4 4 148 
Thr 15 91 10 7 5 113 
Ala 14 104 11 5 3 123 
Pro 13 95 11 8 5 119 
Lys 12 98 8 3 4 116 
Ph e J. 1 100 5 4 3 112 
Fhe 10 110 5 5 3 123 
Ara 9 110 9 : 3 125 
Ile 8 99 2 109 
5cr 7 95 A. 4 2 105 
G:ln 6 88 7 5 3 103 
Arg 5 91 5 5 2 103 
L cu A. 88 9 A. 3 104 
Ser3 83 6 3 3 95 
Leu2 77 7 5 2 89 
67 Synthesis and purification of FreCox IV usinc Acm 
..................c 	trercsidu. 
6.7.1 Synthesis. 
The synthesis was carried out using the cycles 
described in section 6.3.6. The cysteine protecting 
group used was S-acetamidornethyi and the solvent used 
was DMF. During the course of the synthesis various 
couplings were monitored using the spectroscopic method 
described in section 6.3.5. The N-terminal Fmoc 
protecting group was removed on the synthesiser. 
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The coupling of Thr 15 to Arg 16 was monitored and an 
additional H01 single coupling was carried out while 
the resin was crying. The coupling was found to have 
been quantitative. 
Resin samples were removed after the coupling cycle 
of Arg 9 (0.192 mmol g; 99%) and after the HOBT 
coupling of lie S to Ara 9 (0.138 mmci q' 67%). A 
second DIC coupling of lh. was carried out and the 
resin re-analysed ( 0.13:2 mrnol g 	647.) An 
additional coupling with HOBT activated amino acid was 
carried out for lh. Analysis of the resin showed the 
percentage coupling to be unchanged (0.132 mmci g; 
64%) and the synthesis was continued. 
The resin substitution was found to be 66% (0.209 
mmcl g) after the double couple cycle of Ser 7 to 
Ile 8 and 59% (0,189 mmcl g) after the coupling 
cycle of Arg 5. 
A resin sample was removed after the DXC coupling of 
Lou 4 to Ara 5 and resin substitution was found to be 
57% (0.101 mmcl g') of the theoretical value. 
The couplings of the last three residues in the 
synthesis were all checked after the double couple 
cycle: 55% (0.09 mmci g) after 5cr 3, 52% (0.089 
mmcl g') after Lou 2 and 63% (0.072 mmcl c') 
after Met 1. No additional couplings were thought to be 
necessary for these residues. 
6..72Cleveandpurificationof th e oeptid 
A sample of the resin-bound peptide was cleaved as 
described in section 6.5.1 and 6.5.2. The product 
obtained was sparingly soluble in water and was 
dissolved in mixtures of acetic acid and acetonitrile 
for analytical HF'LC (Column 2, Gradient 4). The 
analytical HFLC showed a large number of species to be 
present. 
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A sample of the crude peptide (150 mg) was dissolved 
in 10 ml of ammonium hydroxide (25 mM)/urea (3 M) 
buffer (pH 4.6) after sonication for several hours. 
A gel column was then run in the above buffer. The 
peptidic fraction obtained was dialysed sucessively 
into urea (1.5 M)/ammonium acetate (25 mM) pH 4.6, 
urea (0.7 M)/ammonium acetate (25 mM) pH 4.6 and 
ammonium acetate (25 mM pH 4.6) before lyophilisation. 
The amount of material recovered was 24.5 mg (167.). 
A second sample of the crude peptide (62 mg) was 
dissolved in acetic acid, acetonitrile, water (3710) 
and purified by preparative HPLC (Column 8 Gradient 
4). Thirteen fractions were obtained from the runs, and 
38.3 mg of peptic material was recovered (627.). 
Most of the material eluted from the column with the 
solvent peak (10.6 mg) , and the other most abundant 
fractions, fractions A and B, contained 5.3 and 4.5 mg 
respectively. 
Material A 
Analytical HPLC (Column 2 Gradient 4) showed a major 
peak eluting at 48.5% tleCN and minor peaks at 47.4, 
50.4 and 51.3 7. MeCN. 
Amino acid analysis : Thr 2.4 (2), Ser 4.19 (4), Glu 
100 (1) , Pro 0.58 (1) , Ala 1.18 (1) , Cys 0,88 (1) , Met 
0.76 (1) , Ile 1.01 (1) , Leu 5.59 (5) , Tyr 0.27 (1), Phe 
2.23 (2), Lys 1.15 (1), Arg 4.22 (4). 
Mass spectrometry (FAB) indicated a molecular ion 
(11H) of 3060. 
HRMS found 3059.68444. The Acm protected peptide, 
requires 3059.68428 (<1 ppm) 
Material B 
Analytical HPLC (Column 2 Gradient 4) showed a major 
peak eluting at 51.37. MeCN, with minor components 
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eluting slightly later. 
Arninc, acid analysis: 
0.97 (1), Pro 1..26 (1) 
0..83 (1), Ile 1.16 (1), 
2.10 (2) , Lys 1.11 (1) 
Mass soectrometry (F 
(MH) of 3049.. 
T hr 
Ala 








Ser 3.33 (4) , G.Lu 
(1) 	Cys 0.76 (1), Met 
Tyr 0..81 (1) , F'he 
 
ted a molecular ion 
Clee.vaae usi no th:i oani sole as a scavencer. 
A furth..tr portion of the resin-bound peptide from 
which the Fmcc group had been removed according to the 
procedure in section 6.5,1 (484 mg) was treated with 
cleavage mixture B as described in section 6.5.2.. The 
cleavage time used was 2.5 h.. The product obtained (241 
mg) was analysed by HFL.0 (Column 2 Gradient 4) and 
appeared to contain one major component. 
A pcwtiori of the zaml e (70 mg) was dissolved with 
difficulty in a 1:1 mixture of 	 (7 ml) after 
soni c- at ion for several hours and was purified by 
orroarL.. 	H I C (Column 10 ,j'c'icnt 	) 	Injections of 
oo l were monitored at 229 nm and a flow rate of 
4 m1 min - " was used. 
The main fraction from each run was combined and the 
solvent removed by 1 voph. ii sat:i on to produce Material 
C (21 mg). 
Material C 
Analytical HPLC(Column 5 Gradient 4) indicated that 
there was only one major cornoonent oresent with slight 
shoulders.. When coi niecti ons were run with Materials A 
and B. the major component co-eluted with Material B. 
Amino acid analysis 	Thr 1.97 (2).. 8cr 3..01 (4) 1 G:LLI 
1.05 (1) 	Pro ().96 (1) , Ala 1.11 (1), Cvs 0.73 (1) , Met 
0..74 (1), lie 1,.:10 (1) 1 L..eu 4..95 (5). Tyr 0..99 (1), Phe 
1.80 (2). Lys 1.00 K) 7 Arq 3..49 (4). 
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Mass spectroscopy (FAEi) indicated a molecular ion 
(MH ) of 3049. 
Ootimisation of acid cleavae conditions. 
Portions of the resin-bound peptide were treated to a 
time deprotection study as described in section 6.5.3 
using cleavage mixtures A and S. Portions of the crude 
peptide obtained after 1, 2, 3? 4 and 5 hours were then 
analysed by HFL.0 (column 4; Gradient 4). The peptides 
were searched for components co-eluting with either 
material A (the desiredproduct) or D. 
The cieavaae mixture containing thioanisoie (mixture 
B) produced one major component co-eluting with 
material B. At no time did a component co-eluting with 
material A appear as a major component. 
The cleavage mixture containing anisole (mixture A) 
produced two major components co-eluting with 
materials A and P. .....he proportion of material El in the 
mixture appeared to he greater than material A, 
although the reaction was carried out several times 
under identical conditions and the ratio of the two 
components appeared to vary. 
The optimum cleavage time using cleavage mixture A 
was found to be 4 hours. 
6.8 y 	andurificat±onof PreCcDx 	_g t Bu 
protection Jr 	 :i cyste ne residue. 
6.8.1ynth..i . 
An initial synthesis was carried out on a 0.5 mmoL 
scale using a preloaded resin of functionality 0.889 
rnrnol gi.  The synthesis was monitored by the 
spectroscopic method described in section 6.3.4. and 
used the cycles described in section 6.3.6. 
A second synthesis was later carried out on a 0.25 
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mmol scale using a preloaded resin of functionality 
0.636 mmo:1 pL  This synthesis was monitored using 
the Kaiser test (section 6.3.5 method 2). The coupling 
cycles used were of the double-HOBT type described for 
arginine and glutamine. All other cycles were as 
described in section 6..3.6.. 
6.8.2 Purification with N-terminal Fmoc crou intact. 
A sample of the resin bound Peptide was cleaved from 
the resin and deprotected as described in section 6.5.2 
without prior removal of the Fmoc group. 
The crude product (61 mg) was then purified by ce:L 
chromatography on a Sephadex 650 column. 
One main peak was obtained and the fractions 
corresponding to this peak were combined and 
lyophilised to produce a fluffy white solid (20.5 mg). 
The total amount of material recovered from the column 
was 23 mg (36). 
The product was then dissolved in acetonitrile/water 
(2:1) and analysed by HFLC (Column 1 Gradient 1). 
Preparative HPL.0 (Column Bz Gradient :L flow S m1 
min) was carried out on the sample. Two main 
fractions were obtained from the preparative HPLC. 
Fraction 1 : 	 1.1 ma 
Analytical HFLC (column 2radient 1) indicated the 
presence of 2 major components eluting at 62,:3 (most 
abundant component) and 63.2% acetonitrile. 
Amino acid analysis: Thr 1.86 (2). 5cr 3.25 (4), Glu 
1.09 (1) 1 Ala 1.32 (1) 7 Cys 0.64 (1), Met 0.22 (1), He 
0.85 W, Leu 4.61 (5) , Tyr 1.03 (1), Phe 1.92 (2) , Lys 
1.12 (1), Arc 3.91 (4). 
Fraction 2 	 1.4 ma 
Analytical HPL.0 (column 2;gradient 1) indicated the 
presence of 2 major components eluting at 62.3 and 
63.2'!. (most abundant component) acetonitrile. 
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Amino acid analysis : Thr 1.79 (2), Ser 3.58 (4), Glu 
0.96 (1), Ala 1.20 (1), Cys 0.63 (1), Met 0.72 (1), lie 
0.99 (1), Leu 4.68 (5), Tyr 0.94 (1), Phe 1.84 (2), Phe 
1.84 (2), Lys 1.23 (1), Arg 3.39 (4). 
6.8.3 purification with only the cysteine protecting 
group still present. 
A sample of the resin bound peptide (71.4 mg) was 
deprotected and cleaved as described in section 6.5.1 
and 6.5.2 using cleavage mixture A. The cysteine - 
protecting group was not removed at this stage. 
A time deprotection study was carried out as 
described in section 6.5.3, and the optimum cleavage 
time was found to be A. h. 
Gel chromatography of the crude peptide was carried 
out on Sephadex GSC) as described previously. Two main 
fractions were obtained from the column, the first to 
come off the column being the main fraction (35.6 mg) 
(material D). 
Analysis by HPLC (Column 2, Gradient 1) showed that the 
second gel fraction contained only a very small amount 
of the most abundant peptide component and was 
therefore discarded. 
The crude peptide was then purified by preparative 
HPLC (Column 8, Gradient 2) as described previously. 
The two main fractions were collected and analysed by 
HPLC (Column 2, Gradient 3). Both fractions contained 
substantial amounts of the other component, and the two 
materials were excluded from the column in eluents 
differing by only 2% in acetonitrile. The two fractions 
obtained were therefore combined (material E). 
A sample of material E (1 mg) was sonicated with 
triethanolamine (pH7.7; 20 mM, 200 .l) and hydrochloric 
acid (0.1 M; 20 pl) and the undissolved material was 
filtered off. FPLC of the solution was then carried out 
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on Mono 0 column as described previously, using 
triethanolamine (pH 7.7; 20 mM) as the buffer solution. 
No peaks were observed to elute from the column, 
although the sample was analysed by HPLC (Column 2, 
Gradient 3) and shown to contain the two major peptide 
components previously observed. 
A second sample of Fraction 2 (1 mg) was dissolved as 
described above in aqueous malonic acid (pH 2.5; 20 mM; 
400 p1) and an ion exchange gradient was run on a 
cation exchange column (Mono S) as described above with 
malonic acid (pH 2.5; 20 mM) as the buffer solution. 
However as before no fractions containing the main 
peptide components (as determined by HPLC under the 
same conditions described above) were observed. 
6.8.4 Evaluation of the optimum solvent system for the 
deprotectionof cysteine_residue. 
H.Cys(SBu).OH (9.2 mg, 44 pmol) was stirred with 
the solvent given below (4 ml) under nitrogen. 
Tri-n-butylphosphine (150 p1, 600 pmol) was added and 
the reaction was monitored by t..1.c.. (system C, 
cellulose t.l.c. plates, I vapour detection). 
Standard samples of cysteine, H.Cys(SBu)OH, cystine 
and cysteic acid were obtained or prepared and their 
R '.alues in the above t.l.c. system noted [0.22, 
0.77, 0.04, 0.04 respectively]. The reaction in acetic 
acid (50% aqueous) was very slow (95% complete in 24h.) 
and the product observed had an R of 0.04, indicating 
that the disulphide had formed. 
Other solvent systems tried included sodium 
bicarbonate (0.5 M)/n-propanol (1:1) -major product 
R- 0.22, unidentified impurity R 0.36, reaction 
complete in 30 min., and dioxan/water (8:2) - major 
product R 0.22, reaction complete within 30 mm. The 
latter was found to be the cleanest most efficient 
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solvent for the deprotection of H.Cys(StBu)OH. 
6.8.5 Deprotection of PreCox IV in dioxan/water. 
A sample of material D (9.2 mg, 3.1 Iimol) was stirred 
with dioxan/water (8:2; 1.2 ml) in a 5 ml Wheaton vial. 
Tri-n-butylphosphine (20 p1,43 pmol) was added •and the 
reaction was stirred for 6 h. The reaction mixture was 
then mixed with phosphate buffer (50 mM; pH 5.6; 2 ml) 
dialysed against 6 M urea/phosphate buffer (50 mM; pH 
5.6; 15 mM mercaptoethanol; 1000 ml) and subsequently 
against 3 M and 1 M urea in the same buffer before 
final dialysis ( X3) against the phosphate buffer. 
The dialysed solution had become cloudy and was 
therefore centrifuged and the supernatant concentrated 
in an ultrafiltration cell. A u.v. of the concentrated 
solution was recorded and the absorbance at 267 nm 
measured. It was calculated from the extinction 
coefficients of tyrosine and phenylalanine that the 
solution contained approximately 3 mg of peptidic 
material. 
The concentrate was dialysed against piperazine 
solution (20 mM; pH 5.88; 5 mM mercaptoethanol; 1 1) 
several times before analysis by FPLC. 
The analysis was carried out on an anion exchange 
column (Mono Q) in the manner previously described, 
using 200 p1 samples and Using piperazine (pH 5.89; 20 
mM)as the buffer solution. The different fractions 
obtained from the preparative runs were combined and 
lyophilised. Four fractions were collected and the 
weights of material from the freeze-dried fractions 
were 38, 66, 266 and 400 mg respectively. HPLC analysis 
of the fractions indicated that the desired peptide 
fragment was not present in any of these fractions. 
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6.8.6 Optimum conditions for the deprotection of the 
StBu function. 
The crude peptide previously obtained (171 mg 56 
imol) was sonicated with trifluoroethanol (95% aqueous) 
until completely dissolved. Tri-n-butylphosphine (140 
gil; 560 iimol) was then added and the reaction was 
sonicated for lh. The solution was then concentrated 
in vacuo and the peptide was precipitated by the 
addition of diethyl ether. 
The crude peptide was analysed for free thiol by 
Eliman's test. 1.90 mg of the peptide was dissolved in 
a mixture of 2,2'-dipyridyldisulphide (2-PDS) solution 
(standard of approximately 2 mM 1 ml), pH7 buffer 
solution (2 ml) and acetonitrile (2 ml) in a 5 ml 
volumetric flask. The u.v. absorbance of the peptide 
solution at 343 nm was recorded against a blank of 1 ml 
of 2-PDS solution in acetonitrile (2 ml) and pH7 buffer 
(2 ml). Extrapolation of the absorbance recorded 
(0.337) from a standard graph indicated a concentration 
of free thiol of 0.065 mmol dm, 51% of the value 
expected (0.127 mmol dm). 
6.8.7 Purification of the fully deprotected peptide. 
A sample of the crude fully deprotected peptide (144 
mg) was prepared obtained as described in sections 
6.5.1, 6.5.2 and 6.8.6, and was dissolved in a mixture 
of acetonitrile and water (1:1; 10 ml). The sample was 
then purified by preparative HPLC (Column 9; Gradient 
5) , and two main fractions were obtained. The solvent 
front fraction contained 21 mg of material. The major 
component was isolated and lyophilised (8.9 mg). 
Analytical HPLC (Column 4; Gradient 5) indicated that 
the peptide was not pure. A second preparative run was 
then carried out and the product which was isolated 
(4.0 mg) was analysed by HPLC (Column 4; Gradient 4). 
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The analysis indicated a major component eluting at 
45..5% acetonitrile, with slight impurities. 
It was subsequently discovered that the preparative 
HPLC was significantly simplified if the peptide was 
initially purified using gel filtration.. A sample of 
the crude fully deprotected peptide was prepared as 
described in section 6.8.6, except that the peptide was 
not, precipitated with diethyl ether after the TEE was 
removed. 
The concentrated solution was redissolved in 
acetic acid (1. ml) which was subsequently diluted 
with water (1 ml). The sample was then purified by gel 
chromatography on a Sephadex 625 column, eluted with 
30% aqueous acetic acid as described previously.. 
The fractions obtained from the column were analysed 
by HPLC (Column 4; Gradient 4).. Fractions 61-75, 76-81 
and 82-90 were combined and lyophilised (48.6, 3.3 and 
12.8 mg respectively), and subsequently analysed by 
HPLC (Colunm 4; Gradient 5) 
The major fraction (48.6 mg) was then purified by 
preparative HPLC (Column 9/10/11; Gradient 5; flow rate 
4 ml min - IL). Three series of preparative runs were 
carried out before the product was purified to a 
satisfactory level.. 
6.8.8 Characterisation of pure PreCox IV. 
Analytical HPLC: Column 4, Gradient 4 one peak 
eluting at 45.57. acetonitrile. 
Amino acid analysis: Two sets of data were recorded-
Thr 2.12, 2.12 (2), Ser 3.56, 3.20 (4), Glu 0.62, 1.15 
(1), Pro 1.20, 0.99 (1), Ala 0.99, 0.96 (1), Cys 0.84, 
0.84 (1), Met 0.87, 0.88 (1), Ile 1.04, 1.07 (1), Leu 
5.13, 5.08 (5), Tyr 1.03, 0.90 (1), Phe 2.10, 2.01 (2), 
Lys 1.24, 1.12 (1), Arg 4.05, 3.75 (4). 
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FAB tl/S: 3088, 3044, 2990 (100X; MH). 
HRMS: Caic. for C1H 	NOS 2988.64717 
Found: 2988.64721 (<lppm). 
Sequencing: Met, Lou, Ser, Lou, Ar- g, Gin, Ser, lie, 
Arg, Phe, Phe, Lys, Pro, Ala, Thr, Arg, Thr, Lou, Cys, 
Sor, Ser, Arg, Tyr, Lou, Lou. 
Eliman's test: 1.150 mg of pure PreCox IV was 
dissolved in 1 ml of distilled water (volumetric 
flask). A portion of the solution was then removed (70 
p1) and added to 1 ml of 2-PDS solution which was then 
made up to 5 ml (volumetric flask) with pH7 buffer. 
The absorbance of the above solution at 343 nm was 
then recorded against a blank of 1 ml 2-PDS solution 
made up to 5 ml with pH7 buffer. 
Extrapolation of the absorbance recorded (0.031) 
against a standardised graph indicated a concentration 
of free thiol of 0.0058 mmol l, equivalent to a 
concentration of 0.379 mmol l 	in the original 1 ml 
solution, 98% of the theoretical value (0.385 mmol 
6.9 The synthesis and purification of PreCox IV(11,12). 
MLSLRQSIRFPATRTLCSSRVLL. 
6.9.1 Synthesis. 
The synthesis of this peptide was carried out on the 
ABI 430A automatic peptide synthesiser on a 0.5 mmol 
scale using a preloaded capped rosin (0.423 mmol 
g'). The cycles used were those described in section 
6.3.6 except that activated amino acids were incubated 
for lh. (DIC coupling) and 45 mm. (HOBT coupling) and 
the solvent used was DMF. Serine, threonine and 
tyrosine were protected as Bu ethers, lysine by the 
Soc group, arginine by Pmc and cysteine by the SBLt 
group. 
A resin sample was removed after the second coupling 
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of Arg 20 to Tyr 21. The sample was analysed as 
described in Method 1 section 6.3.5 and the 
substitution was found to be 0.283 mmol g 1 (887.). 
Samples were also removed and analysed after the 
couplings of Ser 19 to Arg 20 (0.318 mmol g; 1127.) 
and Leu 16 to Cys 17 (0.228 mmol g; 907.). An 
additional HOBT coupling of Leu 16 to Cys 17 was 
carried out and the resin was re-analysed. (0.265 mmol 
g'; 1057.). A resin sample was analysed after the 
coupling of Thr 15 to Leu 16 (0.249 mmol gt; 1037.) 
and the coupling of Ala 12 to Thr 13 (0.158 mmol g; 
757.). A second (0.162 mmol g'; 77"!.) and third extra 
HOBT coupling (lh..) was carried out before a 
satisfactory coupling was achieved (0.179 mmol g; 
857.). At this stage half the resin was removed. 
An additional lh. HOBT coupling of Pro 11 to Ala 12 
was carried out before a resin sample was checked 
(0.144 mmol gL;  707.), and the coupling of the next 
residue, Phe 10 to Pro 11 was monitored (0.148 mmol 
g 1 ; 747.). 
Samples were monitored after the coupling of lie 8 to 
Arg 9 (0.180 mmol g; 727.) and Arg 5 to Gin 6 (0.114 
mmol g; 747.). 
The coupling of the final residue (Met 1 to Leu 2) 
was monitored (0.0824 mmol g 1 ; 587.) and an 
additional HOBT coupling (lh. 40 mm.) was carried out. 
The Fmoc protecting group was not removed on the 
synthesiser but capping was carried out before the 
resin was removed, washed with DMF and DCM and dried 
(1.220 g, approx. 747.) 
6.9.2 Cleavage of the peptide from the resin and 
removal of protectjg groups. 
The N-terminal Fmoc group was removed as described 
in section 6.5.1, and a time deprotection cleavage 
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study was carried out as described in section 6.5 using 
cleavage mixture A. The optimum cleavage time for this 
peptide was found to be 2.5 h. Removal of the thiol 
protecting group was achieved using the method 
described in section 6.8.6. Analysis by HPLC (column 
gradient ) and by Eliman's test indicated that the 
cleavage was complete within 1 h. 
6.9.3 Purification of PreCox IV( 11,12). 
The peptide was dissolved in 50% aqueous acetonitrile 
and preparative HPLC was carried out (Columns 9, 
10; Gradient 6). Preparative HPLC was carried out 
sever.al times before a pure product was obtained. It 
was observed that the purepeptide was rapidly 
degraded on standing at room temperature to a mixture 
containing the desired peptide and a component eluting 
at a slightly lower proportion of acetonitrile. When a 
solution of this peptide was sonicated with 
-mercaptoethanoi for 30 mm. the peptide appeared pure 
by HPLC. 
CHARACTERISATION OF PreCox IV( 11,12). 
Analytical HPLC: Column 4, Gradient 4 Main component 
elutes at 35.5% acetonitrile, dimer- elutes at 35.0% 
acetonitri le. 
Amino acid analysis: Thr 2.01 (2), Ser 3.24 (4), Glu 
1.17 (1), Pro 0.99 (1), Ala 1.04 (1), Cys 0.85 (1), Met 
0.80 (1), lie 0.98 (1), Leu 5.20 (5), Tyr 0.98 (1), Phe 
0.98 (1), Arg 4.01 (4). 
FAB M/S: 2990 (1007.; MH). 
HRMS: Calc. for C11H -.N OS: 2713.48370 
Found: 271.48380 (<lppm). 
Sequencing: Met (Leu) , Leu (Ser), Ser (Leu) , Leu 
(Arg), Arg (Gin), Gin (Ser), Ser. (lie), lie (Arg), Arg 
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(Phe), Phe (Pro), Pro (Ala), Ala. (Thr), Thr (Arg), Arg 
(Thr), Thr (Leu), Leu, ? (Ser), Ser, Ser (Arg), Arg 
(Tyr), Tyr (Leu), LeU, Leu. 
6.10 Circular dichroism (CD) studies. 
Far-uv circular dichroism spectra were recorded on a 
JASCO 3600 Spectrophotometer in the region 260-190 
nm using a quartz demountable cell of path length 0_1 
mm or 1 mm.. The spectra were averages of two scans, 
recorded at 10 nm min. - ' with a sensitivity of +1- 10 
millidegrees full scale deflection with an instrumental 
time constant of 4 s. The data are presented as molar 
circular dichroism, calculated using a mean residue 
weight of 113. The data was converted to molar 
ellipticity (see rquation below) and the CD intensity 
at 222 nm was divided by -27900 in order to determine 
the fraction of helix present by the method of Chen et 
al. M. The data were also analysed using the CONTIN 
program (Provencher & Glockner (vi)) which uses CD data 
from 16 proteins of known structure.. 
6.10.1 PreCox IV.. 
A stock solution of PreCox IV was prepared by 
dissolving the peptide (4.000 mg) in 1.000 ml of 
distilled water. However the peptide did not completely 
dissolve even upon the addition of 1 ml of TFA. 
The solution was then filtered and a U.V spectrum of 
the solution was run. Assuming an extinction 
coefficient of 1.15 X 10 M' cm 	at 278 nm, the 
concentration of peptide was calculated to be 3.77 mg 
ml. The concentration of the stock solution was 
later reassesed by quantitative amino acid analysis of 
53 i1 of the peptide solution.. The concentrations (Imol 
ml) obtained per single residue of each amino acid 
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were recorded Thr (0.0465), Ser (0.38), Glu (0.051), 
Pro (0.055), Ala (0.051), Met (0.045), lie (0.049), Leu 
(0.045), Tyr (0.044), Phe (0.047) Lys (0.051), Arg 
(0.046). The average value (0.04823 pmol m1 1 ) and 
standard deviation (0.0034 pmol ml -1 ) were used to 
calculate that the stock solution contained 2.72 +1-
0.2 mg m1 1 . 
The Bradford protein assay was carried out on the a 
portion of the stock solution, as was the Lowry protein 
assay, and the values obtained were 4.35 and 6.42 mg 
ml 	respectively. Bovine serun albumin (BSA) was the 
standard used for the two assays. 
The helical content of the peptide was later 
evaluated based on the concentrations obtained from the 
amino acid analysis. 
A series of C.D. spectra of the peptide were then run 
on diluted portions of the stock solution in a variety 
of buffers, such that the concentration of the peptide 
was always 0.9425 mg m1 1 . 100 il of the solution was 
loaded in a 0.1 mm cell. 
The buffers used were 
20 mM phosphate buffer pH 7.0 - 0 (a), 25 (b) and 
507. TFE (c). 
5 mM Tris buffer pH 8.0 - 0 (a), 25 (b), 40 (c), 50 
(d) and 607. TFE (e). 
10 mM Na-Hepes / 150 mM NaCl 
10 mM Na-Hepes / 150 mM NaCl / Precox IV 
10 mM Na-Hepes / 150 mM NaCl / 20 mM SDS / PreCox IV 
C.D. spectra of solutions were recorded and that of 
(3) was subtracted from (4) and (5) before Contin 
analysis was carried out. 
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Results. 
Buffer Chen helix Contin helix 	Contin sheet 
la 4.8 2.8 
lb 12.6 3.3 
ic 23.7 25.2 
2a 1.8 4,4 
2b 10.6 8.9 
2c 17.8 16.7 
2d 17.8 14.0 
2e 21.4 20.6 
4 - 3.0 	 96.9 
5 20.8 8.5 	 38.5 
Later .a furthur set of spectra were recorded. A fresh 
stock solution of PrCox IV was prepared by dissolving 
1.150 mg of the peptide in 1.0 ml of distilled water. 
Spectra were run either in a 1 mm cell (300 V1 of 
solution required) or in a 0.1 mm cell (100 iil of 
solution required) at a peptide concentration of 0.04 
mg ml -1 . 
The following solutions were then prepared and their 
CD spectra recorded. 
10 mM SDS / 0.3 M NaCl 
PreCox IV / 0.3 M NaCl 
PreCox IV / 10 mM SDS / 0.3 M NaCl 
PreCox IV / 10 mM sodium citrate buffer pH 3.93 - 
0 (a), 30 (b), 50 (c) and 70 (d) 7.TFE. 
The spectrum of (6) was subtracted from (7) and (8) 
by the computer before Contin analysis was carried out. 
r._. .1 A. _ 
Buffer 	Chen helix 	Contin helix 	Contin sheet 
7 	 - 	 - 	 53.5 
8 	 19.4 	 1.3 	 69.6 
9a 	 3.3 	 - 
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Buffer 	Chen helix 	Contin helix 
9b 	 11_1 	 4.6 
9c 	 11.7 	 - 
9d 	 17.3 	 7.2 
Varied concentration studies. 
A series of solutions were prepared in which the 
buffer remained identical, but the concentration of 
the PreCox IV peptide varied. These spectra were run in 
water / IFE mixtures at 0, 30 and 507. TFE at the 
following concentrations 
10) 	0.134 mg m1' 	0(a), 30(b), 50(c), 70(d) /. TFE. 
11) 0.230 mg m1' : 50 7. TFE. 
12) 0.345 mg ml 	: 50 7. TFE. 
13) 0.575 mg ml -1 	0(a), 30(b), 50(c) 7. TEE. 
_._..1 .I._ 
Buffer 	Chen helix 	Contin helix 
10 	 14.4 	 11.8 
11 	 13.0 	 4.6 
12 	 13.0 	 8.3 
13 	 13.0 	 10.1 
6.10.2 PreCox IV(11,12).. 
A stock solution of the peptide was prepared by 
dissolving 1.19 mg of the peptide in 1 ml of water. The 
following solutions were then prepared and their 
spectra recorded in a 1 mm cell (300 p1 solution 
required). The peptide concentration used was 0.04 mg 
ml -1 . 
14) 10 mM sodium citrate pH 3.93 - 0(a), 30(b), 50(c) 
and 70 (d) 7. TEE. 
 10 mM SDS / 0.3 M NaCl 
 PreCox IV(a11,12) 0.04 mg ml' I 0.3 M NaCl 
 PreCox IV(11,12) / 10 mM SDS / 0.3 M NaC1 
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The spectrum Of (15) was subtracted from those of 
(16) and (17) before Contin analysis was carried out. 
.1 4-. 
Buffer Chen helix Contin helix Contin sheet 
14a 3.9 0 72.1 
14b 8.9 2 55.3 
14c 12.2 0 69.7 
16 4.2 0 48.6 
17 10.0 56 43.5 
6.11 NtIR studies on the PreCoxIpeptide. 
NMR experiments were performed on a Varian VXR-5000 
at 600 M Hz. Data sets consisting of 256 t1 
increments of 32 transients were collected for the 
TOCSY experiment, and spectra were resolution enhanced 
by zero-filling and by shifted sine-bell 
multiplication. 
Data sets consisting of 256 ta increments of 16 
transients were collected for the NOESY experiment, 
with a mixing time of 200 ms. Spectra were processed as 
described for the TOCSY experiments. 
The experiments were carried out on a 4.7 mM 
solution of the peptide in either 1:1 HO: d-TFE 
or 1:9 HO:d---TFE at pH 3.9. 
TOCSY spectra were recorded at 30C and 40C, and 
NOESY spectra at 30C. 
A 1-D spectrum of a 2.35 mM solution of the peptide 
at 30C and pH 3.9 was recorded. 
'H-exchange experiments were carried out by 
dissolving the peptide in 11 DO:d-TFE and 
recording the 1-D spectrum of the peptide after various 
time intervals. 
The chemical shift assignments for the PreCox IV 
peptide in 1:1 HO:TFE at 30C are listed below. 
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Residue NH aCH CH's Other protons 
Meti - 4.055 2.11,2.18 '&CH's 2.56 
EMe 2.10 
Leu2 8.36 4.36 1.575 CH's 1.575 
Mes 0.815 
Ser3 8.29 4.43 3.98,3.82 
Leu4 8.36 4.17 1.575 CH's 1.575 
SMe's 1.575 
ArgS 8.055 4.00 1.74,1.60 CH's 1.54 
CH's 3.11 
NH 7.11 
31n6 7.82 4.12 208 CH's 2.31 
NH's 6.64, 
7.25 
Ser7 8.09 4.28 3.96 9 3.85 
11e8 7. E33 3.91 1.82 CH's 1.50, 
1.16 
Me 0.82 
Arg9 7.63 4.05 1.63 CH's 1.38 
CH's 3.01 
NH 7.03 
PhelO 7.73 4.42 2.97,2.79 aromatic 7.17, 
7.01 
Phell 7.84 4.47 3.02 1 2.95 aromatic 7.17, 
7.07 
Lys12 8.00 4.36 1.77,1.64 CH's 1.36 
CHS 1,43 
ECH'S 2.93 
Prol3 - 4.22 0 / V CH's 2.17, 	1.94, 1.82 
CHs 3.51, 	3.42 
A1a14 7.93 4.17 0 Me 	1.38 
ThriS 7.90 4.13 4.01 'Me 1.13 
Arql6. 8.025 4.12 1.805 CH's 1.60 
CH's 3.09 
NH 7.13 
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Thr17 7.80 4.44 
LeulB 7.39 4.18 
Cys19 8.12 4.32 
Ser20 7.85 4.25 
Ser2l 7.98 4.35 
Arg22 7.97 4.15 
Tyr23 	7.70 	4.44 
Leu24 	7.64 	4.27 
Leu25 	7.39 	4.18 
	
3.91 	VMe 	1.13 
1.55 	CH's 	1.55 
6t1E's 0.815 
3. 10,2. 88 
3.84 
3.87,3.82 
1.625 CH's 1.38 
- 6CHS 3.02 
NH 7.03 
3.00,2.97 aromatics 	7.04, 
6.73 
1.55 CH's 1.55 
MEs 0.815 
1.55 jCH's 1.55 
Me's 0.815 
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6.12 Methods and materials used for Microbiological 
Experiments. 
12 1 Strains of ECo1I used and culture conditions. 
The following strains of E.Cc1i were used in the 
course of these experiments: 
Strain 	 Genotype. 
MM294 Pro, endoA, thi, hsdR 
hsdm, 
TG1 	 K12, (lac-pro), SupE, thi, 
hsd5/F'traD36, FroAB, lacI9, 
lacZ MiS 
Culture conditions 
Cells were grown up in L-Broth (LB) me iium with 
antibiotic when required. The antibiotic ampicillin was 
used at concentrations of 100 pg/mi when required 







6. 12.2 Solutions and buffers used 
TE : 10 mM Tris.HC1; 1 mil EDTA pH 7.5 
TEG: 25 mM Tris.HCi 10 mM EDTA 50 mM glucose pHB.0 
Butfers for restriction enzyme digests: The specific 
lOX buffers necessary (REACT3 / REACT 4) was used as 
supplied by the manufacturer. 
Buffers used for the gel electrophoresis of DNA: 
lOX Loading buffer: 	257. (w/v) Ficoll 
0.257. (w/v) Bromophenol blue 
lOX TBE: 0.89 M Tris; 0.89 M boric acid; 20 mM EDTA 
pH 8.0 
Ligationbuffer: SX ligation buffer used as supplied 
by the manufacturer. 
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Buffers used for SDS Polyacrilamide gels: 
Acrylamide stock solution: 30% (w/v) acrylamide 
0.87. (w/v) bisacrylamide 
4X Separating buffer: 1.5 M Tris.HC1 pH 8,8 
0.4'/. (w/v) SDS 
4X Stacking buffer: 0.5 M Tris.HC1 pH 6.8 
0.4% (w/v) SDS 
lOX Running buffer: 0.25 ri Tris; 2.0 N glycine 
17. (w/v) SDS 
Sample buffer: 50 mM Tris.HC1; 2% (w/v) SDS 
0.1% (w/v) Bromophenol blue: 10% (w/v) glycerol; 
100 mM mercaptoethanoL 
Staining solution: 457. methanol, 10% acetic acid 
0.2% PAGE BLUE 
Destain: 5% methanol, 4.2% acetic acid 
Western Blot transfer solution: 
250 mM Tris.HC1 PH 8.3; 1.5 M glycine 
8, TBS : 10 mM Tris,C:L pH 7.5 
iSo mM NaCl.  
6.12.3Isolation of DNA from ECe,ii 
Small and large scale isolation of DNA from 
transformed E.Coli was performed essentially as 
described by Birnboim and Doly (188). Caesium chloride 
/ ethidium bromide gradients were carried out according 
to Maniatis et al. (189). 	 - 
Small scale isolation (linipreps) 
The transformants were grown up in LB-ampicillin 
media to stationary phase. The cells were then spun 
down at 8,000 r.p.m. in a Sorvall centrifuge for 5 mm. 
The pellet was resuspended in TES (100 l) and 
transferred to a sterile 1.5 ml Eppendorf tube. The 
cells were then lysed by the addition of 0.2M NaOH /1'!. 
SDS solution 200 ul) and kept on ice for 5 mm. 
- 	 - 
Chromosomal DNA was then precipitated by the addition 
of sodium acetate solution (3 let, pH 5, 150 p1). The 
mixture was then spun in a micro+uge for 10 mm. at 
4C. The supernatant was removed to another tube and 
was extracted with phenol /chloroform, and ethanol 
precipitated (see next section). 
The DNA pellet obtained was re-dissolved in TE (50 
p:L) and 5 p1 aliquots were digested with the necessary 
restriction enzymes (Hindlil/EcoRi or Kpnh/EcoRI) and 
buffers (REACT3/REACT4) and RNAse (1.25 mg mi) in a 
total volume of 20 p1. 
Large scale isolation of DNA.. 
Overnight cultures of the transformants were grown in 
L-B ampicillin medium and used to inoculate the 
selective medium (2 X 100 ml) which were then grown 
with good aeration at 37C overnight.. 
The cells were then spun down at 8000 r.p.m. in a 
Sorvall SA00 rotor at room temperature, and the pellet 
was resuspended in lEG (4.5 ml). After vortexing the 
suspension was transferred to a 50 ml centrifuge tube. 
A solution of lysozyme (0.5 ml, 15 mg ml ....) in TEG 
was added and the mixture vortexed briefly and left to 
stand on ice for 15 mm. A solution of 0,2 t1 NaOH/17. 
SDS was added to the tube and the contents were mixed 
thoroughly by inversion. After a furthur 5 mm. - 
incubation period on ice, a solution of sodium acetate 
(3 M, 11.25 ml) was added and the suspension mixed 
thoroughly by inversion. After standing on ice for 30 
min.-1 h. the chromosomal DNA was precipitated by 
spinning in a Sorvall SS34 rotor at 1000-20000 r.p.m. 
for 40 mm. at 4 1 C. 
The supernatant was carefully removed to a 300 m1 
Sorvall centrifuge bottle, isopropanol (22.5 ml) was 
added, mixed thoroughly and left at room temperature 
-: 
A 
for -iO mm. The suspension was then spun at 10000 
r.p.m. in a Sorvali SA00 rotor for 10 mm. The 
supernatant was discarded and the pellet was drained 
for about 20 mm. before being dissolved in rE (3 ml) 
to which ethidium bromide (10 mg/ml; 0.1 ml) and 
caesium chloride (3.8 g) were then added. The solution 
was divided equally between two 2 ml ultracentrifuge 
tubes. The tubes were then spun at 80000 r.p.m. 
overniht in a TL-100 ultracentrifuge. 
The plasmid DNA was viewed in the gradient under u.v. 
light and the band corresponding to supercoiled DNA was 
removed from the tube with a syringe (total volume 
removed about 200 p1). 
The ethidium bromide was then removed by extraction of 
the solution with isopropanol saturated with caesium 
chloride solution several times until the aqueous layer 
was no longer coloured. 
The solution was transferred to a 30 ml sterile 
silanied Core,- tube and TE (8 ml) was added. The 
plasmid DNA was precipitated by the addition of 
isopropanol (8 ml) and standing at -20'C for 1 h, 
The suspension was then spun at 8000 r.p.m. for 20 mm, 
the supernatant was poured off and the pellet was 
drained for 20 mm. 
The pellet was resuspended in TE (200 p1) and 
transferred to a sterile 1.5 ml Eppendorf tube. The 
Corex tube was rinsed with a furthur portion of TE (200 
p1). The DNA was obtained by ethanol precipitation of 
the TE solution (see next section). 
Phenol/Chloroform extraction and ethanol_precipitation 
of DNA. 
The DNA was diluted to at least 200 p1 as required 
and the salt concentration was adjusted to 0.3 M with 
3 M sodium acetate tolution. An equal volume of phenol/ 
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chloroform (1:1) was added, the mixture was vortexed 
and spun in a micro-fuge for several minutes. 
The aqueous layer was then transferred to a second 
15 ml Eppendorf tube. An equal volume of chloroform 
was added and the mixture was vortexed and spun in a 
ml crofuge. 
The aqueous layer was removed to another 1.5 ml 
Eppendorf tube and ethanol (0.9 ml) was added. The 
suspension was stored at -20C for at least lh. 
before being spun in a microfuge at 4'C for 20 mm. 
The pellet was drained, vacuum dried and resuspended 
in TE (200 p1). 
6.12.4 RecombinantDNA manipulations. 
Restriction  
Restriction enzyme digests for the preparatibn of 
plasmid fragments were carried out in a total volume of 
100 p1. All digests were carried out as doube-digests 
in a buffer compatible to both restriction enzymes, 
REACT 3 for Hindlil/EcoRl and REACT 4 for KpnI/EcoRI 
digests. and were monitored by agarose gel 
electrophoresis of the digest mixture. Digest mixtures 
were incuoated for between 2 and 24 M at :37 
is of 
. . 
0.8% Agarose ci ectrophoresi s gels were prepared-by 
bringing a mixture of agarose (0.8 g) and TBE (bc) ml) 
to the boil. The solution was allowed to cool to c.a. 
50"C before the addition of ethidium bromide (6 pl). 
The gel was then poured and allowed to set. 
A portion of the restriction enzyme digest was then 
mixed with loading buffer and inserted into the wells 
in the gel. Aliquots of > pnage DNA markers were loaded 
if desired. The gel was then run at a constant voltage 
of c.a. 10 V 	 and the fragments subsequently 
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viewed under u.v. light.  
If preparative gels were run the desired band of DNA 
was cut out of the gel and the fragment obtained by 
electroelution of the gel fragment and subsequent 
ethanol precipitation of the sample obtained The 
Geneclean procedure for the isolation of DNA from gels 
was also satisfactorily carried out, although a 
significant loss of DNA was noticed on occasions 
lion of DNA fragments. 
Ligation of DNA fragments was achieved using 14 DNA 
ligase and incubation in DNA ligase buffer at room 
temperature for 2-12 h The ligation mixture (3 p1) was 
then used to transform competent cells, and the 
transformed cells were then grown on LB ampicillin 
plates. 
612.5 Transformation  of E.Cii with .aLasmid DNA 
Prep aration of tra.nsformatin compet.nt cells. 
A culture of the desired strain was grown to 
stationary phase in 5 ml of LB The culture was then 
diluted 1:100 into 200 ml of fresh medium and grown at 
37'C with shaking to OD..::c O.S.The cells were then 
spun in a Sorvail SA00 rotor at 10000 rpm. for 5 
min at room temperature, and the resultant pelit was 
resuspended in sterile cold calcium chloride solution 
(100 ml; 100 ml) and left to stand on ice for 20 mini 
The cells were spun as above, resuspended in 20% (w/v) 
glycerol in calcium chloride solution (100 mM 20 ml), 
and stored at -80C 
Transformation procedure 
The competent cells (100 p1) were cooled on ice with 
a solution of 10 mM Iris/i0 mM CaCl- 2 i10 mM MgCl 
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(100 p1) and plasmid DNA (1 pi) or ligation mixture (3 
p1). After standing on ice for 20 mm. the cells were 
incubated at 42"C for 2 mm. and grown up in LB for 
1 h. The cells were then spun down in a microfuge and 
plated out.. 
6 	6 Induction of 	cteinsyntesisinE.Co 11. 
P starter culture (5 ml) of cells transformed with 
the appropriate plasmid was grown up overnight, and was 
used to inoccu:late 50 ml of L-8 ampicillin medium.. 
The cells were grown up at 37c  with shaking to 
OD,oc) 0.3 when the culture was divided in half and 
one half was induced with isopropyithioqalactoside 
(IPTGp 10 mg ml; 250 p1). 
Both halves of the culture wereincubated at 37C 
for a furthur 2 h.. The cells were then spun at 5000 
r.p.m. in a Sorva:Ll S34 rotor for 10 mm. and the 
resultant pellet was resuspended in SDS PAGE loading 
buffer (0.75 ml). 
The suspension was transferred to a 1,5 ml Eppendorf 
tube, heated at 90--100'O for 3 mm. and spun 
in a microfuge for 5 mm. The supernatant was then 
transferred to another 1.5 ml Eppendorf tube. 
6.12.7 Sub+ractionaticn of E.Coli cells harbourin 
the cytochrome b aene. 	 - 
starter culture of cells harbouring the desired 
plasmid was grown up overnight, and was used to 
innoculate 200 ml of L-B ampicillmn. 
The cells were grown at 37'C with shaking to ODe::.c 
0.3 when they were induced with IPTG (100 mM; 100 p1). 
after incubation at 37'C for a furthur 90 mm. the 
cells were spun at 8000 r.p.m. in a Sorvall S600 rotor 
for 10 mm. The pellet was then washed twice with 
phosphate buffer (10 mM; pH 7.6) before resuspension in 
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5 ml of the phosphate buffer. 
DNAse was added to a concentration of 50 pg ml - :1  
and lysozyme to a concentration of 100 pg m1'. 
The cells were then lysed by 2-3 passages through a 
French Pressure cell. A portion of the lysate was kept 
as a whole cell extract. 
The lysate was spun at 3000 g in a Sorvall 5534 
rotor, and the pellet of inclusion bodies obtained was 
suspended in SDS sample buffer. 
The supernatant was spun at 100000 g in the TL100 
ultracentrifuge. The resultant membrane fraction pellet 
was washed (X3) with phosphate buffer (10 mM; pH 7.6) 
and resuspended in SDS sample buffer. 
The cytoplasmic proteins were then precipitated by 
treatment of the supernatant with 30% aqueous 
trichioroacetic acid. The precipitated proteins were 
spun down and resuspended in SUS sample buffer. 
The volume of SDS sample buffer used to resuspend the 
various fractions (0.5-1 ml) was kept constant. 
The samples were then heated at 90-100C for 3 mm, 
spun in a microfuae and the supernatant transferred to 
separate 1.5 ml Eppendorf tubes. 
jjyctnqR&oresi s. 
All materials were cleaned before use and glass 
plates were wiped with ethanol. The plates and 
separators were then clamped together and sealed with 
grease. 
The separating gel (lOX) was prepared by mixing 
acrylamide solition (10 ml), distilled water (12.3 ml), 
and 4" separating solution (7.5 ml) , and adding APS 
(200 p1) and TEIIED (40 p1). The gel was then poured, 
overiayeo with n-butanol, saturated with water and left 
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to set. 
The stacking gel (3.37.) was prepared by mixing 
acrylamide solution (1.5 ml), distilled water (9.75 
ml) and 4X stacking solution (3.75 ml) , and adding APS 
solution (100 p1) and TEMED (80 p1) 
The stacking gel was then poured and allowed to set 
before samples were loaded (in SDS loading buffer) into 
the wells and the gel was run in 1X running buffer at 
constant current ( approx. 150 V) until the bromophenol 
blue reached the bottom of the gel. 
The stacking gel was then removed and the gel was 
stained in staining so:Lution for 0,5-i h. The gel was 
then destained until required, changing the destain 
solution frequently. 
6.12.9 Western Blotting. 
The proteins were separated by 8DB-PAGE. After 
discarding the stacking gel and marking the bottom left 
hand corner of the gel, the gel was not stained or 
fixed. 
A piece of HYBOND nylon was cut to fit the gel and 
six sheets of Whatman 3 mm filter paper were cut to fit 
the plastic holders. 
The gel, membrane, sponges and filter paper were then 
soaked in the 1X transfer buffer for 5 mm. and were 
subsequently fitted together to form a sandwich, 
ensuring that no air bubbles were present between the 
the layers. 
The sandwich was then placed in the transfer tank with 
5 1 of 1X transfer buffer ensuring that the gel was 
nearest to the -ye terminal of the tank. 
The proteins were then transferred for 1-2 h. at 0.6-
2 Amps before the sandwich was the removed and the 
membrane was blocked in a solution of 20% dried milk 
powder in lBS overnight. The gel was meanwhile stained 
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and destained to check that transfer had occurred 
The blocked membrane was incubated with shaking in 
20-40 ml milk solution (5X in TBS) with 20 p1 of 
polyclonal antiserum (50 p1 of mouse antiserum) for 3 
h The membrane was then removed and washed (4 X 5 
min) with TBS.  
The washed membrane was incubated with shaking in a 
solution of milk (SX in TES) containing HRF-conjugated 
anti-rabbit (or anti-mouse) antibody for 2h.. or more, 
and was then removed and washed with TES solution as 
described prevaously.  
A solution containing distilled water (19.6 ml), 30% 
hydrogen peroxide (200 p1), imiazoie solution (pH 7.4 
200 p1) and dianisidine (5 mg ml -1 ) was prepared and 
the membrane was incubated in it until a the brown 
colour developed. The reaction was stopped by the 
addition of distilled water and the membrane was then 
dried and photographed.. 
- 1'0 - 
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